Deep brain and cortical stimulation for epilepsy by Sprengers, Mathieu et al.
Cochrane Database of Systematic Reviews
Deep brain and cortical stimulation for epilepsy (Review)
Sprengers M, Vonck K, Carrette E, Marson AG, Boon P
Sprengers M, Vonck K, Carrette E, Marson AG, Boon P.
Deep brain and cortical stimulation for epilepsy.
Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD008497.
DOI: 10.1002/14651858.CD008497.pub3.
www.cochranelibrary.com
Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
9BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
31ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
52DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
101DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Stimulation versus sham stimulation, Outcome 1 Seizure freedom. . . . . . . . . 104
Analysis 1.2. Comparison 1 Stimulation versus sham stimulation, Outcome 2 Responder rate. . . . . . . . . 105
Analysis 1.3. Comparison 1 Stimulation versus sham stimulation, Outcome 3 Seizure frequency reduction. . . . . 107
Analysis 1.4. Comparison 1 Stimulation versus sham stimulation, Outcome 4 Quality of Life. . . . . . . . . 108
Analysis 2.1. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 1 Seizure freedom RR. 109
Analysis 2.2. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 2 Responder rate RR. 111
Analysis 2.3. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 3 Seizure freedom OR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 2.4. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 4 Responder rate OR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 2.5. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 5 Seizure freedom RR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 2.6. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 6 Responder rate RR
0.25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
118APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
121SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
121DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
121INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iDeep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Deep brain and cortical stimulation for epilepsy
Mathieu Sprengers1, Kristl Vonck1, Evelien Carrette1, Anthony G Marson2 , Paul Boon1
1Department of Neurology, Ghent University Hospital, Ghent, Belgium. 2Department of Molecular and Clinical Pharmacology,
Institute of Translational Medicine, University of Liverpool, Liverpool, UK
Contact address: Paul Boon, Department of Neurology, Ghent University Hospital, 1K12, 185 De Pintelaan, Ghent, B-9000, Belgium.
Paul.Boon@UGent.be.
Editorial group: Cochrane Epilepsy Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 7, 2017.
Citation: Sprengers M, Vonck K, Carrette E, Marson AG, Boon P. Deep brain and cortical stimulation for epilepsy. Cochrane Database
of Systematic Reviews 2017, Issue 7. Art. No.: CD008497. DOI: 10.1002/14651858.CD008497.pub3.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Despite optimal medical treatment, including epilepsy surgery, many epilepsy patients have uncontrolled seizures. Since the 1970s
interest has grown in invasive intracranial neurostimulation as a treatment for these patients. Intracranial stimulation includes both
deep brain stimulation (DBS) (stimulation through depth electrodes) and cortical stimulation (subdural electrodes). This is an updated
version of a previous Cochrane review published in 2014.
Objectives
To assess the efficacy, safety and tolerability of DBS and cortical stimulation for refractory epilepsy based on randomized controlled
trials (RCTs).
Search methods
We searched the Cochrane Epilepsy Group Specialized Register on 29 September 2015, but it was not necessary to update this search,
because records in the Specialized Register are included in CENTRAL. We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (the Cochrane Library 2016, Issue 11, 5 November 2016), PubMed (5 November 2016), ClinicalTrials.gov (5 November
2016), the WHO International Clinical Trials Registry Platform ICTRP (5 November 2016) and reference lists of retrieved articles.
We also contacted device manufacturers and other researchers in the field. No language restrictions were imposed.
Selection criteria
RCTs comparing deep brain or cortical stimulation versus sham stimulation, resective surgery, further treatment with antiepileptic
drugs or other neurostimulation treatments (including vagus nerve stimulation).
Data collection and analysis
Four review authors independently selected trials for inclusion. Two review authors independently extracted the relevant data and
assessed trial quality and overall quality of evidence. The outcomes investigated were seizure freedom, responder rate, percentage
seizure frequency reduction, adverse events, neuropsychological outcome and quality of life. If additional data were needed, the study
investigators were contacted. Results were analysed and reported separately for different intracranial targets for reasons of clinical
heterogeneity.
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Main results
Twelve RCTswere identified, eleven of these compared one to threemonths of intracranial neurostimulationwith sham stimulation.One
trial was on anterior thalamic DBS (n = 109; 109 treatment periods); two trials on centromedian thalamic DBS (n = 20; 40 treatment
periods), but only one of the trials (n = 7; 14 treatment periods) reported sufficient information for inclusion in the quantitative meta-
analysis; three trials on cerebellar stimulation (n = 22; 39 treatment periods); three trials on hippocampal DBS (n = 15; 21 treatment
periods); one trial on nucleus accumbens DBS (n = 4; 8 treatment periods); and one trial on responsive ictal onset zone stimulation (n =
191; 191 treatment periods). In addition, one small RCT (n = 6) compared six months of hippocampal DBS versus sham stimulation.
Evidence of selective reporting was present in four trials and the possibility of a carryover effect complicating interpretation of the
results could not be excluded in five cross-over trials without any or a sufficient washout period.
Moderate-quality evidence could not demonstrate statistically or clinically significant changes in the proportion of patients who were
seizure-free or experienced a 50% or greater reduction in seizure frequency (primary outcome measures) after one to three months of
anterior thalamicDBS in (multi)focal epilepsy, responsive ictal onset zone stimulation in (multi)focal epilepsy patients and hippocampal
DBS in (medial) temporal lobe epilepsy. However, a statistically significant reduction in seizure frequency was found for anterior
thalamic DBS (mean difference (MD), -17.4% compared to sham stimulation; 95% confidence interval (CI) -31.2 to -1.0; high-
quality evidence), responsive ictal onset zone stimulation (MD -24.9%; 95% CI -40.1 to -6.0; high-quality evidence) and hippocampal
DBS (MD -28.1%; 95% CI -34.1 to -22.2; moderate-quality evidence). Both anterior thalamic DBS and responsive ictal onset zone
stimulation do not have a clinically meaningful impact on quality life after three months of stimulation (high-quality evidence).
Electrode implantation resulted in postoperative asymptomatic intracranial haemorrhage in 1.6% to 3.7% of the patients included in
the two largest trials and 2.0% to 4.5% had postoperative soft tissue infections (9.4% to 12.7% after five years); no patient reported
permanent symptomatic sequelae. Anterior thalamic DBS was associated with fewer epilepsy-associated injuries (7.4 versus 25.5%; P =
0.01) but higher rates of self-reported depression (14.8 versus 1.8%; P = 0.02) and subjective memory impairment (13.8 versus 1.8%;
P = 0.03); there were no significant differences in formal neuropsychological testing results between the groups. Responsive ictal-onset
zone stimulation seemed to be well-tolerated with few side effects.The limited number of patients preclude firm statements on safety
and tolerability of hippocampal DBS.
With regards to centromedian thalamic DBS, nucleus accumbens DBS and cerebellar stimulation, no statistically significant effects
could be demonstrated but evidence is of only low to very low quality.
Authors’ conclusions
Except for one very small RCT, only short-term RCTs on intracranial neurostimulation for epilepsy are available. Compared to sham
stimulation, one to three months of anterior thalamic DBS ((multi)focal epilepsy), responsive ictal onset zone stimulation ((multi)focal
epilepsy) and hippocampal DBS (temporal lobe epilepsy) moderately reduce seizure frequency in refractory epilepsy patients. Anterior
thalamic DBS is associated with higher rates of self-reported depression and subjective memory impairment. There is insufficient
evidence to make firm conclusive statements on the efficacy and safety of hippocampal DBS, centromedian thalamic DBS, nucleus
accumbens DBS and cerebellar stimulation. There is a need for more, large and well-designed RCTs to validate and optimize the efficacy
and safety of invasive intracranial neurostimulation treatments.
P L A I N L A N G U A G E S U M M A R Y
Electrical stimulation through implanted electrodes in contact with the brain to treat drug-resistant epilepsy
Background
Despite many antiepileptic drugs being available, about 30% of epilepsy patients are not seizure-free. Electrical stimulation through
implanted electrodes in contact with the brain (i.e. intracranial electrical stimulation, referring to ’deep brain stimulation’ and ’cortical
brain stimulation’) has been proposed as an alternative treatment for these patients. This review aimed to evaluate its efficacy, safety
and tolerability.
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Results
Various brain structures have been targeted with scheduled (that is seizure-independent) stimulation, including the anterior thalamic
nucleus (one trial, 109 participants), the centromedian thalamic nucleus (two trials, 20 participants), the cerebellar cortex (three trials,
22 participants), the hippocampus (four trials, 21 participants) and the nucleus accumbens (one trial; 4 participants). In addition,
one trial (191 participants) studied responsive stimulation (that is only upon seizure detection) of the seizure onset zone. There is
evidence for a moderate (15% to 30%) seizure frequency reduction after short-term (one to three months) anterior thalamic nucleus
stimulation in (multi)focal epilepsy, hippocampal stimulation in temporal lobe epilepsy and responsive seizure onset zone stimulation
in (multi)focal epilepsy. However, there is no evidence for significant impact on seizure freedom, the proportion of patients with a
greater than 50% seizure frequency reduction, or quality of life.
Adverse effects of anterior thalamic stimulation include self-reported depression and subjective memory impairment, and possibly
anxiety and confusional state. Responsive seizure onset zone stimulation seemed to be well-tolerated with few side effects.
Evidence on anterior thalamic and responsive ictal onset zone stimulation is of moderate to high quality, whereas the evidence on
hippocampal stimulation is of low to moderate quality. There is insufficient evidence to make firm conclusive statements on the efficacy
or side effects of hippocampal, centromedian thalamic, cerebellar cortical and nucleus accumbens stimulation. Intracranial implantation
of the electrodes was relatively safe without permanent symptomatic sequelae in the patients included in the trials.
Conclusions
More, larger and well-designed trials on intracranial electrical stimulation treatments are needed to validate and optimize its efficacy
and safety and to compare this treatment to currently available treatments (for example, antiepileptic drugs or vagus nerve stimulation).
The evidence is current to 5 November 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anterior thalamic nucleus stimulation for refractory epilepsy
Patient or population: adults with IQ > 70 with ref ractory focal epilepsy
Settings: epilepsy centres in the USA
Intervention: anterior thalamic nucleus st imulat ion
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Anterior Thalamic Nu-
cleus stimulation
Seizure freedom
(3-month blinded evalu-
at ion period)
Observed in Fisher 2010 OR 0.33 (0.01 to 8.36) 109
(1)
⊕⊕⊕©
moderate2
1 per 55 0 per 54
(0 to 7)
Low risk population1
1 per 1000 0 per 1000
(0 to 8)
High risk population1
15 per 1000 5 per 1000
(0 to 113)
Responder rate
(3-month blinded evalu-
at ion period)
26 per 100 30 per 100
(15 to 49)
OR 1.20 (0.52 to 2.80) 108
(1)
⊕⊕⊕©
moderate2
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Seizure frequency re-
duction (%)
(3-month blinded evalu-
at ion period)
Median monthly
seizure f requency re-
duct ions ranged f rom -
14.5 to -28.7%
The mean seizure f re-
quency in the interven-
t ion group was
- 17.4% lower
(-31.2 to -1.0% lower)
108 (1) ⊕⊕⊕⊕
high3
A trend for increas-
ing ef f icacy over t ime
was observed during
the blinded evaluat ion
period and could re-
sult into an underest i-
mation of the treatment
ef fect (treatment ef fect
of month 3: -29%)
Adverse events See comment See comment 109 (1) ⊕⊕⊕©
moderate2
Stimulat ion-related ad-
verse events during the
blinded evaluat ion pe-
riod include (st imula-
t ion versus control): de-
pression (14.8 versus
1.8%, P = 0.02), sub-
ject ive memory impair-
ment (13.8 versus 1.8%,
P = 0.03) and epilepsy-
related injuries (7.4 ver-
sus 25.5%, P = 0.
01). Standard st imula-
t ion parameters could
be inappropriate and
increase seizure f re-
quency in a small m i-
nority of pat ients.4
Asymptomatic intracra-
nial haemorrhages oc-
curred in 3.7% of par-
t icipants af ter the init ial
implant procedure. In 8.
2%of part icipants leads
had to be replaced af ter
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init ial implantat ion out-
side the target. Postop-
erat ive implant site in-
fect ions occurred in 4.
5% of part icipants, in-
creasing to 12.7% af -
ter 5 years of follow-
up urging (temporary)
hardware removal in 8.
2% of part icipants. Im-
plant site pain was
not uncommon (year
1: 10.9%, year 5: 20.
9%). SUDEP rate dur-
ing long-term (includ-
ing open-label) follow-
up was 2.9 per 1000 p-
y which is comparable
to rates reported in re-
f ractory epilepsy popu-
lat ions (2.2-10 per 1000
p-y) (Tellez-Zenteno
2005; Tomson 2008).
Neuropsychological
outcome
(3 months)
See comment See comment 96-100 (1) ⊕⊕⊕©
moderate5
Changes in neuropsy-
chological test scores
for cognit ion and mood
were very sim ilar in
the treatment and con-
trol group and not sig-
nif icant ly dif f erent. In-
dividual pat ient data
show worsening (> 1
SD) of Prof ile of Mood
States Depression sub-
scale (POMS-D) in 3/
8 st imulated part ici-
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pants with self -reported
depression and 0/ 7
pat ients with subjec-
t ive memory impair-
ment showed worsen-
ing (> 1 SD) of verbal or
visual memory scores
Quality of life
(QOLIE-31)
(3 months)
The mean improvement
of the QOLIE-31 score
in the control group was
+2.8 higher
The mean improvement
in QOLIE-31 score in the
intervent ion group was
- 0.30 lower
(-3.50 lower to +2.90
higher)
105 (1) ⊕⊕⊕⊕
high
Posit ive changes in
QOLIE-31 (quality of lif e
in epilepsy 31) scores
indicate improvement.
Changes of 5-11.7 have
been def ined in litera-
ture as being clinically
meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; SUDEP: sudden unexpected death in epilepsy pat ients; p-y: pat ient-years; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risks (low and high) are based on the range of the number of events observed in the sham stimulat ion control
groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 More trials and pat ients are needed to allow more precise est imation of st imulat ion ef fects (including more rare adverse
ef fects) (GRADE -1).
3 The conf idence interval includes clinically non-signif icant changes (GRADE -1), however, the observed trend for increasing
ef f icacy over t ime probably underest imates the treatment ef fect (GRADE +1).
4 One part icipant experienced a spectacular seizure f requency increase af ter init iat ion of st imulat ion, which was reversible
af ter lowering output voltage. New or worse seizures occurred more f requent ly in the st imulat ion group compared to the
control group but dif f erences did not reach stat ist ical signif icance.7
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5 Although clinically meaningful dif f erences in formal neuropsychological test ing results seem unlikely on the group level, the
discrepancy between object ive and subject ive measures needs further clarif icat ion (GRADE -1).
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B A C K G R O U N D
This review is an update of a previously published review in The
Cochrane Database of Systematic Reviews (the Cochrane Library,
2014, Issue 6; Sprenger 2014).
Description of the condition
Epilepsy is a common neurological disorder affecting 0.5% to 1%
of the population (Forsgren 2005). More than 30% of all pa-
tients with epilepsy suffer from uncontrolled seizures or have un-
acceptable medication-related side effects (Kwan 2000). Alterna-
tive treatment options are available for patients with refractory
seizures. Addition of newly developed antiepileptic drugs to the
treatment regimen may result in freedom from seizures in this
population group. However, the chance of becoming seizure-free
with this strategy is limited and estimated to be around 6% when
compared to placebo (Beyenburg 2009). Surgery for epilepsy leads
to long-term freedom from seizures in approximately 58% to 65%
of suitable surgery candidates (Engel 2003; West 2015). For the
remainder, few options are left and neurostimulation may provide
an alternative treatment (Engel 2003).
Description of the intervention
Both extracranial (vagus nerve stimulation) and intracranial (deep
brain stimulation (DBS) and cortical (neocortex and cerebellar
cortex) stimulation) neurostimulation have been used as treat-
ments for epilepsy (Boon 2007a). Intracranial stimulation is the
direct application of an electrical current to central nervous sys-
tem structures by means of implanted (DBS) or subdural (cortical
stimulation) electrodes connected to an implantable pulse gener-
ator.
How the intervention might work
The precise mechanism of action of DBS still needs to be eluci-
dated. Several mechanisms of action have been proposed. By con-
tinuous application of current via the electrodes, the targeted brain
structures may be (functionally) inhibited. This is done in a re-
versible manner since the stimulation can be stopped at any time.
The effect of the inhibition depends on the targeted structures,
thus depending on the location of the implanted electrodes in the
brain. Stimulation of electrodes placed in the epileptic onset re-
gion (for example, the hippocampus) may lead to ’local’ inhibition
of the hyperexcitable region and to seizure suppression. Stimula-
tion of electrodes placed in key structures responsible for seizure
propagation (for example, the thalamus) may additionally lead to
suppression of seizure spread, based on the connections between
the area of stimulation and other parts of the central nervous sys-
tem. This may provide a likely hypothesis when crucial structures
in the epileptogenic networks are involved (Boon 2007a).
Why it is important to do this review
For both deep brain and cortical stimulation, several uncontrolled
and unblinded trials with discongruent results and high risk of
bias exist. Randomized controlled trials have been performed but
not systematically reviewed. Until now, no clear descriptions of
the outcomes and side effects have been available. The aim of this
systematic review is to give an overview of the current evidence for
the use ofDBS and cortical stimulation as treatments for refractory
epilepsy.
O B J E C T I V E S
To assess the efficacy, safety and tolerability of deep brain and
cortical stimulation for refractory epilepsy based on randomized
controlled trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) investigating deep brain or
cortical stimulation in patients with refractory epilepsy were se-
lected. Blinded as well as unblinded studies were considered for
inclusion in this review.
Types of participants
Patients with refractory epilepsy with partial or generalized
seizures, or both. Partial seizures are found in a localization-related
form of epilepsy in which seizure semiology or findings from in-
vestigations disclose a localized origin of the seizures. With gen-
eralized seizures the first clinical changes indicate involvement of
both hemispheres (ILAE classification). Patients are considered to
be refractory if they suffer from uncontrolled seizures despite ade-
quate treatment with at least two first-line antiepileptic drugs (ei-
ther as monotherapy or in combination) that are appropriate for
the epileptic syndrome, or they experience unacceptable medica-
tion-related side effects. In adults, at least two years of treatment
is recommended before drug-resistant epilepsy can be diagnosed
(Kwan 2010; Kwan 2009).
Both patients with normal and abnormal magnetic resonance
imaging (MRI) were included. Patients who had undergone
other treatments besides antiepileptic drugs (for example, resective
surgery or vagus nerve stimulation) were also included.
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Types of interventions
Deep brain stimulation (DBS) (in different intracranial regions)
or cortical (neocortex or cerebellar cortex) stimulation. Both treat-
ments could have been compared to a control patient group: 1)
receiving sham stimulation, 2) undergoing resective surgery, 3)
being further treated with antiepileptic drugs, or 4) other neu-
rostimulation treatments (including vagus nerve stimulation), de-
pending on the study protocol.
Types of outcome measures
Primary outcomes
(1) Seizure freedom: the proportion of participants that was free
of seizures (complete absence of seizures, comparable with Engel
classification class I (Jehi 2008)) during the randomized period,
i.e. the phase of the trial duringwhich, according to treatment allo-
cation, one group of patients received the intracranial neurostim-
ulation treatment and the other group the control treatment (in
contrast to open-label follow-up periods of the same trials dur-
ing which (nearly) all patients received the neurostimulation treat-
ment under investigation in an unblinded manner, without any
control group).
(2) Responder rate: proportion of patients with at least a 50%
seizure frequency reduction, compared to the baseline period,
throughout the randomized period.
Secondary outcomes
(1) Seizure frequency reduction: percentage reduction in seizure
frequency during the randomized phase of the trial compared to
baseline. When the needed data were not presented in the respec-
tive article, they were calculated (if raw data were present) or the
authors were contacted.When necessary to avoid treatment effects
> 100%, we directly compared ’on’ to ’off ’ stimulation periods
instead of referring to baseline seizure frequency (as for Van Buren
1978, see also Appendix 1).
(2) Adverse events: adverse events occurring throughout the ran-
domized period; the primary focus is on the comparison of the
different randomized groups; to inform the reader adverse events
related to the surgical procedure or the chronic presence of an
implanted device (e.g. infection, haemorrhage) occurring in trials
comparing active to sham stimulation (and thus in both groups)
are also reported (including open-label data, if applicable).
(3) Neuropsychological testing: results of neuropsychological test-
ing during or at the end of the randomized period.
(4) Quality of life: results of questionnaires concerning quality of
life that were completed during or at the end of the randomized
period.
Search methods for identification of studies
Cochrane Central Register of Controlled Trials (CENTRAL;
2015, Issue 1) in the Cochrane Library (searched 10 February
2015);
Electronic searches
We searched the following electronic databases, without any lan-
guage restrictions:
(1) Cochrane Epilepsy Group Specialized Register (29 September
2015), using the search strategy outlined in Appendix 2. It is not
necessary to update this search, because records in the Specialized
Register are included in CENTRAL;
(2) Cochrane Central Register of Controlled Trials (CENTRAL;
2016, Issue 11), in the Cochrane Library2016, Issue 11 (searched
5November 2016), using the search strategy outlined in Appendix
2;
(3) PubMed (5 November 2016), using the search strategy out-
lined in Appendix 2;
(4) ClinicalTrials.gov (5 November 2016), using the search strat-
egy outlined in Appendix 2; and
(5) the WHO International Clinical Trials Registry Platform
ICTRP (5 November), using the search strategy outlined in
Appendix 2.
Searching other resources
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant studies.
We contacted authors of relevant trials identified by our search,
other researchers in the field, and manufacturers of the devices to
identify unpublished or ongoing studies, or studies published in
non-English journals.
Data collection and analysis
Selection of studies
Four review authors (Mathieu Sprengers (MS), Kristl Vonck (KV),
EvelienCarrette (EC) and Paul Boon (PB)) independently assessed
the identified trials for inclusion. Any disagreements were resolved
by discussion and by involving another review author (Anthony
Marson (AM)).
Data extraction and management
Relevant data were extracted into a prespecified data extraction
form by two review authors (MS and KV). If additional data were
needed, we contacted the investigators of the studies. Disagree-
ments were resolved by discussion.
The following data were extracted.
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(1) Methodological and trial design:
(a) method of randomization and sequence generation;
(b) method of allocation concealment;
(c) blinding methods (patient, physician, outcome assessor);
(d) information about sponsoring;
(e) whether any participants had been excluded from reported
analyses;
(f ) duration of period between implantation and start of the treat-
ment period;
(g) duration of treatment period and, in the case of a cross-over
design, washout period;
(h) antiepileptic drug (AED) policy.
(2) Participants and demographic information:
(a) number of participants allocated to each treatment group;
(b) age and sex;
(c) information about type of epilepsy and seizures types;
(d) duration of epilepsy;
(e) additional information if applicable and available (intellectual
capacities, neuroimaging results).
(3) Intervention:
(a) stimulation target;
(b) output voltage and current;
(c) stimulation frequency;
(d) pulse width;
(e) continuous, intermittent or responsive (’closed-loop’) stimula-
tion.
(4) Outcomes:
(a) seizure freedom;
(b) responder rate;
(c) seizure frequency reduction;
(d) adverse events;
(e) neuropsychological outcome;
(f ) quality of life.
Assessment of risk of bias in included studies
Themethodological quality of the studies was independently eval-
uated by two review authors (MS and KV) according to the guide-
lines in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011)
1. The risk of bias was assessed for each individual study using
the Cochrane Collaboration’s tool for assessing risk of bias.
2. Randomization: only RCTs were included in this review.
We planned to exclude studies with inadequate methods of
allocation concealment.
3. Blinding of participants, personnel and outcome assessors:
double-blind studies were preferred but single-blind and even
unblinded (comparison to resective surgery or antiepileptic
drugs) studies were also eligible for inclusion in the review.
4. Incomplete outcome data: this was evaluated separately for
each study. We planned to exclude studies where losses to follow-
up differed significantly between the treatment and control
groups.
5. Selective reporting: this was evaluated separately for each
study (selective outcome reporting) and, furthermore, if
sufficient studies were identified, we planned to explore if there
was any evidence of publication bias using funnel plots.
Several studies have reported results thatmay be consistent with an
outlasting effect after intracranial stimulation (Andrade 2006; Lim
2007;McLachlan 2010; Velasco 2007). Such an effect could mask
or reduce any treatment effect if seizure frequency in the control
group is evaluated after previous stimulation without an adequate
washout period. As there is no general consensus concerning this
outlasting effect, we judged the risk of bias in such studies as
’uncertain’, whereas studies without prior stimulation or with an
adequate washout period were classified as ’at low risk of bias’.
Finally, we also made judgements if antiepileptic drugs were
changed during the trial as this could also influence observed treat-
ment effects.
Measures of treatment effect
We planned to express results of categorical outcomes as risk ra-
tios (RR) with 95% confidence intervals (CIs). However, to com-
bine results from parallel-group (unpaired data) and cross-over tri-
als (paired data), we used the method described by Curtin 2002,
Elbourne 2002 and Stedman 2011. This method makes use of
maximum likelihood estimate odds ratios (OR) (Mantel-Haenszel
ORs) for parallel trials and marginal Becker-Balagtas ORs (Becker
1993) for cross-over trials. Treatment effects of continuous out-
comes were expressed as mean differences (MDs) with 95% CIs.
Although quality of life was evaluated using the QOLIE-89,
QOLIE-31 (abbreviated version of QOLIE-89) and QOLIE-31-
P (slightly modified version of QOLIE-31) questionnaires in dif-
ferent trials, we chose the MD approach instead of the standard-
ized mean difference (SMD) approach. Firstly, all questionnaires
have the same range, and for the QOLIE-31 and QOLIE-89
questionnaires, very similar means, standard deviations(SDs) and
minimally clinically important change values in the same popu-
lation have been reported (Cramer 1998; Devinsky 1995; Wiebe
2002); although we could not find similar studies also incorpo-
rating QOLIE-31-P scores, the QOLIE-31-P is an only slightly
modified version of the QOLIE-31 questionnaire. Secondly, we
thought the MD approach would introduce less error then the
SMD approach, which attributes differences in SDs entirely to
differences in measurement scales and ignores real differences in
variability among study populations. Finally, unlike the SMD ap-
proach, the MD approach allows us to combine final values and
change scores. In view of the difficulty in combining neuropsy-
chological data from various studies, we summarized the data for
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this outcome only qualitatively in the text. The same was true for
adverse events, due to their diverse nature.
Unit of analysis issues
Results from cross-over trials were analysed and incorporated in
the meta-analysis as paired data, using the approach proposed by
Curtin 2002.
Dealing with missing data
Where data for our chosen outcomes were not provided in trial re-
ports, we contacted the original investigators and further data were
requested. If raw datawere available,missing outcomeswere calcu-
lated, if possible (for example, seizure frequency reduction).When
losses to follow-up differed significantly between the treatment
and control groups and if sufficient individual patient data were
available, we planned to perform sensitivity analyses using ’best
case scenario’ (treatment group: not seizure-free, responder, 95%
seizure frequency reduction, QOLIE-score +20; control group:
not seizure-free, no responder, 95% seizure frequency increase,
QOLIE-score -20), ’worst case scenario’ (the opposite of the best
case scenario) and ’last observation carried forward’ LOCF) data
imputation.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the clinical and
trial characteristics, and a judgement was made as to whether sig-
nificant clinical heterogeneitywas present. Statistical inconsistency
was assessed by visual inspection of the forest plots and by using
the I² statistic (with an I² statistic of 30% or higher representing
substantial heterogeneity) and the Chi² test (Q test, significance
level set at a P value of 0.10).
Data synthesis
If neither clinical nor statistical heterogeneity were found, results
were pooled using a fixed-effect model. We planned to use the
Mantel-Haenszel method for dichotomous outcomes and the in-
verse variancemethod for continuous outcomes.However, to com-
bine data from parallel and cross-over trials we had to use the
generic inverse variance method. This approach also allowed in-
corporation of treatment effects estimated by regression and other
models.
Subgroup analysis and investigation of heterogeneity
Stimulation of different intracranial structures may not be equally
effective and lead to different adverse events. Therefore, results
were not pooled across different targets but were presented per
individual target for reasons of clinical heterogeneity.
As there is some evidence that the efficacy of deep brain and
cortical stimulation treatments may increase over time (see also
Discussion), results were pooled per three-month stimulation
epochs (one to three months of stimulation, four to six months of
stimulation etc) as planned in the previous version of this review.
Sensitivity analysis
Various sensitivity analyses were planned before any trial had been
identified. First, if sufficient studies were found, we planned to
assess the effect of study quality on the outcome. Second, because
we initially planned to express results of categorical outcomes as
RR instead of OR, we performed a sensitivity analysis using RR
as described by Zou 2007. In summary, they show that, while
two odds ratios (ORs) can be calculated in a pair-matched study
with binary outcome data (the conditional and the marginal OR),
there is only one RR for such design. In their article, they provide
formulae to directly estimate the RR and its variance from the raw
data (instead of obtaining these by conversion of ORs). Third, an
increasing efficacy over time has been suggested for various neu-
rostimulation treatments, including intracranial cortical andDBS.
Therefore we planned to analyze and pool the outcome data per
three-month stimulation epochs (see above). As separate data per
three-month epoch are not always available in trials with a longer
duration of follow-up, we planned to perform a sensitivity analysis
pooling outcome data obtained after different durations of follow-
up, but only if there was no evidence of clinical heterogeneity.
Fourth, if different strategies could be followed, we planned to
analyse their consequences in a sensitivity analysis.
Some sensitivity analysis were planned in the context of general
foreseeable problems after study identification but before any data
analysis was done. First, empty cells hinder calculation of ORs or
RRs. In these situations, it is customary to add +0.5 to each cell (
Deeks 2011). Given the small number of included patients inmost
trials, we examined in a sensitivity analysis if adding + 0.25 instead
of +0.5 would change our conclusions. Second, when necessary
to avoid treatment effects > 100%, we directly compared ’on’ to
’off ’ stimulation periods instead of referring to baseline seizure
frequency (see above and see Appendix 1).We therefore performed
an analysis taking baseline seizure frequency as a reference (and
thus allowing treatment effects > 100%) as a sensitivity analysis.
Finally, several post-hoc sensitivity analyses were only made after
encountering some specific problems associated with particular
trials or meta-analyses: as the two participants inMcLachlan 2010
experienced very similar treatment effects, the standard error (SE)
associated with the MD in seizure frequency in this study was the
lowest among all trials on hippocampal stimulation. In this way,
this very small cross-over study (n = 2) substantially influenced
the pooled mean treatment effect. As its weight in the standard
analysis appeared disproportionally high (94%), we checked the
robustness of the conclusions to the other extreme situation in
which the SE of this trial would be (equal to) the highest of all
trials on hippocampal DBS.
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In Fisher 1992 there was one patient who seemed to benefit from
the stimulation but who was dropped from the blinded protocol
due to a seizure frequency increase during the washout period. The
absence of stimulation OFF data therefore prevented inclusion
of the stimulation ON data of this patient in the paired data
analysis. Besides ’best and worst case scenario’ sensitivity analyses
(see above), we also performed a sensitivity analysis with unpaired
data analysis allowing us to include all available data, but without
any data imputation.
’Summary of findings’ tables
The data are summarized per stimulation target in ’Summary of
findings’ tables. All outcome parameters investigated in the review
are incorporated into the tables. The quality of evidence contribut-
ing to these outcomes was judged using the GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
criteria (Guyatt 2008).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
See Figure 1 for a flow-diagrammatic summary of the search re-
sults. One hundred and eighteen records were identified as poten-
tially eligible for inclusion in this review. Seventy-six records were
excluded as they did not meet the eligibility criteria: 63 records
were not randomized controlled trials (RCTs), 11 assessed in-
tracranial stimulation for other purposes than treating refractory
epilepsy, and in two articles, the efficacy of another intervention
(transcranial direct current stimulation) was evaluated.
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Figure 1. Study flow diagram.
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Five records described four recent parallel-groupRCTs still recruit-
ing participants. Boon 2007b is a trial comparing hippocampal
stimulation, sham stimulation and amygdalohippocampectomy in
refractory temporal lobe epilepsy patients. Chabardes 2014 aims
to compare anterior thalamic nucleus stimulation to ’usual treat-
ment’. Koubeissi 2015 is investigating 1 Hz versus 5 Hz low-fre-
quency stimulation of the fornix in patients with refractory me-
dial temporal lobe epilepsy and in Zhang 2015, refractory focal
epilepsy patients are randomized to anterior thalamic nucleus deep
brain stimulation (DBS) or vagus nerve stimulation.
Two trials are still awaiting classification. Four records mentioned
an RCT evaluating the efficacy and safety of DBS of the mammil-
lary bodies and mammillothalamic tracts (van Rijckevorsel 2004).
However, up to now the results have not been published. As for the
previous version of this review, we again tried to contact the au-
thors but additional information could not be gained. Chabardes
2005 was registered on ClinicalTrials.gov as a cross-over trial eval-
uating subthalamic nucleus DBS in refractory focal epilepsy pa-
tients but had to be preliminarily terminated in 2010 due to insuf-
ficient patient recruitment (n = 4). As the preliminary results have
not been published yet, we in vain tried to contact the authors.
Further efforts to acquire these data will be undertaken by the next
update of this review.
Thirty-two records describing 12 studies fulfilled the criteria for
inclusion in this review. As the results of two of these studies were
only presented in a graph (no exact figures) (Velasco 2000a), or
as an abstract (Wiebe 2013), and additional data could not be
obtained, only 10 studies were fully included in the quantitative
synthesis (meta-analysis).
Included studies
See: Characteristics of included studies.
Eleven out of 12 included studies evaluated the safety and efficacy
of open-loop (scheduled) stimulation, the remaining study con-
cerned closed-loop (responsive) stimulation. Stimulation of the ic-
tal onset zone (including the hippocampus (four studies) and the
trial on responsive stimulation) as well as of more remote network
structures has been studied. The latter included the cerebellar cor-
tex (three studies), the anterior (one study) and centromedian (two
studies) thalamic nucleus and the nucleus accumbens (one study).
1. Anterior thalamic nucleus stimulation
Fisher 2010, also known as the SANTE trial, is a parallel-group
RCT evaluating the efficacy and safety of bilateral anterior thala-
mic nucleus DBS in 109 patients (age 18 to 65 years) with refrac-
tory partial-onset epilepsy (mean duration of epilepsy: 22.3 years,
median baseline seizure frequency: 19.5 per month). After one
month of postoperative recovery, patients entered a three-month
blinded randomized phase during which half of the participants
received stimulation and half did not. This was followed by a nine-
month open-label period during which all patients received stim-
ulation in an unblinded way and stimulation parameters could be
programmed on an individual basis but antiepileptic drugs (AED)
were still kept constant. From the 13th month on, AEDs could
vary freely (’long-term follow-up’). All outcomes considered for
this review were examined.
2. Centromedian thalamic nucleus stimulation
1. Fisher 1992 is a cross-over randomized trial in seven patients
(age 16 to 41 years) who were found to be poor candidates for
epilepsy surgery, two of them having (multi)focal epilepsy and
five generalized epilepsy (2/5 had Lennox-Gestaut syndrome). The
patients had been suffering from epilepsy for 14 to 29 years and
had a mean monthly baseline seizure frequency of 23.4 seizures.
Patients were randomized one to two months postoperatively to
first receive either bilateral centromedian thalamic nucleus (two
hours per day) or sham stimulation. The two treatment blocks
lasted three months with a three-month washout phase between
them. After this nine-month randomized and blinded period, all
patients were stimulated during the long-term open-label follow-
up period. All outcomes considered for this review were studied
and reported except for quality of life.
2. Velasco 2000a is a cross-over randomized trial in 13 patients
(age 4 to 31 years) with refractory epilepsy for 4 to 33 years (eight
with Lennox-Gestaut syndrome and five with localization-related
epilepsy) and a median baseline seizure frequency of 119 seizures
per month. After six to nine months of stimulation in all par-
ticipants, patients entered a six-month randomized double-blind
cross-over protocol. In half of the patients, the stimulator was
turned off for three months, between months six and nine, the
other half underwent the samemanoeuvre nine to 12months post-
operatively. Between months 13 and 15, stimulation was restarted
in all patients in an unblinded manner. Two of the original 15 pa-
tients were explanted before initiation of the randomized double-
blind period due to skin erosions. Seizure frequency during the
blinded three-month period without stimulation was presented in
a graph and compared to the preceding three months (with stim-
ulation). As these three months only coincided with the three-
month stimulation ’on’ period of the double-blind protocol in half
of patients, and furthermore no exact figures were provided, this
study could not be included in the meta-analysis but only in the
qualitative synthesis.
3. Cerebellar stimulation
1. Van Buren 1978 reported their results of cerebellar stimula-
tion (superior surface of the cerebellum parallel to and about 1
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cm from either side of the midline) in five patients (age 18 to
34 years) with refractory epilepsy for eight to 23 years, with a
meanbaseline seizure frequency of 5.1 seizures per day. Presumably
four had (multi)focal epilepsy and one had generalized epilepsy.
Stimulation was initiated as soon as preoperative seizure frequency
had resumed after electrode implantation. Over the ensuing 15
to 21 months, patients were hospitalized three or four times for
four to six weeks. During these admissions, seizure frequency was
evaluated with and without stimulation. This was performed in
a blinded as well as an unblinded way. For this review, only the
double-blind data were considered (in total 26 days ’on’ and 26
days ’off ’). As four out of five patients’ seizure frequency increased
during the trial (with as well as without stimulation), we decided
to directly compare seizure frequency during the stimulation ’on’
and ’off ’ periods to avoid treatment effects with > 100% reduc-
tions in seizure frequency (see Appendix 1). The analysis express-
ing treatment effects with regard to baseline seizure frequency was
performed as a sensitivity analysis.
2. Wright 1984 is a cross-over randomized trial in 12 patients (age
20 to 38 years) who had had epilepsy for 10 to 32 years. Five
patients had only generalized seizures, one only partial seizures,
four partial and generalized seizures, and in two patients seizures
were difficult to classify (complex partial seizures versus complex
absences). The type of epilepsy was not reported. The six-month
randomized phase started several months after electrode implan-
tation, after the patient had returned to his preoperative seizure
frequency, and consisted of three two-month periods: continuous,
contingent (that is, patients received only stimulation when the
’seizure button’ was depressed (during an aura or seizure) and for
two minutes after it was released) and sham stimulation of the
upper surface of the cerebellum (electrodes ± 2 cm parasagittally
from themidline). As there was no baseline period, the sham stim-
ulation period seizure frequency (mean: 62 seizures per month)
served as reference data for the meta-analysis. Apart from quality
of life, all outcomes considered for this review were evaluated.
3. Velasco 2005 studied the efficacy and safety of bilateral stimula-
tion of the superomedial surface of the cerebellum in five patients
(age 16 to 35 years) with generalized (n = 3) or (multi)focal frontal
lobe epilepsy (n = 2) for 11 to 27 years (mean baseline seizure
frequency: 14.1 seizures per month). All patients had generalized
tonic-clonic seizures and 4/5 had tonic seizures. The three-month
parallel-group randomized phase was initiated one month after
electrode implantation and was followed by unblinded stimula-
tion in all patients for 21 months. Seizure frequency and adverse
events were evaluated.
4. Hippocampal stimulation
1. Tellez-Zenteno 2006 is a multiple cross-over RCT in four pa-
tients (age 24 to 37 years) with refractory left medial temporal
lobe epilepsy withmesial temporal sclerosis onmagnetic resonance
imaging (MRI) whose risk of postoperative memory deficits pre-
vented resective surgery. Duration of epilepsy ranged from 16 to
24 years and the mean monthly baseline seizure frequency was
between two and four in three participants and 25 in another.
Left hippocampal stimulation was compared to sham stimulation
in three two-month treatment pairs, each containing one month
with and one month without stimulation. All outcomes consid-
ered for this review were studied. With regards to quality of life,
see Appendix 3.
2. Velasco 2007 reported their results of uni- or bilateral hip-
pocampal stimulation (according to seizure focus) in nine patients
(age 14 to 43 years) with intractable temporal lobe epilepsy for
three to 37 years (mean baseline seizure frequency: 37.9 seizures
per month) who were poor surgery candidates. Five had a normal
MRI and four had hippocampal sclerosis. Seizure frequency and
adverse events were assessed in a double-blind manner during the
first postoperative month during which half of the participants
received stimulation and half did not. After this, randomized one-
month period stimulation was turned on in all patients (follow-
up: 18 to 84 months).
3.McLachlan 2010 is another study evaluating hippocampal stim-
ulation as a treatment for medically intractable epilepsy in two
patients (age 45 to 54 years) with independent bitemporal orig-
inating seizures for 15 to 29 years (with 32 and 16 seizures per
month, respectively).MRIwas normal in one and showed bilateral
hippocampal sclerosis in the other patient. A three-month post-
operative baseline period was followed by a cross-over protocol
which contained three months of bilateral hippocampal stimula-
tion followed by a three-month washout period and three months
of sham stimulation (control). All outcomes considered for this
review were evaluated except for quality of life.
4. Wiebe 2013 is a parallel-group RCT in six patients (age 30
to 46 years) with uni- or bilateral drug-resistant medial temporal
lobe epilepsy treated with uni- or bilateral hippocampal stimula-
tion, respectively (median baseline seizure frequency of 10 to 12
seizures per month). After hippocampal electrode implantation
and one month for ’adjustments of interventions’, patients were
randomized to six months active or sham stimulation. The initial
target sample of 57 participants could not be reached due to dif-
ficulties in patient recruitment despite the five-centre participa-
tion.The results collected in these six patients (active stimulation
n = 2; sham stimulation n = 4) have been published as an abstract.
Many details on the methodology, participants, interventions and
outcomes needed for a complete judgement of the methodology
or for full incorporation into this review are missing. We tried to
contact the authors but could not obtain additional information
or data yet. Another attempt will be made by the next update of
this review. Meanwhile, this trial is mainly incorporated into the
qualitative (and not quantitative) synthesis.
5. Nucleus accumbens stimulation
Kowski 2015 is a cross-over RCT in four patients (age 28 to 44
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years) with pharmaco-resistant partial-onset epilepsy for nine to
15 years. Themean baseline frequency of ’disabling’ seizures (com-
plex partial or generalized tonic-clonic seizures) ranged between
four and 20 seizures per month, one patient additionally reported
99 simple partial seizures per month. Resection or further invasive
assessment had been dismissed or surgery had been unsuccessful
and patients preferred participation in the study above vagus nerve
stimulation or standard anterior thalamic DBS treatment. After a
three-month baseline period, depth electrodes were bilaterally im-
planted in the nucleus accumbens and the anterior nucleus of the
thalamus. One month after surgery, patients were randomized to
receive first either nucleus accumbens stimulation or sham stimu-
lation. These two treatment blocks lasted three months each and
were both followed by a one-month washout period. The blinded
evaluation period (BEP) was followed by a three-month open-la-
bel period during which nucleus accumbens DBS was continued
only in those patients who had experienced a ≥ 50% reduction
in frequency of disabling seizures. Additionally, anterior thalamic
DBS was switched on in all patients. All outcomes considered for
this review were evaluated.
6. Closed-loop ictal onset zone stimulation
Morrell 2011, also known as the Neuropace study, was a parallel-
group RCT in 191 patients (age 18 to 66 years) with intractable
partial-onset seizures for two to 57 years with one (45%) or two
(55%) seizure foci. The mean daily baseline seizure frequency was
1.2. After a 12-week baseline period, one or two recording and
stimulating depth or subdural cortical strip leads, or both, were
surgically placed in the brain according to the seizure focus or
foci. A four-week postoperative stabilization period (neurostimu-
lator programmed to sense and record the electrocorticogram; all
patients) and a four-week stimulation optimization period (opti-
mization of stimulation parameters; only patients randomized to
treatment group) preceded the 12-week BEP during which, in half
of the participants, the seizure focus was stimulated in response to
epileptiform electrographic events. This was followed by an open-
label evaluation period with stimulation ’on’ in all patients. All
outcomes considered for this review were evaluated in this trial.
For the adverse events related to the surgical procedure, the per-
manent presence of an implanted device (e.g. infection) and sud-
den unexpected death in epilepsy patients (SUDEP) rate (adverse
events for which the long-term open-label data were also taken
into account), long-term results in the published articles were of-
ten only reported together with those of a preceding open-label
trial (n = 65, for more details see Bergey et al. 2015 in Morrell
2011).
Excluded studies
Sixty-one trials (63 records) were excluded because they were not
randomized controlled trials. In 11 trials intracranial stimulation
was not used to treat refractory epilepsy patients but served other
purposes (Brown 2006; Esteller 2004; Fell 2013; Galvez-Jimenez
1998;Huang 2008; Levy 2008;Miller 2015;Nguyen1999; Pahwa
1999; Tanriverdi 2009; Torres 2013). Finally, Fregni and col-
leagues evaluated transcranial direct current stimulation instead of
intracranial stimulation (Fregni 2005; Fregni 2006).
Risk of bias in included studies
Detailed assessments of each ’Risk of bias’ item for each included
study can be found in the ’Risk of bias’ tables in the section
’Characteristics of included studies’. A summary of the review au-
thors’ judgements is shown in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
18Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Methods for random sequence generation and treatment alloca-
tion concealment (selection bias) were often poorly described in
the published articles. After personal communication with the
authors, however, these were found to be adequate in all tri-
als for which such additional information could be obtained.
As some authors could not be contacted or provide any further
explanation, there remained some uncertainty about three trials
(Tellez-Zenteno 2006; Wiebe 2013; Wright 1984).
Blinding
All 12 trialswere reported to be double-blindRCTs.However, only
for nine out of the 12 included trials was the blinding of patients,
personnel and outcome assessors assessed as adequate.Some un-
certainty remained with regards to Van Buren 1978. For this RCT
(which contained both double-blind and unblinded evaluation
periods, see above), it was not reported whether neuropsychologi-
cal testing was performed during the blinded or unblinded evalu-
ation period and if the sealed notes containing the treatment code
for the double-blind evaluation period were double-opaque and
by whom they were handled (for more details: see Characteristics
of included studies). Although the double-blinding procedure in
Velasco 2000a seemed adequate, the authors compared seizure fre-
quency between stimulation ’off ’ periods (blinded) and the three-
month periods preceding these. Only in about 50% of partici-
pants, these latter periods coincided with blinded stimulation ’on’
periods. For the other half, these threemonths corresponded toun-
blinded stimulation ’on’ periods, which could have resulted in per-
formance or detection bias (the seizure frequency during blinded
stimulation ’on’ periods could not be obtained from the authors).
Both the protocol and abstract of Wiebe 2013 described the trial
to be double-blind but the lack of further details hindered a more
in-depth judgement of the blinding procedure.
Morrell 2011 was the sole study where patients were asked at the
end of the BEP if they knew or could guess if they had received
’real’ or sham stimulation.Thiswas of particular importance in this
trial as stimulation parameters were determined individually after
randomization and only in patients allocated to the stimulation
group (for more details: see Characteristics of included studies).
Incomplete outcome data
Risk of bias arising from incomplete outcome data was assessed
as high for Fisher 1992. In this study, one of the two patients
who improved noticeably with stimulation experienced a marked
seizure frequency increase in the washout period and, therefore,
was dropped from the blinded protocol, after which stimulation
was successfully reinstalled. As there were only seven patients (two
responders), this one patient represented a significant proportion,
especially when taking into consideration the reason for dropout
and the fact that a paired analysis of outcome data did not allow
inclusion of this patient in the (default) meta-analysis. Although
there is no evidence for incomplete outcome data leading to attri-
tion bias in Wiebe 2013, insufficient details prevented full appre-
ciation.
Selective reporting
Evidence suggesting selective reporting was present for a number
of trials. Statistical analysis included only a subgroup of patients in
Fisher 1992 (only patients with generalized tonic-clonic seizures,
not prespecified in the ’Methods’ section), or a subset of avail-
able data in McLachlan 2010 (median monthly seizure frequency
instead of total number of seizures). As raw data were published
in the original articles or provided upon our request, this had no
influence on the review.
Fisher 2010 did not report on or mention all available outcome
measures in the publishedpaper (for example, seizure-free days and
seizure-free intervals), but only reported that ’changes in additional
outcome measures did not show significant differences’. Again,
this had no direct consequences for this review as these outcome
variables were not taken into consideration.
Only for Kowski 2015 was a detailed study protocol available as
the study had been registered beforehand in the German Trial
Registry. All outcomes mentioned in the protocol were reported
on in the published paper in a very detailed and extensive way.
Such a detailed study protocol was not available for the other trials.
However, as it is unusual for trial protocols to be available unless
the trial is very recent, risk of reporting bias was judged as low
when there was no strong evidence of selective reporting.
In various trials results were incompletely reported, however with-
out strong evidence of selective reporting.
1. As mentioned above, the results of Wiebe 2013 were only
published as an abstract, inherently associated with many missing
details. This prevented full inclusion in our meta-analysis so
results were mainly incorporated in the qualitative synthesis.
2. Seizure frequency reduction in Velasco 2000a and Velasco
2007 was only presented in graphs. As exact figures could only
be provided by Velasco 2007, this prevented inclusion of Velasco
2000a in our meta-analysis.
3. Neuropsychological testing results were often only reported
to be non-significant (Fisher 1992; Wright 1984) or were
incompletely published (Tellez-Zenteno 2006). However, as: 1)
neuropsychological testing yields too abundant data for
publication in a journal article (and therefore not entirely
reporting them does not necessarily reflect study quality), and 2)
we did not attempt to incorporate these results into a meta-
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analysis, but rather described them in a qualitative way; we think
this is of less concern for this review.
4. Finally, as not all exact figures with regards to adverse
events, neuropsychological outcome and quality of life could be
reported in Morrell 2011 (too much data), the authors provided
us with these data.
Outlasting effect after prior stimulation
Five trials with a parallel-group design (Fisher 2010;Morrell 2011;
Velasco 2005; Velasco 2007;Wiebe 2013) and two cross-over trials
with a three-month washout period (Fisher 1992; McLachlan
2010) were judged as being at low risk of bias. Two cross-over
trials (Tellez-Zenteno 2006; Wright 1984) did not contain any
washout period, which could mask or reduce any treatment effect
if stimulation had an outlasting effect. This was even more true
for Van Buren 1978 and Velasco 2000a, two cross-over trials for
which the randomized evaluation took place only after six to 21
months of stimulation, without any washout period. Kowski 2015
was a cross-over study with a one-month washout period after
three months of stimulation which might be too short, although
we recognize that clear judgements on this issue are difficult to
make and arbitrary (unclear risk of bias).
Antiepileptic drug (AED) policy
In all trials providing details on the AED policy, the AED regimen
was kept unchanged except for Tellez-Zenteno 2006 in which it
was changed in three out of four patients during the trial. Morrell
2011 allowed benzodiazepines for seizure clusters or prolonged
seizures, but it was unlikely this significantly influenced the re-
ported results. Only for Wiebe 2013 were details on the AED pol-
icy not available.
Effects of interventions
See: Summary of findings for the main comparison
Anterior thalamic nucleus stimulation; Summary of findings
2 Centromedian thalamic nucleus stimulation; Summary of
findings 3 Cerebellar stimulation; Summary of findings 4
Hippocampal stimulation; Summary of findings 5 Nucleus
accumbens stimulation; Summary of findings 6 Responsive ictal
onset zone stimulation
See: Figure 3; Figure 4; Figure 5; Figure 6.
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Figure 3. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.1 Seizure freedom.
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Figure 4. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.2 Responder rate.
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Figure 5. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.3 Seizure
frequency reduction.Note: Fisher 2010 (anterior thalamic nucleus stimulation) and Morrell 2011 (closed-loop
ictal onset zone stimulation) estimated the treatment effect and its standard error on a logarithmic scale,
using the generalized estimating equation (GEE) model. As in this figure standard errors could not be inputted
on the logarithmic scale, the values for the 95% confidence interval presented here differ slightly from the
(more correct) values mentioned in the text. These correct values are -17.4% with 95% CI [-31.2;-1.0] for
Fisher 2010 and -24.9% with 95% CI [-40.1;-6.0] for Morrell 2011.
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Figure 6. Forest plot of comparison: 1 Stimulation versus sham stimulation, outcome: 1.4 Quality of Life. To
measure quality of life, Tellez-Zenteno 2006 and Morrell 2011 used the QOLIE-89 questionnaire, Fisher 2010
used the QOLIE-31 questionnaire (= abbreviated form of the QOLIE-89 questionnaire) and Kowski 2015 usde
the QOLIE-31-P questionnaire (slightly modified version of the QOLIE-31 questionnaire). These
questionnaires have the same range and for the QOLIE-89 and QOLIE-31 questionnaires very similar means,
standard deviations and minimum clinically important change values in the same population have been
reported (Cramer 1998; Devinsky 1995; Wiebe 2002). For this reason results from the different trials are
presented in one forest plot (see also Methods section). For the QOLIE-89 and QOLIE-31 questionnaires,
improvements of 5-11.7 have been defined in literature (Borghs 2012; Cramer 2004; Wiebe 2002) as being
clinically meaningful, positive is better.
1. Anterior thalamic nucleus stimulation
a. Seizure freedom
During the three-month blinded randomized phase of Fisher 2010
1/55 patients in the control group was seizure-free versus 0/54
in the stimulated group (odds ratio (OR) 0.33; 95% confidence
interval (CI) 0.01 to 8.36; one study, 109 participants; moderate-
quality evidence ) (Analysis 1.1).
b. Responder rate
Responder rate was not significantly different in the stimulated
(29.6%) compared to the control (25.9%) group (OR 1.20; 95%
CI 0.52 to 2.80; one study, 108 participants; moderate-quality
evidence) (Analysis 1.2).
c. Seizure frequency reduction
Over the entire blinded randomized period anterior thalamic
nucleus stimulation resulted in a significantly (mean difference
(MD), -17.4%; 95%CI -31.2 to -1.0; one study, 108 participants;
high-quality evidence) higher seizure frequency reduction com-
pared to sham stimulation (Analysis 1.3). The authors reported
a trend for increasing differences in median monthly seizure fre-
quency reduction over time between the groups (stimulation ver-
sus control: month one: -33.9% versus -25.3%, month two: -
42.1% versus -28.7% and month three: -40.4% versus -14.5%;
the adjusted treatment effects being -10% (P = 0.37), -11% (P =
0.34) and -29% (P = 0.002), respectively).
d. Adverse events
Adverse events were evaluated in one trial (109 participants,
moderate-quality evidence). During the blinded evaluation pe-
riod (BEP), two self-reported adverse events occurred significantly
more frequently in the stimulated group compared to the control
group: depression (14.8% versus 1.8%; P = 0.02, Fisher’s Exact
Test) and subjective memory impairment (13.0% versus 1.8%; P
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= 0.03). On the contrary, there were significantly fewer epilepsy-
related injuries (7.4% versus 25.5%; P = 0.01). Differences for
other adverse events were not statistically significant and included:
confusional state (7.4% versus 0.0%; P = 0.06), anxiety (9.3%
versus 1.8%; P = 0.11), paraesthesia (9.3% versus 3.6%; P = 0.27),
new or worse partial seizures with secondary generalization (9.3%
versus 5.5%; P = 0.48) and new or worse simple (5.6% versus
1.8%; P = 0.36) or complex (9.3% versus 7.3%; P=0.74) partial
seizures. One patient experienced 210 complex partial seizures in
the three days after turning on the stimulator (baseline seizure fre-
quency of 19 seizures per month), resolving with reprogramming
of the stimulator.
Within the first year after implantation, five (4.5%) asymptomatic
haemorrhage events were reported (four after the initial implant
procedure, one following a seizure and a fall and remote from
the lead tract). All were asymptomatic. Ten participants (9.1%;
4.5% within first postoperative month) developed implant site
infections (12.7% after five years of follow-up). There were no
parenchymal brain infections. In five patients (4.5%), this even-
tually led to (temporary) hardware removal (8.2% after five years).
Leads initially implanted outside the target structure had to be re-
placed in 8.2% of participants. Implant site pain was reported by
10.9% of participants during the first year of the trial (20.9% after
five years). Five participants (4.5%) experienced status epilepti-
cus during the first year after electrode implantation, two of them
with stimulation ’on’: one during month two of the blinded phase
(complex partial status), and one when the stimulator was turned
on after the blinded phase (complex partial status, resolving within
five days after switching stimulation off ) (6.4% after five years,
3.6% with stimulation ON). The first reported SUDEP (sud-
den unexpected death in epilepsy patients) rate during stimulation
(two SUDEPs over 325 patient-years with stimulation = 6.2 per
1000 patient-years) fell within the range reported in comparable
refractory epilepsy populations (2.2 to 10 per 1000 patient-years)
(Tellez-Zenteno 2005; Tomson 2008) and long-term open-label
follow-up has now recently reported a SUDEP rate of 2.9 per 1000
patient-years (95% CI 0.3 to 10.4).
e. Neuropsychological outcome
Although self-reported depression and subjective memory impair-
ment occurred significantly more frequently in the stimulated
group (see above), changes in neuropsychological test scores for
cognition and mood were very similar in the treatment and con-
trol groups and were not significantly different (one study, 96 to
100 participants;moderate-quality evidence). The evaluated items
can be found in Characteristics of included studies. Looking at
the individual patients, worsening (> 1 standard deviation change
(SD)) of Profile of Mood States Depression subscale (POMS-D)
was present in 3/8 stimulated participants with self-reported de-
pression. None of the seven patients with subjective memory im-
pairment showed worsening (> 1 SD) of verbal or visual memory
scores.
f. Quality of life
Changes from baseline in overall QOLIE-31 scores were compa-
rable for the treatment (+ 2.5) and control (+ 2.8) group. TheMD
in change score (-0.30) was neither statistically (95% CI -3.50
to 2.90; one study, 105 participants; high-quality evidence) nor
clinically significant (positive is better, improvements of 5 to 11.7
have been defined in the literature (Borghs 2012; Cramer 2004;
Wiebe 2002) as being clinically meaningful) (Analysis 1.4).
2. Centromedian thalamic nucleus stimulation
a. Seizure freedom
None of the patients in the Fisher 1992 trial (two hours of in-
termittent stimulation per day) achieved seizure freedom, neither
with nor without stimulation (OR 1.00; 95%CI 0.11 to 9.39; one
cross-over trial, 12 treatment periods; very low-quality evidence)
(Analysis 1.1).
Although one patient was completely seizure-free at themaximum
open-label follow-up (minimum follow-up of one year, mean 41.2
months), Velasco 2000a (24 hours of intermittent stimulation per
day) did not report on differences in seizure freedom between
stimulation ’on’ versus ’off ’ periods in the double-blind protocol
performed betweenmonth six andmonth 12 of the trial. However,
as mean seizure frequency reductions were very similar in both
groups, major differences in seizure freedom seem unlikely.
b. Responder rate
Statistically significant differences in responder rate, favouring ei-
ther the stimulation or the control group, could not be demon-
strated by Fisher 1992 (OR 1.00; 95% CI 0.27 to 3.69; one
cross-over trial, 12 treatment periods; very low-quality evidence)
(Analysis 1.2). Two patients did experience ≥ 50% seizure fre-
quency reductions with stimulation ’on’ compared to baseline, but
one of them had a similar reduction without stimulation and the
other could not be included in a paired analysis as he was dropped
from the blinded protocol due to a seizure frequency increase dur-
ing the washout period (see also ’Sensitivity analyses’).
Eleven out of 13 patients showed ≥ 50% seizure reductions at
maximum follow-up in Velasco 2000a, but again the authors did
not report on differences in responder rates between stimulation
’on’ versus ’off ’ periods. As for seizure freedom, however, impor-
tant differences in responder rate were improbable as mean seizure
frequency reductions were comparable for stimulation ’on’ and
’off ’ periods.
25Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
c. Seizure frequency reduction
Paired analysis (thus excluding one patient) revealed a non-sig-
nificant 7.1% seizure frequency increase during stimulation ’on’
compared to stimulation ’off ’ periods in Fisher 1992 (95% CI -
44.1 to 58.2; one cross-over trial, 12 treatment periods; very low-
quality evidence) (Analysis 1.3). Successive months of stimulation
were not associated with a clear trend for increasing efficacy over
time during the three-month stimulation ’on’ period.
Velasco 2000a found very similar and statistically not significantly
different reductions in seizure frequency during stimulation ’off ’
periods in the double-blind phase of the trial and the three-month
period preceding it (with stimulation ’on’). Graphs showed ap-
proximately a mean 75% reduction in total seizure frequency dur-
ing stimulation ’on’ as well as stimulation ’off ’ periods (P = 0.23).
Some open-label trials have reported that complex partial seizures
may be less prone to centromedian thalamic nucleus stimulation
(Velasco 1993; Velasco 1995). Excluding patients with only com-
plex partial seizures (n = 1) in a subgroup analysis of Fisher 1992
showed a non-significant -8.9% MD in seizure frequency reduc-
tion (95% CI -79.0 to 61.3%). Although, compared to baseline
seizure frequency, reductions in generalized tonic-clonic seizures
and atypical absences in Velasco 2000a were more pronounced
than those found for complex partial seizures, very similar reduc-
tions in seizure frequency were found for any seizure type during
stimulation ’on’ and ’off ’ periods and statistically significant dif-
ferences could not be demonstrated (P values being 0.27, 0.29 and
0.72, respectively).
d. Adverse events
Stimulation-related side effects did not occur in Fisher 1992 or
Velasco 2000a (two cross-over trials, 38 treatment periods; low-
quality evidence). Fisher 1992 explicitly reported that no single
patient had new seizures or worsening of seizures after initiation
of stimulation.
However, various patients in both trials experienced some device-
or procedure-related adverse events (two cross-over trials, 21 par-
ticipants; low-quality evidence). One patient in Fisher 1992 re-
quired repair of the connection to the pulse generator on one side
because no stimulation effect was evident at any intensity, either
behaviourally or by electroencephalogram (EEG) monitoring. A
post implantation computed tomography (CT) scan in another
patient revealed an asymptomatic and minimal haemorrhage in
the vicinity of one depth electrode. Skin erosion forced explan-
tation in three patients of the Velasco 2000a trial, including two
children (five and six years old) whose stimulators had to be re-
moved before the double-blind protocol took place. Young chil-
dren seemed particularly vulnerable to skin erosions because of the
size of the hardware, which is designed for an adult population.
e. Neuropsychological outcome
Multivariate analysiswith repeatedmeasures showedno significant
differences in any of the neuropsychological tests between baseline
and stimulation ’on’ and ’off ’ periods in Fisher 1992 (one cross-
over trial, 12 treatment periods; very low-quality of evidence). The
cognitive assessment battery can be found in Characteristics of
included studies.
f. Quality of life
Neither of the two studies evaluated the impact of centromedian
thalamic stimulation on quality of life.
3. Cerebellar stimulation
a. Seizure freedom
Regardless of stimulation status, seizure freedom could not be
achieved in any of the trials evaluating cerebellar stimulation
(pooled OR 0.96; 95% CI 0.22 to 4.12; three trials, 39 treatment
periods; moderate-quality evidence) (Analysis 1.1).
b. Responder rate
Cerebellar stimulation did not result in a statistically significantly
higher responder rate compared to sham stimulation (pooled OR
2.43; 95% CI 0.46 to 12.84; three trials, 33 treatment periods;
low-quality evidence) (Analysis 1.2). In the treatment groups, there
were 1/5 (Van Buren 1978), 1/9 (Wright 1984) and 2/3 (Velasco
2005) responders, whereas sham stimulation was associated with a
≥ 50% reduction in seizure frequency in 1/5, 0/9 and 0/2 patients,
respectively.
There were no responders with contingent stimulation in Wright
1984 (OR 1.00; 95% CI 0.12 to 8.64).
c. Seizure frequency reduction
The pooled mean treatment effect was a MD -12.4% change in
seizure frequency in favour of cerebellar stimulation, but this effect
did not reach statistical significance (95% CI -35.3 to 10.6; three
trials, 33 treatment periods; low-quality evidence) (Analysis 1.3).
Only Velasco 2005 reported enough details to evaluate a possible
trend for increasing efficacy over successive months of stimulation.
Although the treatment effect was most pronounced in the third
month of stimulation (month one: -54%versus -29%,month two:
-31% versus -14%, month three: -82% versus -14%), the small
number of patients and the observed variability make it premature
to draw any conclusions on this issue. Finally, Van Buren 1978
stated that no slow trends toward improvement could be noticed.
Contingent stimulation was not associated with changes in seizure
frequency inWright 1984 (treatment effect +0.9%; 95% CI -23.2
to 24.9%).
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d. Adverse events
Stimulation-related side effects were not reported in any of the tri-
als (three trials, 39 treatment periods; low-quality evidence). Psy-
chiatric evaluation after completion of the Wright 1984 trial did
not detect adverse psychiatric sequelae as a result of the stimula-
tion trial.
In contrast, device- or procedure-related adverse events were not
uncommon (three trials, 22 participants; low-quality evidence).
Electrode migration necessitating repeated surgery occurred in 3/
12 and 3/5 patients in Wright 1984 and Velasco 2005, respec-
tively. An electrode lead causing pain needed to be repositioned
in one patient and a receiver pocket that had burst open had to
be resutured in another (Wright 1984). Leakage of cerebrospinal
fluid into the subcutaneous apparatus tracts required resuturing
in 3/5 patients of Van Buren 1978, and Wright 1984 reported
that most patients experienced temporary swelling over one or
both receiver sites, presumably due to cerebrospinal fluid accu-
mulation, but that this spontaneously resolved. A subcutaneous
seroma had to be drained in one of the patients in Velasco 2005.
Wound infections could be settled with antibiotics in two patients
but required total hardware removal in one patient (Velasco 2005;
Wright 1984). Finally, repeated surgery was performed in another
two patients due to a defective receiver and abdominal wound
erosion (Wright 1984). Taken all together, in every trial about half
of the patients required repeated surgery (3/5 in Van Buren 1978,
6/12 in Wright 1984 and 3/5 in Velasco 2005).
e. Neuropsychological outcome
Neuropsychological outcome was assessed in two cross-over trials
(32 treatment periods; very low-quality evidence). Each patient in
Wright 1984 was assessed by a clinical psychologist in every phase
of the trial but ’psychometry’ could not reveal any major change in
any of the patients.More detailswere provided byVan Buren 1978.
Consistent changes in full scale intelligence or memory quotients
could not be detected, nor were there any significant changes in
subtests (performance and oral intelligence quotient). Comparing
’on’ to ’off ’ stimulation, the test scores of the four individuals
they evaluated showed very similar results in two participants,
a moderate increase in one patient, and a moderate decrease in
another.
f. Quality of life
None of the trials on cerebellar stimulation formally evaluated
impact on quality of life (very low-quality evidence). However,
Wright 1984 reported that all his patients but one felt better for
cerebellar stimulation, thought it had helped them, and wished
to continue it after completion of the trial. However, only five
patients chose one phase of the trial as being different from the
others: two singled out the continuous, one the contingent, and
two others the no-stimulation phase. Moreover, only one patient’s
subjective impression agreed with the authors’ assessment and in
this patient the no-stimulation period was his best. Finally, one pa-
tient reported a reduction of episodes of incontinence with contin-
gent but not continuous stimulation, which beneficially affected
his social possibilities.
4. Hippocampal stimulation
Four trials evaluated hippocampal stimulation, three of these had
a BEP with one to three months of active stimulation and one
parallel-groupRCT (Wiebe 2013) had a six-month BEP. As results
of the first three-month epoch of the latter were not reported and
could not be obtained, we could not include this trial into the
analyses on the effect of one to three months of hippocampal
stimulation.
4.1 Hippocampal stimulation (one to three months of
stimulation)
a. Seizure freedom
No single patient was seizure-free for the duration of the RCT they
had been included in (pooledOR1.03; 95%CI 0.21 to 5.15; three
trials, 21 treatment periods; moderate-quality evidence) (Analysis
1.1).
b. Responder rate
Hippocampal stimulation was not associated with significantly
higher responder rates compared to sham stimulation (pooled OR
1.20; 95% CI 0.36 to 4.01; three trials, 21 treatment periods;
low-quality evidence) (Analysis 1.2). There were no responders in
McLachlan 2010, 1/4 patient experienced a ≥ 50% reduction in
seizure frequency with as well as without stimulation in Tellez-
Zenteno 2006, and Velasco 2007 reported 1/4 responder in the
treatment group compared to 0/5 in the control group.
c. Seizure frequency reduction
Hippocampal stimulation significantly reduced seizure frequency
with a pooled mean treatment effect of -28.1% (95% CI -34.1
to -22.2; three trials, 21 treatment periods; moderate-quality evi-
dence) (Analysis 1.3). None of the authors provided enough data
to allow evaluation for trends of increasing efficacy over time.
d. Adverse events
No adverse events occurred in relation to stimulation and there
were no early surgical complications in any of the trials (McLachlan
2010; Tellez-Zenteno 2006; Velasco 2007; 15 participants, 21
treatment periods; low-quality evidence). However, skin erosion
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and local infection 24 months after implantation required explan-
tation in 3/9 patients in Velasco 2007.
e. Neuropsychological outcome
Neuropscychological outcome was assessed in two cross-over tri-
als (12 treatment periods; very low- quality evidence). Neuropsy-
chological testing in Tellez-Zenteno 2006 could not reveal signif-
icant differences between baseline, ’on’ and ’off ’ periods in any of
the formal or subjective measures (see Characteristics of included
studies for the different tests they performed). Moreover, reported
mean scores were exactly or nearly the same for the ’on’ and ’off ’
periods. Of particular interest was a patient who previously had
a right temporal lobectomy and whose memory scores were not
influenced by left hippocampal stimulation. The Center for Epi-
demiologic Studies Depression (CES-D) scale could not demon-
strate meaningful changes in mood states during baseline (19),
’on’ (20) and ’off ’ (18) stimulation periods.
McLachlan 2010 assessed the objective and subjective memory of
their two patients during baseline, ’on’, washout and ’off ’ periods.
They found no changes in one participant and contradictory re-
sults in the other. This latter patient reported improved subjective
memory during the stimulation ’on’ period (baseline second, ’off ’
third to sixth and ’on’ 12th to 13th percentile (pc), higher was
better) but formal testing pointed towards worsening of verbal
(baseline first, ’off ’ 14th and ’on’ second pc) as well as visuospatial
(baseline 21st, ’off ’ 42nd and ’on’ first pc) memory.
f. Quality of life
Only Tellez-Zenteno 2006 evaluated the impact of hippocampal
DBS on quality of life (six treatment periods; very low-quality
evidence). Repeated (once per month) testing in three patients
could not demonstrate statistically significant differences between
QOLIE-89 scores during baseline (57), ’on’ (55) and ’off ’ (60) pe-
riods (treatment effect -5.0; 95%CI -53.3 to 43.3), which was ob-
viously not surprising given the small number of patients (Analysis
1.4). This five-point difference was clinically of borderline signif-
icance (positive was better, improvements of 5 to 11.7 have been
defined in the literature (Borghs 2012;Cramer2004;Wiebe 2002)
as being clinically meaningful).
4.2 Hippocampal stimulation (four to six months of
stimulation)
a. Seizure freedom
None of the patients were seizure-free during either sham (n = 0/
4) or hippocampal (n = 0/2) stimulation (OR 1.80; 95% CI 0.03
to 121.68; one study, six participants; very low-quality evidence)
(Analysis 1.1).
b. Responder rate
One out of two patients in the active stimulation group experi-
enced a≥50% reduction in seizure frequency compared to 0/4 in
the sham group (OR 9.00; 95% CI 0.22 to 362.46; one study, six
participants; very low-quality evidence) (Analysis 1.2).
c. Seizure frequency reduction
The sham stimulation group reported a median seizure frequency
increase of 60% compared to a 45% decrease in the stimulation
group (P > 0.05, no information on statistical dispersion available;
one study, six participants; very low-quality evidence). When only
counting complex partial and generalized tonic-clonic seizures, the
sham stimulation group experienced a 31.3% increase compared
to a 50% increase in the stimulation group.
d. Adverse events
Adverse events were not reported (one study, six participants; very
low-quality evidence).
e. Neuropyschological outcome
Scores of cognitive scales assessing recall (Rey Auditory Verbal
Learning Test, Rey Complex Figure Test) were generally lower in
the active stimulation compared to the sham group (P > 0.05; one
study, six participants; very low-quality evidence).
f. Quality of life
The overall QOLIE-89 score at seven months was worse by 13
points with sham stimulation compared to an improvement of
three points with active stimulation (P > 0.05; one study, six par-
ticipants; very low-quality evidence). Positive changes correspond
to a better quality of life, improvements of 5 to 11.7 points have
been defined in the literature (Borghs 2012; Cramer 2004; Wiebe
2002) as being clinically meaningful.
Subjective memory scores using QOLIE-89 memory scales de-
creased by 34 points with sham stimulation and increased by 10
points with active stimulation (P > 0.05). The QOLIE-89 atten-
tion/concentration scores decreased by four points with sham and
increased by 20 points with active stimulation (borderline statis-
tically significant difference, P < 0.06)
5. Nucleus accumbens stimulation
a. Seizure freedom
None of the four patients in Kowski 2015 was seizure-free during
either nucleus accumbens or sham stimulation (OR 1.00; 95%CI
0.07 to 13.64; one cross-over trial, eight treatment periods; low-
quality evidence) (Analysis 1.1).
28Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
b. Responder rate
Three out of four patients experienced a ≥50% seizure reduc-
tion during nucleus accumbens stimulation, whereas there were
no responders during sham stimulation (OR 10.00; 95% CI
0.53 to 189.15; one cross-over trial, eight treatment periods; low-
quality evidence) (Analysis 1.2). The same figures are obtained
when excluding simple partial seizures (these only occurred in the
non-responding patient) and only taking into account the ’dis-
abling’ seizures (sum of complex partial and generalized tonic-
clonic seizures).
c. Seizure frequency reduction
Nucleus accumbens stimulation was associated with a statistically
non-significant -33.8% lower frequency compared to sham stim-
ulation (95% CI -117.4 to 49.8; one cross-over trial, eight treat-
ment periods; low-quality evidence) (Analysis 1.3). Exclusion of
the simple partial seizures of the non-responding patient yielded
a -22.9% lower frequency of disabling seizures during nucleus ac-
cumbens compared to sham stimulation (95%CI -139.8 to 94.0).
d. Adverse events
Three out of four patients reported adverse events during the
BEP (one cross-over trial, eight treatment periods; low-quality ev-
idence). However, except for one patient feeling sad for two weeks
during the active stimulation period after a close relative had died,
there were no adverse events that were exclusively linked to the
active stimulation period. Reported adverse events included: an
increased frequency of disabling seizures (n = 1, both during sham
and active stimulation), loss of interests (n = 1, both during sham
and active stimulation), sleep disturbance (n = 2, one both during
sham and active stimulation, one only during sham stimulation),
a first-time generalized tonic-clonic seizure (n = 1, sham stimula-
tion), depressive mood (n = 1, sham stimulation) and listlessness
(n = 1, sham stimulation). Device- or procedure-related adverse
events occurred in one patient who developed a local subcutaneous
infection with colonization of the pulse generator and the leads
two weeks post-surgery urging antibiotic therapy and hardware
removal. This patient consented to participate again nine months
later.
e. Neuropsychological outcome
Neurocognitive test scores were similar and not statistically signif-
icantly different during sham and active stimulation in this small
trial (one cross-over trial, eight treatment periods; low-quality ev-
idence). There were no categorical changes in Beck-Depression-
Inventory scores during the BEP.However, theMini International
Neuropsychiatric Interview revealed a new-onset major depres-
sion under nucleus accumbens stimulation in one patient and an
ongoing low suicidal risk following one suicide attempt 10 years
before the trial in another patient.
f. Quality of life
Compared to baseline, mean QOLIE-31-P total score was -2.1
lower during active stimulation and -4.9 lower during sham stim-
ulation (treatment effect +2.8; 95%CI -7.4 to 13.0; one cross-over
trial, eight treatment periods; low-quality evidence) (Analysis 1.4).
The QOLIE-31-P is a (slightly) modified version of the QOLIE-
31 questionnaire for which changes of 5 to 11.7 have been defined
in the literature (Borghs 2012; Cramer 2004; Wiebe 2002) as be-
ing clinically meaningful; positive scores indicate improvement.
6. Closed-loop ictal onset zone stimulation
a. Seizure freedom
There were no statistically significant differences in seizures free-
dom during the three-month BEP of Morrell 2011, with 2/97
and 0/94 patients being seizure-free in the treatment and control
group, respectively (OR 4.95; 95% CI 0.23 to 104.44; one study,
191 participants; moderate-quality evidence) (Analysis 1.1).
b. Responder rate
With 28.9% of participants experiencing ≥ 50% reductions in
seizure frequency in the treatment group compared to 26.6% in
the group receiving sham stimulation, stimulation status did not
significantly influence responder rates (OR 1.12; 95% CI 0.59
to 2.11; one study, 191 participants; moderate-quality evidence)
(Analysis 1.2).
c. Seizure frequency reduction
Closed-loop stimulation of the ictal onset zone significantly re-
duced seizure frequency, the treatment effect being -24.9% (95%
CI -40.1% to -6.0%; one study, 191 participants; high-quality
evidence) (Analysis 1.3). A trend for increasing efficacy over time
could be observed during the three-month BEP, with statistically
significant reductions in seizure frequency from the secondmonth
of stimulation on (treatment versus control group: month one:
-34.2% versus -25.2% (P = 0.28), month two: -38.1% versus -
17.2% (P = 0.016) and month three: -41.5% versus -9.4% (P =
0.008)).
d. Adverse events
There were no significant differences between the treatment and
sham groups in the percentages of patients with mild or serious
adverse events (overall or for any type) (one study, 191 partici-
pants; moderate-quality evidence). In fact, with the exception of
increased complex partial seizures (treatment versus sham: n = 2
versus n = 2), headache (n = 3 versus n = 1) and incision site in-
fection (n = 2 versus n = 0), each individual type of device-related
29Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(definite or uncertain) adverse event occurred in nomore than one
participant in the treatment group. Two participants had device-
related serious adverse events: one patient in the treatment group
and another in the control group had one and three events related
to a change in seizures, respectively.
Postoperative intracranial haemorrhage considered as serious ad-
verse events occurred in 1.6% of patients but none of the pa-
tients had permanent neurologic sequelae. After five years, seri-
ous intracranial haemorrhages had occurred in 4.7% of patients
(additional cases mainly due to seizure-related trauma). Postop-
erative implant or incision site soft tissue infections occurred in
2.0% of patients, urging explantation in 0.5%. After five years,
9.4% of patients had experienced soft tissue infection (additional
cases mainly upon battery replacement, explantation in the ma-
jority of cases). There were no parenchymal brain infections. The
most frequently reported adverse events during the first year of the
trial were related to the cranial implantation of the pulse gener-
ator and included implant site pain (15.7%), headache (10.5%),
procedural headache (9.4%) and dysaesthesia (6.3%). Although
the SUDEP rate reported in the first manuscript (four SUDEPs
over 340 patient-years = 11.8 per 1000 patient-years) was slightly
higher than that usually reported in refractory epilepsy patients
(2.2 to 10 per 1000 patient-years) (Tellez-Zenteno 2005; Tomson
2008), longer follow-up during the open-label period has now re-
ported reassuring figures: SUDEP rates of 3.5 per 1000 patient
implant years (95% CI 1.5 to 8.5) and of 2.6 per 1000 patient
stimulation years (95% CI 1.0 to 7.0).
e. Neuropsychological outcome
Neuropsychological assessment at the end of the BEP could not
reveal any significant differences between the treatment and sham
groups in any measure (one study, 160 to 177 participants; high-
quality evidence). In addition, there were no adverse changes in
mood inventories at the end of the blinded phase of the trial. The
neuropsychological and mood assessment batteries can be found
in Characteristics of included studies. Self-reported depression oc-
curred in one patient in each group and subjective memory im-
pairment was reported by one participant belonging to the treat-
ment group.
f. Quality of life
Changes from baseline in overall QOLIE-89 scores were compa-
rable for the treatment (+2.04) and control (+2.18) groups. The
MD in change score (-0.14) was neither statistically (95% CI -
2.88 to 2.60; one study, 180 participants; high-quality evidence)
nor clinically significant (positive was better, improvements of 5
to 11.7 have been defined in the literature (Borghs 2012; Cramer
2004; Wiebe 2002) as being clinically meaningful) (Analysis 1.4).
These conclusions applied to the overall as well as any subscale
QOLIE-89 score.
Sensitivity analyses
Expressing treatment effects of dichotomous outcomes as risk ra-
tios (RR) instead of odds ratios (OR) did not change our conclu-
sions (Analysis 2.1; Analysis 2.2). For seizure freedom (Analysis
2.1), effect estimators were nearly identical however with slightly
smaller CIs. With regards to the responder rate (Analysis 2.2), ef-
fect estimators were (discretely) lower and CIs smaller when using
RR.
Empty cells hindered calculation of ORs or RRs. In these situa-
tions, it is customary to add +0.5 to each cell (Deeks 2011). Given
the small number of included patients in most trials, we examined
if adding +0.25 instead of +0.5 would change our conclusions
(Analysis 2.3; Analysis 2.4; Analysis 2.5; Analysis 2.6). In general,
this was not the case. Concerning seizure freedom (Analysis 2.3;
Analysis 2.5), however, CIs were larger (for all targeted structures,
for OR as well as RR) and the treatment effect seemed more pro-
nounced (but with higher uncertainty) for closed-loop stimula-
tion of the ictal onset zone. With regards to the responder rate
(,Analysis 2.4; Analysis 2.6) treatment effect estimators and CIs
were generally comparable although effect estimators were higher,
but with a greater degree of uncertainty for nucleus accumbens
stimulation and hippocampal DBS (four to six months of stimu-
lation) besides a larger 95% CI for cerebellar stimulation.
Including only trials with a low risk of bias due to an outlasting
effect after prior stimulation (and thus excluding three cross-over
trials without washout periods) did not change our conclusions.
For cerebellar stimulation only one trial remained (Velasco 2005);
and for hippocampal stimulation (one to three months of stimula-
tion), the following pooled effect estimates were calculated: seizure
freedomOR 1.06 (95% CI 0.12 to 9.62), responder rate OR 1.75
(95% CI 0.22 to 14.13) and seizure frequency reduction -28.5%
(95% CI -34.6 to -22.4). Risks of other types of bias which could
have directly influenced our conclusions were mainly present in
the three cross-over trials.
As the two participants in McLachlan 2010 experienced very sim-
ilar treatment effects, the standard error associated with the MD
in seizure frequency in this study was the lowest (3.13) among
all trials on hippocampal stimulation. In this way, this very small
cross-over study (n = 2) substantially influenced the pooled mean
treatment effect. As its weight in the standard analysis appeared
disproportionally high (94%), we checked the robustness of the
conclusions to the other extreme situation in which the standard
error of this trial would be (equal to) the highest of all trials on
hippocampal DBS. The sensitivity analysis using 29.01 (the stan-
dard error of Velasco 2007) instead of 3.13 as the standard error
for McLachlan 2010 yielded a similar -28.2% treatment effect,
however with a higher degree of uncertainty (95% CI -50.7 to -
5.8). Excluding Tellez-Zenteno 2006 (a cross-over trial without
washout period) in this latter analysis resulted in a -45.7% treat-
ment effect for hippocampal stimulation (95% CI -85.9 to -5.5).
To avoid treatment effects > 100%, we directly compared ’on’
and ’off ’ stimulation periods for Van Buren 1978 (see Appendix
30Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1). However, taking baseline seizure frequency as the reference
also for Van Buren 1978 (responder rate OR 2.40; 95% CI 0.21
to 26.82; seizure frequency reduction -123.5%; 95% CI -280.3
to 33.3) did not change our conclusion regarding the efficacy of
cerebellar stimulation (responder rate OR 2.85; 95% CI 0.64 to
12.68; seizure frequency reduction -15.9%; 95% CI -40.3 to 8.5).
An unpaired analysis of Fisher 1992, including the patient who
seemed to benefit from stimulation but whose absence of stimula-
tion ’off ’ data (see Characteristics of included studies) prevented
inclusion in a paired analysis, could not demonstrate a significant
responder rate increase (OR 2.00; 95% CI 0.13 to 29.81) or re-
duction in seizure frequency (-6.6%; 95% CI -93.7 to 80.5), even
after exclusion of a patient with only complex partial seizures (OR
2.00; 95%CI 0.13 to 31.98; -20.7%95%CI -101.6 to 60.2). Also
other sensitivity analyses using data imputation to allow paired
analyses did not change the conclusions on centromedian thalamic
DBS, irrespective whether data imputation was done with a ’best-
case scenario’ (responder rate 1.75 with 95% CI 0.38 to 8.06;
mean seizure frequency -20.2% with 95% CI -100 to +65.6%),
a ’worst-case scenario’ (responder rate 1.00 with 95% CI 0.36
to 2.66; mean seizure frequency +6.9% with 95% CI -47.0 to
60.8%) or a ’last observation carried forward scenario’ (responder
rate 1.00 with 95% CI 0.36 to 2.66; mean seizure frequency +6.1
with 95% CI -47.9 to 60.0%).
As there is some evidence for increasing efficacy of intracranial
neurostimulation treatments over time, we decided to pool results
per three-month stimulation epochs only. As we could only iden-
tify one small trial with a BEP with active stimulation longer than
three months (Wiebe 2013), this was in practice only relevant for
the estimated pooled treatment effect of hippocampal stimulation.
Combining all trials on hippocampal stimulation irrespective of
the duration of active stimulation period did not change the con-
clusions of this review but did result into slightly more favourable
pooled treatment effects for seizure freedom (OR 1.11; 95% CI
0.25 to 4.98) and the 50% responder rate (OR 1.46; 95% 0.47
to 4.58) (sensitivity analysis not possible for other outcomes due
to lack of details on statistical dispersion).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Centromedian thalamic nucleus stimulation for refractory epilepsy
Patient or population: pat ients with ref ractory (mult i)f ocal or generalized epilepsy
Settings: epilepsy centres in the USA and in Mexico
Intervention: centromedian thalamic nucleus st imulat ion
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Centromedian thala-
mic nucleus stimula-
tion
Seizure freedom
(3-month blinded evalu-
at ion period)
Observed in Fisher 1992 OR 1.00 (0.11 to 9.39) 6 (1)2 ⊕©©©
very low3,4
0 per 6 0 per 6
(not est imable)
Low risk population1
1 per 1000 1 per 1000
(0 to 9)
High risk population1
15 per 1000 15 per 1000
(2 to 125)
Responder rate
(3-month blinded evalu-
at ion period)
Low risk population1 OR 1.00
(0.27 to 3.69)
6 (1)2 ⊕©©©
very low3,4,5
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10 per 100 10 per 1000
(3 to 29)
Medium-high risk population1
25 per 100 25 per 1000
(8 to 55)
Seizure frequency re-
duction
(3-month blinded evalu-
at ion period)
The mean seizure f re-
quency reduct ion in the
control group was - 0.
4%
The mean seizure f re-
quency in the interven-
t ion groups was
+7.1% higher
(-44.1% lower to +58.
2% higher)
6 (1)2 ⊕©©©
very low3,4,5
Also another trial (
Velasco 2000a) (n =
13) could not demon-
strate signif icant dif f er-
ences between st imula-
t ion ON and OFF peri-
ods. However, its cross-
over design without any
washout period could
mask a possible treat-
ment ef fect
Adverse events See comment See comment 19 (2)2
21 (2)2
⊕⊕©©
low4,6
Stimulat ion-related ad-
verse events did not oc-
cur.
Postoperat ive CT re-
vealed an asymp-
tomatic and minimal
haemorrhage in one pa-
t ient, 1 pat ient required
repair of the connect ion
to the pulse generator
and skin erosion urged
device explantat ion in 3
other pat ients (includ-
ing 2 young children)
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Neuropsychological
outcome
(3 months)
See comment See comment 6 (1)2 ⊕©©©
very low3,4
There were no signif i-
cant dif f erences in any
of the neuropsychologi-
cal tests between base-
line, st imulat ion ON and
OFF periods
Quality of life See comment See comment 0 (0) See comment Impact of centrome-
dian thalamic nucleus
st imulat ion on quality
of lif e has not been
studied yet
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risks (low, medium and high) are based on the range of the number of events observed in the sham stimulat ion
control groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 Cross-over trial(s).
3 No more than one small RCT was ident if ied, result ing into wide 95% conf idence intervals (GRADE score -2). This is of
part icular concern for neuropsychological outcome, as no exact f igures were reported or could be provided, so evaluat ion of
certain stat ist ically non-signif icant trends is not possible.
4 Only 2 hours of interm it tent st imulat ion per day in Fisher 1992 (GRADE score -1).
5 Incomplete outcome data may introduce bias (GRADE score -1).
6 Number of part icipants too low to ident if y less f requent adverse events (GRADE score -1)
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Cerebellar stimulation for refractory epilepsy
Patient or population: pat ients with ref ractory (mult i)f ocal or generalized epilepsy
Settings: epilepsy centres in the USA and in Mexico
Intervention: st imulat ion of the superomedial surface of the cerebellum
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Cerebellar stimulation
Seizure freedom
(1- to 3-month blinded
evaluat ion period)
Observed OR 0.96
(0.22 to 4.12)
22 (3)2 ⊕⊕⊕©
moderate3
0 per 19 0 per 20
(not est imable)
Low risk population1
1 per 1000 1 per 1000
(0 to 4)
High risk population1
15 per 1000 14 per 1000
(3 to 59)
Responder rate
(1- to 3-month blinded
evaluat ion period)
Low risk population1 OR 2.43
(0.46 to 12.84)
19 (3)2 ⊕⊕©©
low3,4
10 per 100 21 per 100
(5 to 59)
Medium-high risk population1
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25 per 100 45 per 100
(13 to 81)
Seizure frequency re-
duction
(1- to 3-month blinded
evaluat ion period)
The mean seizure f re-
quency re-
duct ion ranged across
control groups f rom 0
to -18.8%
The mean seizure f re-
quency in the interven-
t ion groups was
- 12.4% lower
(-35.3% lower to +10.
6% higher)
19 (3)2 ⊕⊕©©
low3,4
Adverse events See comment See comment 22 (3)2 ⊕⊕©©
low3,5
Stimulat ion-related ad-
verse events were not
reported in any of the
trials
In contrast, about half
of the pat ients in ev-
ery trial required re-
peated surgery due to
electrode migrat ion (n
= 6), leakage of cere-
brospinal f luid (n = 3)
, wound infect ion (n =
1), skin erosion (n = 2)
, lead problems (n = 1)
, subcutaneous seroma
drainage (n = 1) and
defect ive hardware (n
= 1). Wound infect ions
were solved with ant ibi-
ot ics only in 2 addi-
t ional pat ients. In par-
t icular, electrode migra-
t ion remains of spe-
cif ic concern, even in
the most recent trial
(Velasco 2005) (occur-
ring in 3/ 5 pat ients).3
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Neuropsychological
outcome
(1 to 2 months)
See comment See comment 16 (2)2 ⊕©©©
very low3,4,6
’Psy-
chometry’ did not reveal
any major change in any
pat ient in any phase of
the Wright 1984 trial.
Comparing ON to OFF
stimulat ion full scale in-
telligence and memory
scores in Van Buren
1978 showed very sim i-
lar results in two part ic-
ipants, a moderate in-
crease in one pat ient
and a moderate de-
crease in another
Quality of life
(2 months)
See comment See comment 12 (1)7 ⊕©©©
very low3,4,8
Eleven out of 12 pa-
t ients in Wright 1984
felt better for cere-
bellar st imulat ion, but
only 5 chose one phase
as being dif ferent f rom
the others, being either
the cont inuous (n = 2)
, cont ingent (n = 1) or
no-st imulat ion (n = 2)
phase
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.3
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1 The assumed risks (low, medium and high) are based on the range of the number of events observed in the sham stimulat ion
control groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 Including 2 cross-over trials: Van Buren 1978 (n = 4-5) and Wright 1984 (n = 9-12)
3 The small number of pat ients leave a considerable amount of uncertainty with regards to st imulat ion ef fects (GRADE -1).
4 Wright 1984 and Van Buren 1978 are cross-over trials without any washout period which could mask or reduce potent ial
benef its of cerebellar st imulat ion (and explain some heterogeneity) (GRADE -1).
5 Unclear if , how and to what extent st imulat ion-related side ef fects were evaluated in Van Buren 1978 and Wright 1984
(GRADE -1).
6 Unclear what neuropsychological tests were performed in Wright 1984 (’psychometry’). Moreover, as test ing scores were
not published and could not be provided, evaluat ion of certain stat ist ically non-signif icant trends is not possible. Unclear if
neuropsychological test ing in Van Buren 1978 was done in blinded or unblinded evaluat ion periods (GRADE-1).
7 Cross-over trial: Wright 1984 (n = 12).
8 No formal scoring of quality of lif e but evaluat ion of pat ients’ impressions on cerebellar st imulat ion (GRADE -1).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Hippocampal stimulation for refractory epilepsy
Patient or population: pat ients with ref ractory medial temporal lobe epilepsy
Settings: epilepsy centres in Canada and in Mexico
Intervention: hippocampal deep brain st imulat ion
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Hippocampal stimula-
tion
Seizure freedom
(1- to 3-month blinded
evaluat ion periods)
Observed OR 1.03
(0.21 to 5.15)
15 (3)2 ⊕⊕⊕©
moderate3
Also in Wiebe 2013
4 no single pat ient
achieved seizure f ree-
dom af ter six months of
hippocampal act ive or
sham stimulat ion
0 per 11 0 per 10
(not est imable)
Low risk population1
1 per 1000 1 per 1000
(0 to 5)
High risk population1
15 per 1000 15 per 1000
(3 to 73)
Responder rate
(1- to 3-month blinded
evaluat ion periods)
Low risk population1 OR 1.20
(0.36 to 4.01)
15 (3)2 ⊕⊕©©
low3,5
In Wiebe 20134there
was one responder in
the st imulat ion group (n
= 2) compared to none
in the sham group (n =
4) af ter six months of
follow-up39
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10 per 100 12 per 100
(4 to 31)
Medium-high risk population1
25 per 100 29 per 100
(11 to 57)
Seizure frequency
(1- to 3-month blinded
evaluat ion periods)
The mean change
in seizure f requency
ranged across control
groups f rom - 4.7% to
+33.7%
The mean seizure f re-
quency in the interven-
t ion groups was
- 28.1% lower
(-34.1 to -22.2% lower)
15 (3)2 ⊕⊕⊕©
moderate3
One trial
(Tellez-Zenteno 2006)
has a cross-over design
without any washout
period which could re-
sult into an underest i-
mation of the true treat-
ment ef fect
In Wiebe 20134 the
sham stimulat ion group
reported a median
seizure f requency in-
crease of 60% com-
pared to a 45% de-
crease in the st imu-
lat ion group af ter 6
months of follow-up
Adverse events See comment See comment 15 (3)2 ⊕⊕©©
low6
There were neither
st imulat ion-related ad-
verse events, nor early
surgical complicat ions.
Skin erosion and lo-
cal infect ion required
explantat ion af ter >2
years in 3/ 9 pat ients in
Velasco 2007.
Wiebe 20134 also did
4
0
D
e
e
p
b
ra
in
a
n
d
c
o
rtic
a
l
stim
u
la
tio
n
fo
r
e
p
ile
p
sy
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
not report any adverse
event af ter 6 months of
follow-up
Neuropsychological
outcome
(1- to 3-month periods)
See comment See comment 6 (2)2 ⊕©©©
very low5,6
Neu-
ropsychological test re-
sults were the same or
very sim ilar during st im-
ulat ion ON and OFF pe-
riods in Tellez-Zenteno
2006 (n = 4) and in one
pat ient in McLachlan
2010. The other pa-
t ient in McLachlan 2010
showed worse verbal
and visuospat ial mem-
ory scores when st im-
ulated, notwithstanding
that he reported subjec-
t ive memory improve-
ment during the same
period
At seven months in
Wiebe 20134, scores
of cognit ive scales as-
sessing recall (Rey Au-
ditory Verbal Learning
Test, Rey Complex Fig-
ure Test) were generally
lower in the act ive st im-
ulat ion compared to the
sham group (p>0.05)
Quality of life
(QOLIE-89)
(1- to 3-month periods)
The mean QOLIE-89
score in the control
group was 60
The mean QOLIE-89 in
the intervent ion group
was - 5 lower (-53 lower
to +43 higher).
3 (1)7 ⊕©©©
very low5,6
Posit ive changes in
QOLIE-89 (quality of lif e
in epilepsy 89) scores
indicate improvement.
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Changes of 5-11.7 have
been def ined in litera-
ture as being clinically
meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
The overall QOLIE-
89 score at seven
months in Wiebe 2013
4 worsened by 13
points with sham stim-
ulat ion compared to
an improvement of 3
points with act ive st im-
ulat ion (p>0.05), and
there was a trend
for increased QOLIE-
89 subject ive memory
and attent ion/ concen-
trat ion scores
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risks (low, medium and high) are based on the range of the number of events observed in the sham stimulat ion
control groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 Including two cross-over trials: McLachlan 2010 (n = 2) and Tellez-Zenteno 2006 (n = 4)
3 The small number of pat ients preclude more def init ive judgements on ef fects of hippocampal st imulat ion (GRADE -1).
4 Wiebe 2013 is a small parallel-group RCT (n = 6) with a 6-month blinded evaluat ion period. As there were no more than 2
part icipants in the act ive st imulat ion group and details needed for full methodological assessment are missing, the quality of
the evidence is very low and we decided not to create separate 6-month outcomes or a separate summary of f indings table4
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but only to describe the results. As the results of the f irst 3-month epoch were not reported, the data of this trial could not be
combined with the other trials evaluat ing one to three months of hippocampal st imulat ion. However, the reported six-month
results are generally compatible and in line with the est imated three-month results. For more details and a sensit ivity analysis
combining all t rials on hippocampal st imulat ion irrespect ive of the BEP durat ion, see text.
5 One trial (Tellez-Zenteno 2006) had a cross-over design without any washout period and allowed important changes in
ant iepilept ic drugs, both of which could reduce or mask more important treatment ef fects. See also ’Sensit ivity analyses’
(GRADE -1).
6 Number of pat ients is too low to ident if y less f requent adverse events or changes in neuropsychological outcome or quality
of lif e (GRADE-score -2).
7 One cross-over trial: Tellez-Zenteno 2006 (n = 3)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Nucleus accumbens stimulation for refractory epilepsy
Patient or population: adults with IQ >70 with ref ractory focal epilepsy
Settings: epilepsy centre in Germany
Intervention: nucleus accumbens st imulat ion
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Nucleus accumbens
stimulation
Seizure freedom
(3-month blinded evalu-
at ion period)
Observed in Kowski 2015 OR 1.00
(0.07 to 13.64)
4 (1)2 ⊕⊕©©
low3
0 per 4 0 per 4
(not est imable)
Low risk population1
1 per 1000 1 per 1000
(0 to 13)
High risk population1
15 per 1000 15 per 1000
(0 to 172)
Responder rate
(3-month blinded evalu-
at ion period)
Low risk population1 OR 10.0
(0.53 to 189.15)
4 (1)2 ⊕⊕©©
low3
10 per 100 53 per 100
(6 to 95)
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Medium risk population1
25 per 100 77 per 100
(15 to 98)
Seizure frequency re-
duction
(3-month blinded evalu-
at ion period)
The mean change in
seizure f requency in the
control group was -13.
8%
The mean seizure f re-
quency in the interven-
t ion group was
- 33.8% lower
(-100% lower to +49.8%
higher)
4 (1)2 ⊕⊕©©
low3
When focusing on ’dis-
abling seizures’ only
and excluding simple
part ial seizures (occur-
ring in one pat ient), the
mean change in seizure
f requency in the control
group was +8.2% with
a -22.9% lower seizure
f requency in the in-
tervent ion group (-100
lower to +94.0 higher)
Adverse events See comment See comment 4 (1)2 ⊕⊕©©
low3
Except for one pat ient
feeling sad for two
weeks during the act ive
st imulat ion period af -
ter a close relat ive had
died, there were no ad-
verse events that were
exclusively linked to the
act ive st imulat ion pe-
riod (although various
adverse events were re-
ported in the sham and
the act ive st imulat ion
group, see text)
One pat ient developed
a local subcutaneous
infect ion with coloniza-
t ion of the pulse gen-
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erator and the leads
2 weeks post-surgery
urging ant ibiot ic ther-
apy and temporary
hardware removal
Neuropsychological
outcome
(3 months)
See comment See comment 4 (1)2 ⊕⊕©©
low3
Neurocognit ive
test scores were sim i-
lar and not stat ist ically
signif icant ly dif f erent
during sham and ac-
t ive st imulat ion in this
small t rial. There were
no categorical changes
in Beck-Depression-In-
ventory scores during
the BEP. However, the
Mini Internat ional Neu-
ropsychiatric Interview
revealed a new-onset
major depression un-
der nucleus accumbens
st imulat ion in one pa-
t ient, besides an ongo-
ing low suicidal risk fol-
lowing one suicide at-
tempt 10 years before
the trial in another pa-
t ient
Quality of Life
(QOLIE-31-P)
(3 months)
The mean change in the
QOLIE-31-P score in the
control group was - 4.9
lower
The mean change in the
QOLIE-31-P score in the
intervent ion group was
+2.8 higher
(-7.4 lower to +13.0
higher)
4 (1)2 ⊕⊕©©
low3
The QOLIE-31-P is a
(slight ly) modif ied ver-
sion of the QOLIE-31
quest ionnaire for which
changes of 5 to 11.7
have been def ined in
the literature (Cramer
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2004; Wiebe 2002;
Borghs 2012) as be-
ing clinically meaning-
ful; posit ive scores indi-
cate improvement
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; OR: Odds Ratio; BEP: blinded evaluat ion period
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risks (low, medium and high) are based on the range of the number of events observed in the sham stimulat ion
control groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 Cross-over trial
3No more than one small RCT was ident if ied which leaves a considerable amount of uncertainty with regards to st imulat ion
ef fects (GRADE score -2).
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Closed- loop stimulation of the ictal onset zone for refractory epilepsy
Patient or population: adults with ref ractory focal epilepsy (1 or 2 epileptogenic regions)
Settings: epilepsy centres in the USA
Intervention: responsive st imulat ion of the ictal onset zone(s)
Comparison: sham stimulat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham stimulation Responsive ictal onset
zone stimulation
Seizure freedom
(3-month blinded evalu-
at ion period)
Observed in Morrell 2011 OR 4.95
(0.23 to 104.44)
191 (1) ⊕⊕⊕©
moderate2
0 per 94 2 per 97
(not est imable)
Low risk population1
1 per 1000 5 per 1000
(0 to 95)
High risk population1
15 per 1000 70 per 1000
(3 to 614)
Responder rate
(3-month blinded evalu-
at ion period)
27 per 100 29 per 100
(18 to 43)
OR 1.12
(0.59 to 2.11)
191 (1) ⊕⊕⊕©
moderate2
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Seizure frequency re-
duction
(3-month blinded evalu-
at ion period)
The mean est imated
seizure f requency re-
duct ion in the control
group was - 17.3%
The mean seizure f re-
quency in the interven-
t ion group was
- 24.9% lower
(-40.1 to -6.0% lower)
191 (1) ⊕⊕⊕⊕
high3
A trend for increas-
ing ef f icacy over t ime
was observed during
the blinded evaluat ion
period and could re-
sult into an underest i-
mation of the treatment
ef fect (treatment ef fect
of month 3: -32%)
Adverse events See comment See comment 191 (1)
256 (2)
⊕⊕⊕©
moderate2
Adverse events during
the blinded evaluat ion
period were rare and
there were no signif -
icant dif f erences be-
tween the treatment
and control group
Asymptomatic intracra-
nial haemorrhages con-
sidered as serious ad-
verse event were found
postoperat ively in 1.6%
of part icipants. Postop-
erat ive implant or inci-
sion site infect ion oc-
curred in 2.0%of part ic-
ipants, increasing to 9.
4% of part icipants af ter
5 years of follow-up (ad-
dit ional cases mainly
upon battery replace-
ment; urge for (tem-
porary) explantat ion in
the majority of cases)
. Cranial implantat ion
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of the neurost imulator
was the probable cause
of most adverse events,
which include: implant
site pain (16% during
the f irst year of the
trial), headache (11%)
, procedural headache
(9%) and dysaesthe-
sia (6%). Although the
SUDEP rate (4 SUDEPs
over 340 pat ient-years
= 11.8 per 1000 pa-
t ient-years) reported in
the init ial manuscript
was slight ly higher than
those usually reported
in ref ractory epilepsy
pat ients (2.2 to 10
per 1000 p-y) (Tellez-
Zenteno 2005; Tomson
2008), long-term open-
label follow-up has now
reported reassuring f ig-
ures (SUDEP rates of 3.
5 per 1000 implant p-y
or 2.6 per 1000 st imu-
lat ion p-y)
Neuropsychological
outcome
(3 months)
See comment See comment 160-177
(1)
⊕⊕⊕⊕
high
Changes in neuropsy-
chological test ing re-
sults were very sim i-
lar in both groups and
95% conf idence inter-
vals did not include clin-
ically meaningful dif f er-
ences
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Quality of life
(QOLIE-89)
(3 months)
The mean improvement
of the QOLIE-31 score
in the control group was
+2.18 higher
The mean improvement
in QOLIE-31 score in the
intervent ion group was
- 0.14 lower
(-2.88 lower to +2.60
higher)
180
(1)
⊕⊕⊕⊕
high
Posit ive changes in
QOLIE-89 (quality of lif e
in epilepsy 89) scores
indicate improvement.
Changes of 5-11.7 have
been def ined in litera-
ture as being clinically
meaningful (Borghs
2012; Cramer 2004;
Wiebe 2002).
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; SUDEP: sudden unexpected death in epilepsy pat ients; p-y: pat ient-years
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The assumed risks (low and high) are based on the range of the number of events observed in the sham stimulat ion control
groups of all RCTs evaluat ing deep brain and cort ical st imulat ion in ref ractory epilepsy pat ients
2 More trials and pat ients are needed to allow more precise est imation of st imulat ion ef fects (GRADE -1).
3 The conf idence interval includes clinically non-signif icant changes (GRADE -1), however, the observed trend for increasing
ef f icacy over t ime probably underest imates the treatment ef fect (GRADE +1).
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D I S C U S S I O N
More than 30% of all epilepsy patients have pharmacologically
refractory epilepsy (Kwan 2000). Epilepsy surgery is the first treat-
ment of choice for these patients. However, most patients are not
suitable surgical candidates, some are reluctant to undergo brain
surgery, and many do not achieve long-term seizure freedom (de
Tisi 2011; Engel 2003). Other treatment options include vagus
nerve stimulation, the ketogenic diet or inclusion in trials with
newly developed drugs. However, these options yield seizure free-
dom in only a small minority of patients. Invasive brain stimu-
lation, including deep brain and cortical stimulation, may be an
alternative treatment for these patients. Uncontrolled open-label
trials have often shown promising but at the same time mixed re-
sults, and in addition are at high risk of bias. To increase our un-
derstanding of the efficacy and safety of invasive brain stimulation
we performed a systematic review of the literature selecting only
randomized controlled trials (RCTs).
Summary of main results
For a more detailed summary, see Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5; Summary of
findings 6.
We identified 10 RCTs which met our eligibility criteria and
could be fully included in the meta-analysis, including one trial
on anterior thalamic nucleus deep brain stimulation (DBS) for
(multi)focal epilepsy (n = 109), one trial on centromedian thala-
mic DBS for (multi)focal or generalized epilepsy (n = 7; 14 treat-
ment periods due to cross-over design), three trials on cerebellar
stimulation for (multi)focal or generalized epilepsy (n = 22; 39
treatment periods), three RCTs on hippocampal DBS for medial
temporal lobe epilepsy (n = 15; 21 treatment periods), one trial on
nucleus accumbens stimulation (n = 4; eight treatment periods)
and one trial on responsive stimulation of the ictal onset zone (one
or two epileptogenic regions) (n = 191). In addition, the results
of two RCTs were mainly qualitatively described as the unavail-
ability of at least some exact figures prevented full inclusion in the
meta-analysis: one trial investigated centromedian thalamic DBS
for (multi)focal or generalized epilepsy (n = 13; 26 treatment peri-
ods), and another compared six months of hippocampal stimula-
tion to sham stimulation (n = 6). All trials compared active versus
sham stimulation. For reasons of clinical heterogeneity, we did not
combine results across different stimulated targets but pooled data
per individual target. As an increasing efficacy over time has been
reported in various trials (see also below) results were pooled per
three-month stimulation epochs.
Statistically significant effects on seizure freedom during the
blinded evaluation periods (BEPs) (one to three months except for
Wiebe 2013) could not be demonstrated for any target. However,
the small number of trials and patients cannot exclude the possi-
bility of clinically meaningful improvements for any target. Nev-
ertheless, it should be noticed that across all different trials only
three patients were seizure-free for the duration of the BEP. Two
of these belonged to the treatment group of the RCT evaluating
closed-loop stimulation of the ictal onset zone (OR 4.95; 95% CI
0.23 to 104.44) and another to the sham group of the trial on
anterior thalamic nucleus DBS (OR 0.33; 95% CI 0.01 to 8.36).
Besides seizure freedom, the 50% responder rate was our other pri-
mary outcome measure. Statistically significant effects on respon-
der rates after one to three months of stimulation could not be ob-
served for any target, but again the wide CIs cannot exclude clini-
cally meaningful changes for either the stimulation or the control
group. The fact that ORs were ≥ 1.00 in every single trial and >
1.00 for every target (except for centromedian thalamic DBS: OR
1.00; 95% CI 0.27 to 3.69) do not suggest equivalence. However,
apart from cerebellar (OR 2.43; 95% CI 0.46 to 12.84), nucleus
accumbens (OR 10.0; 95% CI 0.53 to 189.15) and six months of
hippocampal stimulation (OR 9.00; 95% CI 0.22 to 362.46), the
pooled effect estimates seem of little clinical importance for ante-
rior thalamic nucleus DBS (OR 1.20; 95% CI 0.52 to 2.80), one
to three months of hippocampal DBS (OR 1.20; 95% CI 0.36 to
4.01) and responsive ictal onset zone stimulation (OR 1.12; 95%
CI 0.59 to 2.11).
Statistically significant seizure frequency reductions due to one to
three months of active stimulation were demonstrated for anterior
thalamic DBS (-17.4%; 95% CI -31.2 to -1.0) hippocampal DBS
(-28.1%; 95% CI -34.1 to -22.2) and responsive ictal onset zone
stimulation (-24.9%; 95% CI -40.1 to -6.0). When interpreting
these results, one should keep in mind that these effect estimates
may be rather conservative due to observed trends for increasing
efficacy over time for anterior thalamic DBS (month one: -10%,
month three: -29%) and responsive ictal onset zone stimulation
(month one: -9%, month three: -32%) and a possible outlasting
effect in the stimulation ’off ’ period in Tellez-Zenteno 2006, a
cross-over trial on hippocampal DBSwithout any washout period.
Significant reductions could not be demonstrated for cerebellar (-
12.4%; 95%CI -35.3 to 10.6%), centromedian thalamic (+7.1%;
95% -44.1% to 58.2%; no effect in another cross-over trial (
Velasco 2000a), P = 0.23), nucleus accumbens (-33.4%; 95% CI
-100% to +49.8%) or six months of hippocampal (active -45%
versus sham +60%, P > 0.05) stimulation, although the small
number of patients and possible carryover effects in stimulation
’off ’ periods in Velasco 2000a (centromedian thalamic DBS), Van
Buren 1978 and Wright 1984 (cerebellar stimulation) preclude
more definitive judgements.
Only for anterior thalamic DBS were there statistically significant
differences in stimulation-related adverse events. These included
(treatment versus control group) depression (14.8% versus 1.8%;
P = 0.02), subjective memory impairment (13.8% versus 1.8%;
P = 0.03) and epilepsy-related injuries (7.4% versus 25.5%; P =
0.01). In addition, confusional state and anxiety were more fre-
quent, and standard stimulation parameters could be inappropri-
ate and increase seizure frequency in a small minority of patients.
52Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For the other targets, stimulation-related adverse events did not
occur (centromedian thalamic DBS, cerebellar and hippocampal
stimulation), or were not more prevalent in the treatment group
(responsive ictal onset zone and nucleus accumbens stimulation).
In general, however, the size of the included studies (in particu-
lar those on centromedian thalamic DBS, cerebellar, hippocam-
pal and nucleus accumbens stimulation) is too limited to make
more conclusive statements, although responsive ictal onset zone
stimulation seems to be well-tolerated. After initial concerns about
the slightly elevated sudden unexpected death in epilepsy patients
(SUDEP) rate mentioned in the first paper on responsive ictal
onset zone stimulation, long-term open-label follow-up has now
been reassuring both for anterior thalamic DBS and responsive
ictal onset zone stimulation.
The invasive nature of direct brain stimulation treatments resulted
in various surgery- or device-related adverse events. In the two
largest trials, asymptomatic intracranial haemorrhages were de-
tected postoperatively in 1.6% to 3.7% of participants and post-
operative implant or incision site infection occurred in 2.0% to
4.5% of participants, increasing to 9.4% to 12.7% after five years
of follow-up urging (temporary) hardware removal in the major-
ity of cases (Fisher 2010; Morrell 2011). Inadequate stereotactic
placement of electrodes needed repeated surgery in 8.2% of pa-
tients in Fisher 2010. Electrodemigration seems of particular con-
cern for cerebellar stimulation electrodes (n = 6/22). Other adverse
events included skin erosions, defective hardware, leakage of cere-
brospinal fluid, a lead causing pain and a subcutaneous seroma.
Cranial implantation of the neurostimulator in Morrell 2011 was
associated with implant site pain (16% in year one), headache
(11%), procedural headache (9%) and dysaesthesia (6%).
Statistically significant differences in formal neuropsychological
testing results could not be demonstrated on the group level for
any target. However, only for responsive ictal onset zone stimula-
tion is there reasonable evidence for the absence of adverse neu-
ropsychological sequelae. In contrast, the higher prevalence of de-
pression and subjective memory impairment with anterior thala-
micDBS (see above) and the lownumber of (neuropsychologically
tested) participants in studies on centromedian thalamic, cerebel-
lar, nucleus accumbens and hippocampal stimulation urge further
research. In this respect, it should be mentioned that one (n = 1/
6) patient receiving one to three months of hippocampal stimula-
tion showed objective worsening of memory scores (although he
reported a subjective memory improvement) and cognitive scales
assessing recall were generally lower after six months of active com-
pared to sham hippocampal stimulation (again, in contrast to in-
creased subjective QOLIE-89 memory and attention/concentra-
tion scales). In addition, results were often incompletely published
and the content of the neuropsychological test battery was not
clear for Wright 1984 (cerebellar stimulation) and Wiebe 2013
(six months of hippocampal stimulation).
Anterior thalamic nucleus DBS and responsive ictal onset zone
stimulation do not significantly improve or worsen quality of
life after three months of stimulation. With regards to the other
targets, only two trials on hippocampal stimulation (n = 9)
(Tellez-Zenteno 2006; Wiebe 2013) and one trial on nucleus ac-
cumbens stimulation (n = 4) (Kowski 2015) have formally evalu-
ated quality of life, while inWright 1984, the patients’ impressions
on cerebellar stimulation were described. Even for those targets,
however, data are too sparse to make any sensible conclusion.
Overall completeness and applicability of
evidence
Currently available evidence is far from complete. The complete-
ness and applicability of the evidence are highly dependent on its
quality. All factors limiting the quality of the evidence at the same
time limit, to a greater or lesser extent, the completeness and ap-
plicability of the evidence. In this review this is especially the case
for the small number of trials and patients in which deep brain
and cortical stimulation have been studied. Furthermore, only a
subset of trials have evaluated the impact of stimulation on the
neuropsychological outcome (nine out of 12 trials, with varying
degree of extensiveness of testing) and on quality of life (only five
to six out of 10 trials). More large and well-designed RCTs are def-
initely needed to demonstrate or exclude benefits and side effects
of invasive brain stimulation therapies. This applies to every single
target although there are important differences between the differ-
ent targeted structures. Taken together, evidence is most complete
for responsive ictal onset zone stimulation, followed by anterior
thalamic DBS, hippocampal DBS, cerebellar cortical stimulation,
nucleus accumbens DBS and finally centromedian thalamic DBS.
In addition, several other targets have yielded promising results
in uncontrolled open-label trials but have not been studied in
blinded and randomized conditions (or the results have not been
published yet), for example the subthalamic nucleus (Chabardes
2002; Wille 2011), the caudate nucleus (Chkhenkeli 2004) and
the motor cortex (Elisevich 2006).
Trials on cerebellar and centromedian thalamicDBS includedboth
patients with (multi)focal epilepsy and patients suffering from
generalized epilepsy. In contrast, trials on anterior thalamic DBS,
hippocampal DBS, nucleus accumbens DBS and responsive ictal
onset zone stimulation recruited only (multi)focal, temporal lobe,
focal and focal (one or two epileptogenic regions) epilepsy patients,
respectively. Although this makes sense for hippocampal DBS and
responsive ictal onset zone stimulation, further studies are needed
to determine if anterior thalamic or nucleus accumbensDBS could
also be useful for generalized epilepsy patients.
Only Velasco 2000a (centromedian thalamic DBS) recruited a
substantial number of minors; 5/13 or 7/15 patients were between
four and 15 years old. Authors reported that skin erosion may be
of particular concern in children under eight years of age as a re-
sult of the relatively large size of the pulse generator and the leads,
originally designed for an adult population. Of the other trials,
Fisher 1992 (centromedian thalamic DBS), Velasco 2005 (cere-
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bellar stimulation) and Velasco 2007 (hippocampal stimulation),
each included one 14 to 16 year old adolescent, whereas in all
other trials all patients were adult. Therefore, current evidence is
basically limited to adult refractory epilepsy patients. Fisher 2010
(anterior thalamic DBS) and Wiebe 2013 (hippocampal DBS, six
months) only allowed adults with normal mental capacities (in-
telligence quotient (IQ) > 70). These are important restrictions
which should be taken into consideration when evaluating the
overall completeness and applicability of current evidence. Fur-
thermore, evidence is limited to stimulation parameters or param-
eter strategies used in the respective trials and to the RNS®System
(NeuroPace, Mountain View, CA) for responsive ictal onset zone
stimulation.
Besides the low number of trials and patients, the limited duration
of the BEPs (one to three-month stimulation ’on’ periods in all but
one small trial on hippocampal stimulation) represents a second
major gap in the available evidence. This seems of particular con-
cern for invasive brain stimulation therapies as increasing efficacy
over time has been reported during BEPs in some RCTs (Fisher
2010; Morrell 2011), during open-label follow-up after comple-
tion of RCTs (Fisher 2010; Morrell 2011; Velasco 2007), and in
some small open-label trials (Franzini 2008; Khan 2009). Various
RCTs have followed their patients for many months or years after
the randomized and blinded phase had been finished and it may
be relevant for the reader to cite the results they reported to illus-
trate the shortcomings of today’s evidence. Fisher 2010 (anterior
thalamic DBS) reported seizure freedom in 0% at the end of the
BEP (n = 54), in 2.0% at the end of the ensuing nine month open-
label period (stimulation parameters adjusted on an individual ba-
sis, antiepileptic drug (AEDs) unchanged) (n = 99) and 11 of 83
(13.3%; 10% of all implanted participants) participants that were
still in the trial after five years of follow-up were seizure-free for at
least six months at the five-year assessment (changes in the AED
regimen were allowed). Responder rates were 30%, 43% (n = 99
participants with at least 70 diary days) and 68% (n = 59) respec-
tively, with mean seizure frequency reductions of -40%, -41% and
-69%. Fisher 1992 (centromedian thalamicDBS) observed a 50%
seizure reduction in 3/7 patients (2/7 during the BEP) after an ad-
ditional three to 13 months of open-label follow-up (24 hours of
stimulation per day), the mean reduction in seizure frequency be-
ing -30% (-7% during the BEP). With regards to the same target,
Velasco 2000a reported seizure freedom in 1/13 patients (7.7%), a
85% responder rate and a mean 72% seizure frequency reduction
at maximum follow-up (12 to 94 months). Velasco 2005 (cere-
bellar stimulation) showed a 50% improvement in 2/3 patients
during the BEP (mean seizure frequency reduction of 56%) and
in 4/5 patients after 12 to 24 months follow-up (68% reduction).
The most spectacular improvement was found in Velasco 2007
(hippocampal stimulation) who reported seizure freedom in 4/9
patients after 18 months follow-up (0/4 during the BEP), a 50%
reduction in all nine patients (1/4 during the BEP) and a mean
seizure frequency reduction of -85% (-30% during the BEP). Fi-
nally, three-month seizure freedom, the 50% responder rate and
the median reduction in seizure frequency after two years of open-
label follow-up (n = 174) in Morrell 2011 (responsive ictal onset
zone stimulation) were 7.1%, 55% and 53% compared to 2.1%,
29% and 37.9%, respectively during the BEP. Notwithstanding
that these open-label data often show very favourable results, we
would like to emphasize that at the same time these are at high
risk of bias, including but not limited to placebo effects and im-
provements due to changes in AED or spontaneous evolution of
the disease (see also below). Only one small RCT with longer than
three months of active stimulation has been published to date and
data are too sparse to make any sensible conclusion. More RCTs
with a more extensive BEP are needed to unequivocally determine
whether and to what extent the efficacy of invasive brain stimula-
tion treatments increases over time. Meanwhile, we pooled results
per three-month stimulation epochs and reported for each indi-
vidual study if and to what extent such an increasing efficacy over
time was observed during the BEP.
Finally, although three RCTs are currently recruiting patients to
compare deep brain stimulation (DBSI with resective surgery,
’usual’ treatment and vagus nerve stimulation, respectively, all tri-
als published so far have compared active to sham stimulation only.
Quality of the evidence
For a more detailed assessment of the quality of the evidence
see Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6.
Several factors affect the quality of currently available evidence.
Of major importance is the limited number of trials, which in
addition mostly have very small sample sizes. Although this holds
true for every target, this is of particular concern for centromedian
thalamic DBS, cerebellar, hippocampal and nucleus accumbens
stimulation. Moreover, neuropsychological testing and assessment
of quality of life were only performed in a subset of trials. These
limitations make it harder to demonstrate the statistical signifi-
cance of clinically meaningful differences or to exclude the possi-
bility of such improvements when clinically non-meaningful dif-
ferences are found.
In five cross-over RCTs on cerebellar (n = 2/3), centromedian tha-
lamic (n = 1/2), hippocampal (n = 1/4) and nucleus accumbens (n
= 1/1) DBS, there was no or a possibly too short washout period
before outcome measures were evaluated during stimulation ’off ’
periods (Kowski 2015; Tellez-Zenteno 2006; Van Buren 1978;
Velasco 2000a; Wright 1984). As some or all patients had pre-
viously been stimulated and findings consistent with a carryover
effect of invasive neurostimulation have been reported in the liter-
ature (Andrade 2006; Lim 2007; McLachlan 2010; Velasco 2007;
Vonck 2013), this may mask or reduce possible beneficial or ad-
verse effects of stimulation. In addition, changes in the antiepilep-
tic drug (AED) regimen in3/4patients during the trialmay further
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have influenced the results of Tellez-Zenteno 2006 (hippocampal
stimulation, one to three months stimulation). A sensitivity anal-
ysis excluding those four trials did not change our main conclu-
sions, although this did result in more pronounced estimates of
stimulation effects for cerebellar (responder rate OR 8.33; 95%
CI 0.22 to 320.4; seizure frequency reduction -36.7%; 95% CI -
95.5 to 21.1) and hippocampal stimulation (one to three months
of stimulation) (responder rate OR 1.75; 95% CI 0.22 to 14.1;
if also larger standard error for McLachlan 2010 for seizure fre-
quency reduction of -45.7%; 95% CI -85.9 to -5.5). Obviously,
in the case of a clear absence of any effect (for example, on seizure
freedom), the possibility of an outlasting effect in these trials does
not complicate interpretation of the results.
The quality of the evidence on centromedian thalamicDBS is very
low. Two RCTs were identified in the literature. However, one trial
(Velasco 2000a) (n = 13) evaluated stimulation ’off ’ periods after
six to nine months of stimulation without any washout period.
The trial only studied two outcome measures (seizure frequency
reduction and adverse events), compared blinded stimulation ’off ’
to the three months preceding it (instead of consistently compar-
ing outcomes to blinded stimulation ’on’ periods), and the non-
reporting of exact figures prevented inclusion in themeta-analysis.
In the second trial (Fisher 1992), seven patients received only two
hours of stimulation per day and incomplete outcome data could
have biased the results.
Risk of bias was present or unclear in various other trials. It was
unclear if the neuropsychological outcome in Van Buren 1978
(cerebellar stimulation) was assessed during blinded or unblinded
evaluation periods; methods for random sequence generation and
allocation concealment were not well-described in Tellez-Zenteno
2006 (hippocampal stimulation, one to three months) andWright
1984 (cerebellar cortical stimulation), and evidence of selective
reporting was present in two other trials (Fisher 2010 for anterior
thalamic DBS; McLachlan 2010 for hippocampal DBS, one to
threemonths), althoughwe think the latter has not greatly affected
the results of this review. Some trials also reported their results in-
completely (mainly neuropsychological testing results) and with-
out evidence for selective reporting (Fisher 1992 for centrome-
dian thalamic DBS; Tellez-Zenteno 2006 for hippocampal DBS;
Wright 1984 for cerebellar cortical stimulation).Wiebe 2013 (hip-
pocampal stimulation, six months) was only published as an ab-
stract with many details missing for a more in depth methodolog-
ical assessment or for full incorporation in the quantitative syn-
thesis.
As no more than three trials could be identified for each individual
target (per three-month epoch in case of hippocampal stimula-
tion), we were not able to assess the risk of publication bias.
For more detailed assessments of the quality of the evidence per
outcome parameter and per stimulation target we refer to the
’Summary of findings’ tables. In general, the quality of the evi-
dence was rated as moderate to high for responsive ictal-onset zone
stimulation and anterior thalamic DBS. The two trials evaluating
these targets were well-designed and each included more than 100
participants. Nevertheless, more trials are needed to obtain high-
quality evidence on all outcome parameters. The quality of the
evidence on hippocampal DBS (one to three months of stimula-
tion) and cerebellar stimulation is limited by some potential biases
in the individual trials (see above) and the overall low number of
participants, ranging from very low tomoderate depending on the
outcome parameter taken into consideration. Nucleus accumbens
and hippocampal (four to six months) DBS were each studied in
only one very small trial. For nucleus accumbens DBS, this trial
was methodologically well-designed resulting into low-quality evi-
dence overall. As details needed for full methodological assessment
of the trial on hippocampal DBS (four to six months) are missing,
the quality of the evidence was rated as very low. For reasons out-
lined above, the quality of the evidence on centromedian thalamic
DBS is only very low.
Potential biases in the review process
When performing meta-analyses, the results of various trials are
pooled yielding pooled treatment effects of which the precision
and accuracy depend on the quality of the individual trials. There-
fore, pooling results of various trials including some trials with a
risk of bias adds some risk of bias to the review process. For this
specific review, besides of course other types of bias, this remark
particularly holds true for the inclusion of four cross-over trials
without any washout period as outlasting effects after neurostim-
ulation treatments have been described (although still being con-
troversial). We therefore performed a sensitivity analysis excluding
these trials. Although this resulted in a slightly more favourable
effect estimate, it did not change the review’s main conclusions.
As empty cells hinder calculation of odds ratios (seizure freedom,
responder rate), it is customary to add +0.5 to each cell if appli-
cable (Deeks 2011). However, given the small number of patients
included in most trials, this approach may have biased our results.
A sensitivity analysis adding +0.25 instead of +0.5 did not change
our main conclusions, but did increase the degree of uncertainty
around the effect estimates for seizure freedom.
For cerebellar and hippocampal stimulation, results of BEPs
with different durations of active stimulation BEP (one to three
months) were pooled. As some reports have suggested increasing
efficacy over time, this may have lead to an overestimation com-
pared to the one-month treatment effect and an underestimation
compared to the three-month treatment effect. We therefore refer
to the observed treatment effects as occurring after ’one to three
months’ of stimulation. In addition, we described in the text if and
to what extent increasing efficacy over time was observed during
the BEP of each individual trial. As outlined in the previous ver-
sion of this review, results of RCTs with longer BEPs are pooled
per three-month epochs. So far, only one very small RCT on hip-
pocampal DBS (Wiebe 2013) had a BEP with longer than six
months of active stimulation. A sensitivity analysis combining all
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trials on hippocampal DBS irrespective of the BEP duration did
not change the conclusions of this review.
Agreements and disagreements with other
studies or reviews
Although various non-systematic reviews have been published the
past years, to our knowledge this is the first systematic review on
RCTs studying deep brain and cortical stimulation. The non-sys-
tematic reviews also discussed uncontrolled, often unblinded tri-
als. These uncontrolled and unblinded trials have often yielded
remarkably more favourable results than the RCTs. Besides the
placebo effect, several other factors may account for this dis-
crepancy. First of all, RCTs compare real stimulation to sham
stimulation, whereas in uncontrolled trials baseline seizure fre-
quency is taken for the reference data. Accordingly, seizure fre-
quency reductions due to (temporary) implantation effects (Fisher
2010; Hodaie 2002;Lim 2007; Morrell 2011) and microlesions
resulting from electrode insertion (Boëx 2011; Katariwala 2001;
Schulze-Bonhage 2010) contribute to the observed treatment ef-
fects in uncontrolled trials, whereas they do not in RCTs. Sec-
ond, uncontrolled trials have longer follow-up periods and in-
creasing efficacy over time has been suggested (see above). How-
ever, one should realize that medication-induced and spontaneous
improvements can be quite impressive on a group level (Neligan
2012; Selwa 2003) and therefore are likely to contribute to the
more favourable results obtained in uncontrolled trials. Third, the
cross-over design used in four RCTs without any washout period
may undervalue the efficacy of neurostimulation treatments, as
discussed above. Finally, further improvements due to optimiza-
tion of stimulation parameter settings have been reported (Boëx
2011; Vonck 2013; Wille 2011) and uncontrolled trials often use
variable parameter settings, whereas RCTs have a fixed stimulation
protocol. In conclusion, it is likely that several factors overestimate
the efficacy of invasive neurostimulation in uncontrolled trials,
whereas some others may contribute to an underestimation of its
full potential in RCTs.
Vagus nerve stimulation is another type of invasive neurostimu-
lation which nowadays has become routinely available in many
epilepsy centres worldwide. Although the treatment effects re-
ported in two large RCTs (-12.7% and -18.4%) (Handforth 1998;
VNS Study Group 1995) were similar or slightly inferior to those
of anterior thalamic DBS (-17.4%), hippocampal DBS (-28.1%)
and closed-loop ictal onset zone stimulation (-24.9%), a Cochrane
Review on vagus nerve stimulation did demonstrate a significantly
higher responder rate with vagus nerve stimulation using a high
stimulation paradigm (’standard stimulation’) compared to a low
stimulation paradigm (’sham stimulation’) (RR1.73; 95%CI 1.13
to 2.64) (Panebianco 2015). As outlined above, we did not find
such a significant improvement for any intracranial target.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Making general recommendations about the practical usefulness
of intracranial neurostimulation treatments implies making trade-
offs between potential benefits and harms, costs, healthcare re-
sources and alternative treatments such as newly developed drugs,
the ketogenic diet, vagus nerve stimulation and epilepsy surgery.
We believe such a trade-off should be made on an individual pa-
tient basis, differing from country to country, and therefore goes
beyond the scope of this review. In this section we will conse-
quently only focus on available evidence on the benefits and harms
of intracranial neurostimulation treatments.
Of all potential intracranial targets, only six have been studied in
randomized and double-blind conditions so far. The main limi-
tation is the number of trials, which in addition mostly have very
small sample sizes and are of short duration. Nevertheless, high-
quality evidence is available that three months of anterior thala-
mic nucleus deep brain stimulation (DBS) and responsive ictal
onset zone stimulation can reduce seizure frequency in refractory
(multi)focal epilepsy patients, whereas moderate-quality evidence
shows the same for one to three months of hippocampal DBS
in refractory temporal lobe epilepsy patients. However, compared
to sham stimulation, the observed improvements were moder-
ate (ranging between 17% and 28%) and there is no evidence
for either a clinically or statistically significant impact on seizure
freedom, responder rate or quality of life (although anterior tha-
lamic DBS did reduce epilepsy-associated injuries). Given these
rather moderate improvements, possible harms should be care-
fully considered. Anterior thalamic DBS and responsive ictal on-
set zone stimulation were in general safe and well-tolerated, how-
ever, anterior thalamic DBS was associated with statistically sig-
nificant higher incidences of self-reported depression (no group-
level changes in objective measures) and subjective memory im-
pairment (no group-level changes in objective measures) besides
statistically non-significant increases in anxiety, confusional state
and seizure frequency in somepatients.HippocampalDBS seemed
safe and relatively well-tolerated but these findings should be con-
firmed in more and larger trials, with particular concern for mem-
ory impairment. Besides stimulation-related side effects, the in-
vasive nature of these treatments resulted in soft tissue infections
and asymptomatic intracranial haemorrhages, but no permanent
symptomatic sequelae resulting from electrode implantation were
reported. Finally, when balancing benefits and risks of the afore-
mentioned treatments, one should keep in mind that many of the
patients included in the trials on intracranial neurostimulation had
previously turned out to be refractory to various other treatments
(including antiepileptic drugs (AEDs), resective surgery and vagal
nerve stimulation) and had no other evident or ideal treatment
options.
Besides the three targets mentioned in the previous paragraph,
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centromedian thalamic nucleus DBS, cerebellar cortical stimula-
tion and nucleus accumbens DBS have been studied in random-
ized controlled trials (RCTs) but no statistically significant effects
were found in these small trials, which in addition often suffered
from various other limitations. In conclusion, there is insufficient
evidence to accept or refute their efficacy or tolerability. No tri-
als comparing intracranial stimulation to ’best medical practice’,
surgery or vagus nerve stimulation have been published yet.
Implications for research
Given the limited number of RCTs identified in the literature,
more double-blind randomized controlled clinical trials are re-
quired to provide evidence on the efficacy and safety of intracranial
neurostimulation treatments for refractory epilepsy. These trials
should preferably consider the following points.
• Include large numbers of patients. However, given the
limited number of patients included in RCTs so far, even smaller
trials would increase the available evidence and are therefore
worthwhile to be undertaken. For the same reason, results of
preliminary terminated trials (e.g. due to insufficient patient
enrolment) should be published. Given the difficulties in patient
recruitment, multicentre participation may be recommended.
• Make interpretation easier by avoiding possible outlasting
effects of stimulation. The most straightforward way to do so is
using a parallel study design. When a cross-over design is used,
due to difficulties in patient recruitment, a washout period
should be introduced (e.g. three months without stimulation
after three months of stimulation).
• Make interpretation easier by avoiding possible
implantation effects (as in Fisher 2010 and Morrell 2011) by
using a sufficient time window (e.g. four months) between
electrode implantation and the start of the blinded evaluation
period.
• Assess and report all significant outcome variables,
including seizure freedom, responder rate, seizure frequency
reduction, adverse events, neuropsychological outcome and
quality of life.
Additionally, there is a need for RCTs comparing intracranial neu-
rostimulation treatments to ’best medical practice’ (including va-
gal nerve stimulation); reported trends for increasing efficacy over
time should be verified in randomized and if possible double-blind
conditions (comparison to ’best medical treatment’ could over-
come ethical issues); and, finally, more efforts should be made to
identify optimal stimulation parameter paradigms, which could
be patient-specific.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fisher 1992
Methods Double-blind balanced cross-over randomized controlled trial
• prospective baseline seizure frequency recording for several months
• electrode implantation
• stimulators OFF until randomization 1 to 2 months postoperatively
• cross-over design of 3-month treatment blocks (receiving each treatment once)
with a 3-month washout phase
• long-term open-label follow-up with stimulation ON in all patients
Participants n = 7, 42.9% male, mean age 28.0 years (range 16-41 y), duration of epilepsy ranged
from 14 to 29 years
2 patients with focal epilepsy (one with and one without secondary generalization), 5
patients with generalized epilepsy (2/5 had Lennox-Gestaut syndrome); poor candidates
for resective surgery
mean baseline seizure frequency of 23.4 (SD 15.9) seizures per month
Interventions Active: bilateral stimulation of the centromedian thalamic nucleus
• output voltage was set to half the sensory threshold and ranged from 0.5 to 10 V
• stimulation frequency of 65 Hz
• pulse width 90 µsec
• 1 minute of bipolar stimulation each 5 minutes for 2 hours per day
Control: sham stimulation (output voltage set at zero)
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (spontaneous reporting, postoperative CT scan)
(5) Neuropsychological outcome [tests of general intelligence (WAIS-R), speech and
language functions (the Boston Naming Test, the Controlled Oral Word Association
Test, a written description of theCookie Theft Picture from the BDAE), visual and verbal
memory functions (the Weschler Memory Scale, the Rey Auditory Verbal Learning Test
with delayed recall and the Warrington Recongnition Memory Test (words and faces)
), parietal lobe-type functions (the Rey Osterreith Complex Figure Test with delayed
recall), frontal lobe-type functions (the Wisconsin Card Sorting Test) and psychomotor
functions (the Trial Making Test (A and B) and the Perdue Grooved Pegboard)]
Notes The study was supported by Medtronic Inc. (Minneapolis, MN) who also donated
hardware for the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Fisher 1992 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized to either
stimulation ON for A and OFF for B or to
stimulation OFF for A and ON for B”
Personal communication: “envelopes were
chosen at random picking from a pile for
each patient”
Allocation concealment (selection bias) Low risk Quote: “randomization order was provided
in a sealed envelope”
Personal communication: sealed and se-
quentially numbered envelopes, unclear if
they were specific opaque envelopes (study
was conducted more than 20 years ago);
however, randomization was performed by
a third person, not involved in selecting,
treating or evaluating patients
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither patient, families, treat-
ing medical team nor data analysts knew
whether the stimulator was ON or OFF
during phases A and B”; “patients could
not detect when stimulation was ON or
OFF”; “stimulation was set to half the sen-
sory threshold”; “a single unblinded in-
dividual was aware of treatment parame-
ters and tested stimulator function at each
monthly visit”
Personal communication: the single un-
blinded individual was not involved in
treating or evaluating patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above; seizure frequencywas
recorded in a seizure calendar
Incomplete outcome data (attrition bias)
All outcomes
High risk One of the two patients who improved
markedly with centromedian thalamic
stimulation experienced several episodes of
multiple daily seizures in the washout pe-
riod and therefore was dropped from the
blinded protocol and stimulation was rein-
stalled. As there were only seven patients,
with only two responders, this one patient
represents a significant proportion
Selective reporting (reporting bias) High risk - The results of a statistical analysis includ-
ing all patients, to evaluate the efficacy of
the intervention on seizure frequency, are
not reported. Instead, only the results of
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Fisher 1992 (Continued)
an analysis including all patients with (pri-
marily or secondarily) generalized seizures
are presented (thus excluding one patient
with only complex partial seizures). This
was not prespecified in the Methods sec-
tion. However, as all raw data are present
in the article, all information necessary for
this review is available
- Concerning the neuropsychological out-
come: “multivariate analysis with repeated
measures showed no significant differences
in any measure between baseline, placebo
(OFF) and treatment (ON) conditions”
Personal communication: exact figures no
longer available
Comment: no exact figures were reported,
probably because there was too much data
for a journal article (rather incomplete than
selective reporting)
Outlasting effect due to prior stimulation Low risk Comment: cross-over design, but with a 3-
month washout period
Anti-epileptic drug policy Low risk Quote: “AED dosages were kept constant
throughout the study”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Fisher 2010
Methods Multicentre, double-blind, parallel-design, randomized controlled trial:
• 3-month baseline period
• electrode implantation
• 1 month of recovery
• 3-month blinded randomized phase during which half of participants received
stimulation and half did not; stimulation parameters and AEDs were kept constant
• 9-month open-label unblinded stimulation in all patients; AEDs were kept
constant but limited stimulation parameter changes were allowed
• long-term follow-up unblinded stimulation in which AEDs and stimulation
parameters could vary freely
Participants n = 109, 50.0% male, mean age 36.1 years (inclusion criterion:18-65 y), mean duration
of epilepsy was 22.3 (SD 13.3) years;
all patients suffered from partial-onset epilepsy (partial seizures and/or secondarily gen-
eralized seizures), IQ > 70 in all patients, 24.5% and 44.5% had prior resection and
vagus nerve stimulation, respectively;
median baseline seizure frequency of 19.5 seizures per month (inclusion criterion: ≥6
seizures)
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Fisher 2010 (Continued)
Interventions Active (n = 55): bilateral anterior thalamic nucleus stimulation
• stimulation intensity was set at 5 V
• stimulation frequency of 145 Hz
• pulse width of 90 µsec
• intermittent (1 min ON, 5 min OFF) monopolar cathodal stimulation
Control (n = 54): sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (based on spontaneous reporting by patients, postoperative MRI)
(5) Neuropsychological outcome (attention, executive function, verbal memory, visual
memory, intelligence, expressive language, depression, tension / anxiety, total mood
disturbance, confusion, subjective cognitive function)
(6) Quality of life (QOLIE-31)
Notes The study was supported by Medtronic Inc. (Minneapolis, MN)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was done by a cen-
tral statistical site, using random numbers
tables, a one-to-one allocation to active
stimulation versus control, balanced at each
study site and with no weighting for any
subject characteristics”
Allocation concealment (selection bias) Low risk Quote: “randomization was done by a cen-
tral statistical site”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “no care or assessment personnel
knew the voltage settings” and “participants
were unaware of their treatment group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “no care or assessment personnel
knew the voltage settings”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 108 out of 109 randomized patients com-
pleted the blindedphase.One patient (con-
trol group) developed an infection requir-
ing explant, but was included in all analyses
as randomized
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Fisher 2010 (Continued)
Selective reporting (reporting bias) High risk Quote: “Changes in additional outcome
measures did not show significant (...) dif-
ferences during the double-blind phase,
including 50% responder rates, Liverpool
Seizure Severity Scale and Qulatiy of Life
in Epilepsy scores”
Comment 1: not all available (as can be
deducted from the protocol on clinical-
trials.gov or the online “Medtronic DBS
therapy for epilepsy sponsor information”,
www.fda.gov) outcome measures (includ-
ing seizure-free days and seizure-free inter-
vals) were mentioned or reported in the pa-
per in Epilepsia
Comment 2: different analyses were per-
formed; one patient of the treatment group
who experienced a marked seizure fre-
quency increase was excluded (not prespec-
ified) and another patient with only 66
of 70 protocol-required diary days was in-
cluded (ITTanalysis) in the analysis used to
estimate the treatment effect for the entire
BEP (and not per month). As there were
good reasons to do so and the results of
the other prespecified analysis were also re-
ported, we do not consider this as a major
source of selective reporting
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized phase
Anti-epileptic drug policy Low risk Quote: “medication were kept constant
during the 3-month blinded phase and the
9-month unblinded phase”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
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Kowski 2015
Methods Double-blind cross-over randomized controlled trial
• 3-month baseline period
• bilateral implantation of electrodes in the nucleus accumbens and in the anterior
thalamic nucleus (4 electrodes in total)
• stimulation OFF during the first postoperative month (note: testing for side
effects of stimulation day 3 and day 7 of electrode implantation)
• 3-month nucleus accumbens stimulation ON / OFF (randomized)
• 1-month washout period
• 3-month nucleus accumbens stimulation OFF / ON (randomized)
• 1-month washout period
• 3-month open-label period with bilateral anterior thalamic DBS in all patients,
and additional bilateral nucleus accumbens DBS if the patient had experienced a ≥
50% reduction in seizure frequency during the randomized double-blind phase of the
trial
Participants n = 4, 25% male, mean age 36.7 years (range 28-44 y), mean duration of epilepsy was
12.5 years (range 9-15 years); all patients suffered from pharmaco-resistant partial-onset
epilepsy, resection or further invasive assessment had been dismissed or surgery had been
unsuccessful, patients preferred participation in the study aboveVNSor standard anterior
thalamic DBS treatment, region of seizure onset was bilateral frontal in 2 patients and
bilateral temporal in the 2 other patients
mean baseline seizure frequency of 7.3, 4.3, 10.5 and 20.3 ’disabling’ seizures (complex
partial or generalized tonic-clonic seizure) per month (inclusion criterion: at least 3
’disabling’ seizures every 4 weeks during the 12-week baseline period), 1 of the patients
also experienced 99.2 simple partial seizures per month
Interventions Active: bilateral nucleus accumbens stimulation
• stimulation intensity was set at 5 V
• stimulation frequency of 125 Hz
• pulse width of 90 µsec
• intermittent (1 min ON, 5 min OFF) bipolar stimulation with the most centrally
located contacts selected as cathode aiming for stimulation of the medial, central and
lateral part of the nucleus accumbens
Control: sham stimulation
Note: all patients had quadripolar electrodes implanted in both the nucleus accumbens
and the anterior nucleus of the thalamus
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events
(5) Neuropsychological outcome (Test of Attentional Performance, Trail Making Test,
Performance Evaluation System subtest 7 (Leistungspruefungssystem (LPS), subtest 7)
, d2-Attention Stress Test, ’Regensburger’ Word Fluency Test, Hamasch 5-Point Test,
Verbal Learning and Memory Test, Wechsler Memory Scale-Revised, and the Boston
Naming Test; during the visits (V1-V8) different tests were done; Beck-Depression-
Inventory Version IA; Mini International Neuropsychiatric Interview)
(6) Quality of life (QOLIE-31-P)
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Kowski 2015 (Continued)
Notes Institutional budget, no external funding for this trial; several authors had previously
received reimbursement for travelling expenses and/or speaker honoraria fromMedtronic
Inc. (Minneapolis, MN) and 1 author also served as consultant for Medtronic Inc.
(Minneapolis, MN) and Sapiens Inc. (California, CA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the sequence was randomized us-
ing an internet-randomizing tool (www.
random.org)”
Allocation concealment (selection bias) Low risk Quote: “individuals not involved in the
study performed allocation process”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “individuals not involved in the
study performed allocation process and
change of stimulation parameters. Pa-
tients and assessing epileptologists re-
mained blinded until start of the open-la-
bel phase”; “none of the patients reported
to notice nucleus accumbens, anterior tha-
lamic nucleus or combined nucleus accum-
bens / anterior thalamic nucleus stimula-
tion”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “individuals not involved in the
study performed allocation process and
change of stimulation parameters. Pa-
tients and assessing epileptologists re-
mained blinded until start of the open-la-
bel phase”; “none of the patients reported
to notice nucleus accumbens, anterior tha-
lamic nucleus or combined nucleus accum-
bens / anterior thalamic nucleus stimula-
tion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 4 patients underwent electrode
implantation for DBS and all outcomes are
reported for all patients
Selective reporting (reporting bias) Low risk Comment: selective reporting very un-
likely. The study was registered in the
German Trial Registry (http://www.drks.
de/DRKS00003148). All outcomes men-
tioned in this protocol are reported on in
the published paper (including online sup-
72Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kowski 2015 (Continued)
porting information) in a very detailed and
extensive way. The only shortcoming is the
fact that specific details on the measure-
ments that were planned to be used to assess
the outcomesmentionedwere not provided
in the protocol. However, the published re-
port includes all expected outcomes
Outlasting effect due to prior stimulation Unclear risk Comment: cross-over study with a 1-
month washout period after 3 months of
stimulation which might be too short al-
though we recognize that clear judgements
on this issue are difficult to make and arbi-
trary
Anti-epileptic drug policy Low risk Quote: “antiepileptic drug dosages re-
mained unchanged in all patients. Further-
more, serum concentrations of antiepilep-
tic drugs (except retigabine/ezogabine)
were determined at each visit and showed
no clinically relevant variability”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
McLachlan 2010
Methods Double-blind balanced cross-over randomized controlled trial
Total duration 15 months:
• implantation of the electrodes
• 3-month baseline period without stimulation
• 3 months ON / OFF (randomized)
• 3-month washout period (if ON)
• 3 months OFF / ON (opposite of month 4-6)
• 3-month washout period (if ON)
Participants n = 2, 50% male, 45 and 54 years old, duration of epilepsy was 15 and 29 years;
medically intractable focal epilepsy, poor candidates for resective surgery on the basis
of independent bitemporal originating seizures, normal MRI in patient 1 and bilateral
hippocampal sclerosis in patient 2;
baseline seizure frequency of 32 and 16 seizures per month
Interventions Active: bilateral hippocampal stimulation
• output voltage was determined by starting at 0.5V and increasing until symptoms
occurred, the voltage was then decreased until it was subthreshold for conscious
appreciation
• stimulation frequency of 185 Hz
• pulse width 90 µsec
• continuous monopolar bilateral stimulation
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McLachlan 2010 (Continued)
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (standard questionnaire)
(5) Neuropsychological outcome (objective memory: Hopkins Verbal Learning Test-
Revised and the Brief visuospatial Memory Test-Revised; subjective memory: Memory
Assessment Clinic Self-Rating Scale)
Notes No external funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization of the first treat-
ment”
Personal communication: computer-gen-
erated randomized sequences
Allocation concealment (selection bias) Low risk Quote: “randomization of the first treat-
ment was determined independently by the
research unit and placed in a sealed enve-
lope”
Personal communication: sealed, double-
opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “both the treating neurologist and
patient were blind to the stimulator sta-
tus”; “the voltage was decreased until it was
subthreshold for conscious appreciation so
that patients were unaware of the status of
the stimulator”; “neither patient was able to
accurately assess when the stimulator was
ON or OFF”; “the envelope with the stim-
ulation sequence was given to a neurosur-
geon not involved in outcome assessment
who turned the device ON or OFF at each
3-month visit”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above, only one neurosur-
geon, not involved in outcome assessment,
knew the stimulator status
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: for the ON- and OFF-period
all data were available; only the objective
memory data of one patient in the washout
74Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McLachlan 2010 (Continued)
period were not available
Selective reporting (reporting bias) High risk Quote: in theMethods section: “differences
in mean monthly seizure frequency were
assessed using repeated measures ANOVA”
; in the Results section: “ANOVA re-
vealed a significant difference in the me-
dian monthly seizure frequency between
the four epochs (p<0.01)”
Comment: unclear why (only) the median
monthly seizure frequency was used in this
analysis instead of all available data, i.e. to-
tal number of seizures (or mean monthly
seizure frequency, as announced in the
methods section and aswas indeed reported
as a descriptive variable to quantify the
treatment effect); however, as all available
individual patient data were provided to us
by the author, this had no influence on this
review
Outlasting effect due to prior stimulation Low risk Comment: cross-over study, but with a 3-
month washout phase
Anti-epileptic drug policy Low risk Quote: “(...) antiseizure drugs, which re-
mained unchanged during the study”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Morrell 2011
Methods Multicentre, double-blind, parallel-design, randomized controlled trial:
• 12-week baseline period
• implantation of the electrodes: 1 or 2 recording and stimulating depth or subdural
cortical strip leads were surgically placed in the brain according to the seizure focus
• 4-week postoperative stabilization period: the neurostimulator was programmed
to sense and record the electrocorticogram, but not to deliver stimulation
• randomization
• 4-week stimulation optimization period: neurostimulators only of patients in the
treatment group were programmed to deliver stimulation (not in the sham group)
• 12-week blinded evaluation period (BEP): treatment versus sham group
• open-label evaluation period: all patients were able to receive responsive
stimulation
Participants n = 191, 52% male, mean age 34.9 years (range 18-66 y), duration of epilepsy ranged
from 2 to 57 years
all patients suffered from medically intractable partial onset seizures, 45% had only one
seizure focus and 55% had two seizure foci, 32 and 34% had prior therapeutic surgery
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and vagus nerve stimulation, respectively
mean baseline seizure frequency of 1.2 (SD 2.2) seizures per day (inclusion criterion ≥3
seizures per month)
Interventions Active (n = 97): stimulation directly to the seizure focus in response to epileptiform
electrographic events (device: RNS® System, NeuroPace, Mountain View, CA)
• stimulation parameters were determined individually during the 4-week
stimulation optimization period
• amplitude (range used): 0.5 - 12 mA
• frequency (range used): 2-333 Hz
• pulse width (range used): 40-520 µsec
• responsive stimulation, burst duration (range used): 10-1000 msec
Control (n = 94): sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (as assessed by clinicians, additionally vital signs were collected and a
neurological examination was conducted at every office appointment)
(5) Neuropsychological outcome [visual motor speed (trailmaking part A and B), motor
speed / dexterity (grooved pegboard, dominant and nondominant), auditory attention
(Wechsler Adult Intelligence Scale (WAIS)-III digit span), general verbal ability (WAIS-
III information), general visuospatial ability (WAIS-III block design), verbal memory
(Rey Auditory Verbal Learning Test (RAVLT) I-V, VII (delayed recall) and memory
recognition), visuospatial memory (Brief Visuospatial Memory Test-Revised (BVMT-
R) total recall, delayed recall and recognition discrimination index), language (Boston
Naming Test (60 items) spontaneous with semantic clue; Delis-Kaplan Executive Func-
tion System (D-KEFS) verbal fluency test, condition 1: letter fluency), design fluency
(D-KEFS design fluency, total composite); mood inventories included the Beck Depres-
sion Inventory II (BDI-II) and the Center for Epidemiologic Studies Depression Scale
(CES-D)]
(6) Quality of life (QOLIE-89)
Notes The study was sponsored by NeuroPace Inc., Mountain View, California (USA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “subjects were assigned 1:1 to treat-
ment or shamgroups using an adaptive ran-
domization algorithm controlling for in-
vestigational site, location and number of
seizure onsets and prior epilepsy surgery”
Personal communication: “computer based
random sequence generation”, “an adaptive
randomization process was used to mini-
mize the imbalance within the covariates
76Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morrell 2011 (Continued)
listed above: imbalance was calculated for
each covariate and each potential therapy
allocation, the less-imbalancing therapy al-
location was selected with a 75% probabil-
ity, and the more-imbalancing therapy al-
location was selected with a 25% probabil-
ity”
Allocation concealment (selection bias) Low risk Personal communication: central alloca-
tion, “An adaptive randomization was per-
formed tominimize imbalance (...). So that
therapy allocation could not be guessed or
determined for a given subject (even with
knowledge of the therapy allocation of all
other subjects), the final therapy allocation
for a subject was selected with a 75% prob-
ability towards the less imbalancing alloca-
tion and 25% probability towards themore
imbalancing allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a blinded physician gathered all
outcome data and a nonblinded physician
managed the neurostimulator”; “to main-
tain the subject blind, all subjects under-
went actual or sham programming of the
neurostimulator to ensure that time with
the physician was similar”; “the blind was
successfully maintained. At the end of the
BEP 24% said that they did not know to
which group they had been randomized,
33% guessed incorrectly and 43% guessed
correctly”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Active stimulation group: 95/97 partici-
pants completed the trial: one patient did
not complete the stimulation optimization
period (participant preference), one did not
complete the BEP (emergent explant)
Sham stimulation group: 92/94 partici-
pants completed the trial: one patient did
not complete the stimulation optimization
period (death), one did not complete the
BEP (emergent explant)
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Selective reporting (reporting bias) Low risk Comment:
- no evidence of selective reporting; study
was registered on www.clinicaltrials.gov
but outcome measures were not men-
tioned;
- concerning the neuropsychological out-
come, quality of life and adverse events, no
or not all exact figures per group (sham ver-
sus treatment group) were reported, they
only mentioned that there were no signif-
icant differences. Probably this was due to
the fact that there was too much data for
publication (rather incomplete than selec-
tive reporting). Authors provided us these
data upon our request
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized phase
Anti-epileptic drug policy Low risk Quote: “anti-epileptic drugs were to be
held constant through the BEP, and then
could be adjusted as needed; benzodi-
azepines for seizure clusters or prolonged
seizures were permitted”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Tellez-Zenteno 2006
Methods Double-blind, multiple cross-over, constrained (paired) randomized controlled design
• 3-month baseline period (unclear if this was before or after electrode
implantation)
• three 2-month treatment pairs during which the stimulator was randomly
allocated to be ON for 1 month and OFF for 1 month
Participants n = 4, 25% male, mean age 31.8 years (range 24-37 y), duration of epilepsy ranged from
16 to 24 years
the patients suffered from refractory left unilateral medial temporal lobe epilepsy whose
risk to memory contraindicated temporal lobe resection, all patients showed mesial
temporal sclerosis on MRI
mean baseline seizure frequency of 4, 2.3, 25 and 4 seizures per month
Interventions Active: left hippocampal stimulation
• intensity was determined individually so that it was subthreshold for conscious
appreciation (range 1.8 to 4.5V)
• stimulation frequency of 190 Hz
• pulse width 90 µsec
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• continuous monopolar stimulation
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (open questions)
(5) Neuropsychological outcome (this included alternate forms of the Boston Naming
Test; alternate forms of the Digit Span Test; Hopkins Verbal Learning Test; the Brief
Visual Memory Test; Memory Assessment Clinic Self-Rating Scale; due to concerns
with potential floor effects associated with standard neuropsychological memory tests,
one patient underwent some alternative tests; the Center for Epidemiologic Studies
Depression (CES-D) scale was used to assess mood)
(6) Quality of Life (QOLIE-89)
Notes The authors reported no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Allocation concealment (selection bias) Low risk Quote: “randomization to one of the eight
possible sequences was done independently
by the research unit, eachmonth’s sequence
was placed in sealed, double-opaque, se-
quentially numbered envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “patients, treating clinicians and
outcome assessors were blinded”; “stimula-
tion was set subthreshold for conscious ap-
preciation”; “the patients’ ability to guess
ON or OFF status was no better than
chance”; “a neurosurgeon not involved in
outcome assessment or medical therapy
received one envelope each month and
turned the stimulator ON or OFF”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: one patient did not complete
quality of life related assessments; however,
this was the case both during active and
sham stimulation, so no real risk of attrition
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bias; all other outcome data were complete
Selective reporting (reporting bias) Low risk - Quote: “neuropsychological testing re-
vealed no differences betweenON,OFF or
baseline periods in any of the patients on
any of the formal measures, or in the sub-
jective memory scale”
Comment: exact figures were not reported
for the subjective memory scores (the
Memory Assessment Clinic Self-Rating
Scale) and for none of the test results mea-
sures of variance were provided. However,
this seemsmore a case of incomplete rather
than selective reporting.
- No evidence of selective reporting for
other outcomes, but no protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: multiple cross-over design
without washout period
Anti-epileptic drug policy High risk Comment: anti-epileptic drugs remained
unchanged in only one patient
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Van Buren 1978
Methods Double-blind, multiple cross-over, randomized controlled trial
• preoperative seizure rates were observed in the hospital before implantation
(baseline seizure frequency)
• implantation
• stimulation ON as soon as preoperative seizure frequency had resumed after
surgery
• seizure frequency was evaluated in hospital during 3 or 4 admissions over the
ensuing 15-21 months, each lasting 4 to 6 weeks; this time was made up of 1 or more
weeks of ON-and-OFF stimulation without double-blind conditions and a roughly
similar period of ON-and-OFF stimulation in the double-blind mode; for this review,
only double-blind data were considered (in total 26 days ON and 26 days OFF)
Participants n = 5, mean age 27.2 years (range 18-34 y), duration of epilepsy ranged from 8 to 23
years
the patients suffered from medically intractable seizures; seizures were not classified
but described; presumably, four suffered from focal epilepsy with partial seizures (and
secondarily generalized seizures in two patients) and one from generalized epilepsy (with
myoclonic seizures and unresponsive episodes with prolonged bilateral jerking)
mean baseline seizure frequency of 0.6 to 21.2 seizures per day (mean 5.1)
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Interventions Active: bilateral stimulation of the superior surface of the cerebellum parallel to and
about 1 cm from either side of the midline
• stimulation was carried out at levels just below that producing sensation referable
to meningeal irritation, usually at 10 to 14 V
• stimulation frequency of 10 Hz (200 Hz in case of myoclonic seizures)
• pulse width not reported
• 8-minute periods of stimulation alternating from one side of the cerebellum to
the other
Control: same procedure, but with inserting an adhesive pad that had a layer of alu-
minium foil within it, which blocked radiofrequency transmission and in this way pre-
vented true stimulation (versus active group: adhesive pad which consisted solely of ad-
hesive plaster)
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events
(5)Neuropsychological outcome (full scale intelligence quotients andmemory quotients)
Notes No statement concerning external support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the pairs of pads (with or without
an aluminium foil within it) were selected
at random”
Comment: probably completely random
selection (picking one out of two)
Allocation concealment (selection bias) Low risk Quote: “the pairs of pads were marked
with identifying letters”; “the pair contain-
ing the foil was identified in a sealed note,
which was opened only after the patient’s
observation period”
Comment: although it was not mentioned
explicitly, one could expect that the pads
(note: the pads were selected randomly, not
the notes) had an identical appearance (foil
was within it) and the identifying letters
were non-disclosing (as efforts were made
to conceal their meaning)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”; “the pairs of pads
were marked with identifying letters”; “the
pair containing the foil was identified in a
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sealed note, which was opened only after
the patient’s observation period”
Comment 1: although it was not men-
tioned explicitly, one could expect that the
pads had an identical appearance (foil was
within it) and the identifying letters were
non-disclosing (as efforts were made to
conceal theirmeaning); unclear if the sealed
notes were double-opaque and by whom
they were handled
Comment 2: not mentioned if neuropsy-
chological testing was performed during
the double-blind or the unblinded evalua-
tion period
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk - Although in two patients only three inpa-
tient evaluations were performed (instead
of the four planned), enough data are avail-
able to evaluate the effects of the interven-
tion
- Neuropsychological testing was not per-
formed in one patient (not testable due
to myoclonus), but low risk of attrition
bias as this was the case both during ef-
fective and sham stimulation; incomplete
preoperative neuropsychological testing in
two additional patients, however postop-
erative evaluations (most important ones)
were complete
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing, but no protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: multiple cross-over study with-
out washout period; inpatient evaluations
after 1 to 21 months of stimulation
Anti-epileptic drug policy Low risk Quote: “serum levels of phenytoin, primi-
done and phenobarbital were verified sev-
eral times during each admission”; “addi-
tional (to the above mentioned drugs) di-
azepamwas given in two patients and etho-
suximide in one patient, but the serum lev-
els were not monitored”
Comment: probably a policy to keep anti-
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epileptic drugs / their serum levels un-
changed
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Velasco 2000a
Methods Double-blind, cross-over randomized controlled trial
• a 3-month baseline period
• electrode implantation
• 6-9 months of stimulation in all patients
• a 6-month randomized double-blind cross-over (2 x 3 months) phase (ON/OFF
or OFF/ON)
• stimulation again ON in all patients
Participants n = 13, 62% male, mean age 19.2 years (range 4-31 y), duration of epilepsy ranged from
4 to 33 years
there were 8 patients with Lennox-Gastaut syndrome (suffering mainly from atypical
absences and generalized tonic-clonic seizures), and 5 with refractory localization-related
epilepsy (suffering mainly from complex partial and secondarily generalized seizures)
mean baseline seizure frequency of 1051 (SD 1434) seizures per month (median 119,
interquartile range 56, 2576)
Interventions Active: stimulation of the centromedian thalamic nucleus
• stimulation amplitude of 4-6 V (400-600 µA)
• stimulation frequency of 60 Hz
• pulse width 450 µsec
• one minute of bipolar stimulation, alternating between the left and the right side
with a 4-minute interval
Control: sham stimulation
Outcomes (1) Seizure frequency reduction
(2) Adverse events (open questions (not systematically) and physical examination - spon-
taneous reporting; postoperative MRI)
Notes Medtronic Inc. (Minneapolis, MN) donated the neurostimulators for the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients entered into a double-
blind protocol”
Personal communication: random selec-
tion of a folded paper (with a number on
it) out of a box by the patient, who did not
know the meaning of the number
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Allocation concealment (selection bias) Low risk Personal communication: the folded paper
was randomly selected by the patient, who
did not know the meaning of number (i.e.
if it corresponded to switching stimulation
OFF between months 6 and 9 or between
months 9 and 12)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “patients entered into a double-
blind protocol”; “because neither the pa-
tient nor the examiner could determine
when the stimulator was OFF, the double-
blind protocol was considered valid”
Personal communication: only an EEG
technicianwhowas not involved in treating
or evaluating the patients knew the stimu-
lation status
Comment: although the blinding proce-
dure seems adequate, performance bias
may exist as the double-blind stimulation
OFF periods were compared to the 3-
month periods preceding them (stimula-
tion ON in all patients, but double-blind
in only half of patients!) instead of consis-
tently comparing to the double-blind stim-
ulation ON periods
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: see above, as outcome was as-
sessed by the patient and the treating physi-
cian
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: despite good initial seizure con-
trol, neurostimulators were explanted in 2/
15 patients originally included in the study
due to skin erosions along the internalized
stimulation system; however, this occurred
before the patients entered the randomized
phase
Selective reporting (reporting bias) Low risk Comment 1: no evidence of selective re-
porting, but no protocol available
Comment 2: although there is no evidence
of selective reporting, authors reported
their findings incompletely: exact figures of
seizure frequency (reduction) were not re-
ported and are no longer readily available
(personal communication), which prevents
inclusion into themeta-analysis (the results
were only presented in graphs in the origi-
nal article)
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Outlasting effect due to prior stimulation Unclear risk Comment: cross-over protocol with 6 to 9
months of stimulation before the random-
ized phase and without washout period
Anti-epileptic drug policy Low risk Quote: “anticonvulsive medication re-
mained unchanged and anticonvulsive
blood levels were repeated every 3 to 6
months throughout the study”
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Velasco 2005
Methods Double-blind, parallel-group randomized controlled trial
• a 3-month baseline period
• implantation of the electrodes
• sham (= OFF) stimulation during the first postoperative month
• a 3-month randomized double-blind phase during which three patients received
cerebellar stimulation and two did not
• stimulation ON (unblinded) in all patients after the fourth month after
implantation (21 months)
Participants n = 5, 80% male, mean age 26.0 years (range 16-35 y), duration of epilepsy ranged from
11 to 27 years
three patients had generalized epilepsy and two patients (multi)focal epilepsy of frontal
origin; all patients suffered from generalized tonic-clonic seizures, 4/5 patients also had
tonic seizures, 2/5 had drop attacks and 1/5 had myoclonic seizures / atypical absences
mean baseline seizure frequency of 14.1 (SD 6.2) seizures per month (generalized tonic-
clonic seizures 6.3 (SD 3.1))
Interventions Active (n = 3): bilateral stimulation of the superomedial surface of the cerebellum
• stimulation intensity of 3.8 mA, which was equivalent to a charge density of 2.0
µC/cm²/phase (the voltage needed for this was calculated at each visit by measuring the
electrodes’ impedance)
• stimulation frequency of 10 Hz
• pulse width of 450 µsec
• monopolar stimulation turned ON for 4 min alternating with 4 min OFF
Control (n = 2): sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (standard open questions, postoperative CT scan or MRI)
Notes Medtronic Inc. (Minneapolis, MN) supported the study by providing the cerebellar
stimulation systems
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the procedure used for randomi-
sation was to assign patients a lottery num-
ber”
Personal communication: random selec-
tion of a folded paper (with a number on
it) out of a box by the patient, who did not
know the meaning of the number
Allocation concealment (selection bias) Low risk Personal communication: the folded paper
was randomly selected by the patient, who
did not know the meaning of number (i.e.
if it corresponded to ON or OFF)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “both patients and the evaluator
were blinded with regard to whether the
stimulator was ON or OFF, a different
investigator manipulated the stimulation
code”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients completed the dou-
ble-blind randomized phase and all data
were available
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing, but no protocol available
Outlasting effect due to prior stimulation Low risk Comment: parallel-group design, no stim-
ulation prior to the randomized double-
blind phase
Anti-epileptic drug policy Low risk Quote: “All patients but one contin-
ued baseline AEDs throughout the study.
Phenytoin was reduced from 300 to 200
mg per day in case 5 because of drug in-
tolerance. Seizure decreases were not likely
to be due to AEDs, because they were not
modified.”
Personal communication: phenytoin dose
reduction in case 5 was at the seventh
month of the study
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Comment: AEDswere not changed during
the randomized double-blind phase of the
trial
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Velasco 2007
Methods Double-blind, parallel-group, randomized controlled trial
• 3-month baseline period
• electrode implantation
• 1-month double blind randomized phase (stimulator ON or OFF)
• long-term follow-up (range 18-84 months) with stimulation ON in all patients
Participants n = 9, 66% male, mean age 29.1 years (range 14-43 y), duration of epilepsy ranged from
3 to 37 years
intractable temporal lobe epilepsy patients, poor surgery candidates (bilateral indepen-
dent foci (n = 4), unilateral focus (n = 3), lateralization not completely clear (n = 2));
neuroimaging: normal MRI (n = 5), left (n = 3) or bilateral (n = 1) hippocampal sclerosis;
6 patients had mild memory impairment in neuropsychological tests, three had severe
abnormalities
mean baseline seizure frequency of 37.9 (SD 16.8) seizures per month
Interventions Active (n = 4): uni- or bilateral hippocampal stimulation (according to seizure focus)
• stimulation amplitude of 300 µA (= 50% of the amplitude needed to obtain
electrocortical responses)
• stimulation frequency of 130 Hz
• pulse width of 450 µsec
• cyclic bipolar stimulation with 1-min trains with a 4 min interstimulus interval;
in case of bilateral stimulation: alternating 1-min stimulation on one side with a 4-min
interval between right and left sides
Control (n = 5): sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events (open questions (not systematically) - spontaneous reporting; post-
operative MRI)
Notes No statement concerning external support
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “an aleatory (randomized by lottery
number) double-blind maneuver”
Personal communication: a non see-
through box with small folded pieces of pa-
per (with a code on it) within it, out of
which one was randomly taken by the pa-
tient who did not know the meaning of the
code
Allocation concealment (selection bias) Low risk Personal communication: “folded papers in
a non see-through box” and the aleatory
manoeuvre was performed by the patient
who did not know the meaning of the code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”; “because the stim-
ulation at the therapeutic stimulation pa-
rameters induced no subjective or objective
sensation, the double-blind maneuver was
considered valid”
Personal communication: the only person
who knew if the stimulation was ON or
OFF was an EEG technician who was not
involved in other parts of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no data missing or patients ex-
cluded from analyses
Selective reporting (reporting bias) Low risk Comment:
- exact figures of seizure frequency with
stimulation ON during the blinded period
were not reported (only graphs of individ-
ual patient data, fromwhich one could esti-
mate these exact figures). We consider this
more as incomplete rather than selective re-
porting. The authors provided us these data
upon our request
- no evidence of selective reporting, but no
protocol available
Outlasting effect due to prior stimulation Low risk Parallel-group design, no stimulation prior
to the randomized phase
Anti-epileptic drug policy Low risk Quote: anti-epileptic drug therapy was
maintained with no modifications during
follow-up
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Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Wiebe 2013
Methods Five-centre parallel-group, double-blind (participant, caregiver, investigator andoutcome
assessor) randomized controlled trial:
• baseline period (?) (? months)
• electrode implantation
• 1 month for ’adjustments of interventions’
• 6-month randomized double-blind phase with stimulation ON or OFF
Participants n = 6 (sham stimulation: n = 4; active stimulation: n = 2), age 30-46 years, IQ ≥70
adults with refractory uni- (n = 4) or bilateral (n = 2) mesial temporal lobe epilepsy
(failure of≥ 2 AEDs), preference for non-resective surgery, or not a candidate for mesial
temporal resection
median baseline monthly seizure frequency of 10 (all seizures; CPS + GTCS = 1) in the
sham group and 12 (CPS + GTCS = 2) in the stimulation group
Interventions Active (n = 2): uni- or bilateral hippocampal stimulation for 6 months
• stimulation intensity unknown
• stimulation frequency of 135 Hz
• pulse width unknown
• continuous cathodal stimulation of all electrodes involved in seizure generation
Control (n = 4): sham stimulation for 6 months
Outcomes (1) Seizure freedom
(2) Responder rate
(3) Seizure frequency reduction
(4) Adverse events
(5) Neuropsychological outcome
(6) Quality of life
Notes The study has been preliminary terminated in March 2012 after recruitment of only 6
participants (target sample = 57) due to difficulties in patient recruitment despite the
multicentre participation; the results collected in those 6 patients were published as an
abstract. However, many details on the methodology, participants, interventions and
outcomes are missing for a complete judgement of the methodology used or for full
incorporation into this review. We tried to contact the authors but could not obtain
additional information or data yet. Another attempt will be made by the next update of
this review
The trial was sponsored by the University of Calgary, no evidence for external funding
Risk of bias
Bias Authors’ judgement Support for judgement
89Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wiebe 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ’randomized’
Comment: additional information on the
methods used for random sequence gener-
ation could not be obtained
Allocation concealment (selection bias) Unclear risk Quote: ’randomized’
Comment: additional information on the
methods used for concealment of treatment
allocation could not be obtained
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’double-blind (subject, caregiver,
investigator and outcome assessor)’
Comment: additional information on the
methods used for blinding could not be ob-
tained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ’double-blind (subject, caregiver,
investigator and outcome assessor)’
Comment: additional information on the
methods used for blinding could not be ob-
tained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no evidence for incomplete out-
come data leading to attrition bias but in-
sufficient details available for full apprecia-
tion
Selective reporting (reporting bias) Low risk Comment 1: no clear evidence for selec-
tive reporting, all outcome measures men-
tioned in the protocol were briefly dis-
cussed in the abstract although many de-
tails are missing for full appreciation (see
comment 2);
Comment 2: although there was no evi-
dence for selective reporting, the authors
reported their results incompletely as these
were only published as an abstract and
many details on the collected outcomes
are missing for full incorporation of this
trial into the review (e.g. results after 3
months, detailed neuropsychological out-
comes, variance between participants...)
Outlasting effect due to prior stimulation Low risk Quote: parallel-group randomized con-
trolled trial
Anti-epileptic drug policy Unclear risk Comment: AED policy not specified
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Wiebe 2013 (Continued)
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
Wright 1984
Methods Double-blind, cross-over randomized controlled study
• electrode implantation
• the first phase of the trial was begun several months after implantation when the
individual had returned to his or her preoperative seizure frequency
• a 6-month double-blind randomized phase, consisting of three 2-month periods
(continuous, contingent and sham stimulation)
Participants n = 12, 83% male, mean age 30 years (range 20-38 y), duration of epilepsy ranged from
10 to 32 years
type of epilepsy not reported, 5/12 patients had only generalized seizures, 1/12 only
partial seizures, 4/12 partial and generalized seizures, 2/12 dd complex partial seizures
versus complex absences; in addition it was reported that the EEG in each case contained
quantifiable generalized paroxysmal activity, but six patients showed additional focal
activity in the frontal or temporal regions, all patients had an IQ of ≥ 80
mean seizure frequency during sham stimulation: 61.7 (SD 53.3) seizures per month
Interventions Electrode pads were placed on the upper surface of the cerebellum, positioned parasagit-
tally approximately 2 cm from the midline on each side; stimulation parameters were:
• stimulation amplitude: 7 mA in 8/12 patients (default), 5 mA in 3/12 patients (in
2/3 because 7 mA could be detected by the patients), 7 mA (one side) and 1 mA (other
side) due to technical reasons in 1/12 patients
• stimulation frequency 10 Hz (default); 200 Hz (5 mA) in one patient because he
showed reduction in the amplitude of somatosensory evoked potentials during one
recording session after bursts of stimulation with these parameters
• pulse width not reported
• bipolar stimulation
Treatment 1: continuous stimulation
• continuous stimulation alternating from one cerebellar hemisphere to the other
every minute
Treatment 2: contingent (responsive) stimulation
• intermittent contingent stimulation of both cerebellar hemispheres occurred
whilst the “seizure button” on the transmitter was depressed (during an aura or seizure)
and for two minutes after it was released
Control: sham stimulation
Outcomes (1) Proportion of participants who were seizure-free
(2) Proportion of participants with a ≥ 50% seizure frequency reduction (responder
rate)
(3) Seizure frequency reduction
(4) Adverse events
(5) Neuropsychological outcome (’psychometry’)
(6) ’Proxy’ of quality of life (patients’ impressions on cerebellar stimulation)
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Wright 1984 (Continued)
Notes Baseline seizure frequency was not reported, changes in seizure frequency are therefore
expressed relative to the sham stimulation phase; no statement concerning external sup-
port
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the sequence of the phaseswas ran-
domly allocated”
Allocation concealment (selection bias) Unclear risk Quote: “the sequence of the phaseswas ran-
domly allocated”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”; “the sequence of
the phases was randomly allocated and the
codewas not broken until the trial had been
completed”; “stimulation was set at stimu-
lation parameters that couldn’t be detected
by the patients”; “before surgery and at the
end of each phase of the trial, each patient
was assessed clinically by two independent
consultant neurologists who were not in-
volved in the trial or the patient’s routine
management”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: see above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: seizure frequency during the
three phases was not fully quantifiable in
3/12 patients (reasons: 1) one patient be-
came uncooperative; 2) one patient mislaid
some of his records; 3) one patient suffered
prolonged periods of confusion associated
with absence attacks and myoclonic jerks
which were difficult to quantify); however,
this was the case for each phase of the study;
moreover, the evolution of the seizure fre-
quency during the three phases of the trial
was qualitatively described
Selective reporting (reporting bias) Low risk Quote: “psychometry did not reveal any
major changes in any patients in any of the
phases of the trial”
Comment: no exact figures were provided,
probably because there was too much data
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Wright 1984 (Continued)
for publication in the journal article (rather
incomplete than selective reporting)
Comment: no evidence of selective report-
ing concerning the other outcomes, but no
protocol available
Outlasting effect due to prior stimulation Unclear risk Comment: cross-over design without a
washout period between the different treat-
ment phases
Anti-epileptic drug policy Low risk Quote: “at the time of admission to the
trial they were considered to be on the
best combination of anticonvulsants at op-
timumdosage and this dosage had not been
changed during the previous six months”
Comment: although it was not stated
explicitly, it seems unlikely that the
antiepileptic drug regimen was changed
during the trial
Other bias Low risk Comment: there is no clear evidence for a
risk of ’other bias’
AED: antiepileptic drug
BEP: blinded evaluation period
CT: computed tomography
DBS: deep brain stimulation
ITT: intention-to-treat
MRI: magnetic resonance imaging
SD: standard deviation
VNS: Vagus Nerve Stimulation
WAIS: Wechsler Adult Intelligence Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alaraj 2001 not a randomized controlled trial
Anderson 2008 4/7 patients not in a randomized controlled trial; 3/7 patients participated in a randomized trial but no
information about outcomes relevant to this study; additionally patients were also included in a large
randomized controlled trial already included in this review (Morrell 2011)
Andrade 2006 not a randomized controlled trial
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(Continued)
Bidzi ski 1981 not a randomized controlled trial
Boon 2007a not a randomized controlled trial
Boëx 2011 not a randomized controlled trial
Brown 2006 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Chabardes 2002 not a randomized controlled trial
Child 2014 not a randomized controlled trial
Chkhenkeli 2004 not a randomized controlled trial
Cooper 1976 not a randomized controlled trial
Cordella 2013 not a randomized controlled trial
Cukiert 2009 not a randomized controlled trial
Cukiert 2014 not a randomized controlled trial
Davis 1992 not a randomized controlled trial
Davis 2000 not a randomized controlled trial
Ding 2016 not a randomized controlled trial
Dinner 2002 not a randomized controlled trial
Elisevich 2006 not a randomized controlled trial
Esteller 2004 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Feinstein 1989 not a randomized controlled trial
Fell 2013 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Fountas 2005 not a randomized controlled trial
Fountas 2007 not a randomized controlled trial
Franzini 2008 not a randomized controlled trial
Fregni 2005 not intracranial stimulation
Fregni 2006 not intracranial stimulation
Galvez-Jimenez 1998 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
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(Continued)
Handforth 2006 not a randomized controlled trial
Hodaie 2002 not a randomized controlled trial
Huang 2008 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Kerrigan 2004 not a randomized controlled trial
Khan 2009 not a randomized controlled trial
Kossoff 2004 not a randomized controlled trial
Koubeissi 2013 not a randomized controlled trial
Larkin 2016 not a randomized controlled trial / no new randomized controlled trials included
Lee 2006 not a randomized controlled trial
Lee 2012 not a randomized controlled trial
Levy 2008 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Lim 2007 not a randomized controlled trial
Loddenkemper 2001 not a randomized controlled trial
Marras 2011 not a randomized controlled trial
Miatton 2011 not a randomized controlled trial
Miller 2015 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Nguyen 1999 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Osorio 2001 not a randomized controlled trial
Osorio 2005 not a randomized controlled trial
Osorio 2007 not a randomized controlled trial
Pahwa 1999 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Riklan 1976 not a randomized controlled trial
Rocha 2007 not a randomized controlled trial
Savard 2003 not a randomized controlled trial
Schmitt 2014 not a randomized controlled trial
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(Continued)
Schulze-Bonhage 2016 not a randomized controlled trial
Spencer 2011 not a randomized controlled trial
Sussman 1988 not a randomized controlled trial
Tanriverdi 2009 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Torres 2013 intracranial stimulation for other purposes / not to treat refractory epilepsy patients
Tyrand 2012 not a randomized controlled trial
Upton 1985 not a randomized controlled trial
Valentin 2013 not a randomized controlled trial
Velasco 1987 not a randomized controlled trial
Velasco 1993 not a randomized controlled trial
Velasco 1995 not a randomized controlled trial
Velasco 2000b not a randomized controlled trial
Velasco 2001 not a randomized controlled trial
Velasco 2006 not a randomized controlled trial
Velasco 2009 not a randomized controlled trial
Vonck 2002 not a randomized controlled trial
Vonck 2013 not a randomized controlled trial
Wakerley 2011 not a randomized controlled trial
Wei 2016 not a randomized controlled trial
Wille 2011 not a randomized controlled trial
Yamamoto 2006 not a randomized controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Chabardes 2005
Methods Double-blind (participant, investigator, outcome assessor), randomized controlled clinical trial with two cross-over
groups
Participants Epilepsy resistant to AEDs and dopaminergic D2-agonist
Curative resective surgery not possible
Metabolism deficiency of DOPA above 1 DS, evaluated by Positron Emission Tomography (PET) using fluorodopa
Age ranging from 18 to 50
Interventions Group 1: 3 months high-frequency stimulation of the subthalamic nucleus followed by 3 months SHAM stimulation
Group 2: 3 months SHAM stimulation followed by 3 months high-frequency stimulation of the subthalamic nucleus
Outcomes (1) Proportion of participants with a ≥ 50% seizure frequency reduction (responder rate)
(2) Seizure frequency reduction
(3) Adverse events
(4) Neuropsychological outcome (WAIS, GROBER and Busckhe, Wisconsin Card Sorting Test, TRAIL test, LURIA
test, Beck Depression Inventory, verbal flow test, empathy test)
(5) Quality of life (SEALS, QOLIE-31 and NHP scales)
Notes The study has been preliminary terminated in March 2010 due to insufficient patient recruitment. Four participants
were recruited. Results have not been published yet. We tried to contact the authors but could not obtain any results
yet. Further efforts will be made
van Rijckevorsel 2004
Methods
Participants
Interventions
Outcomes
Notes A randomized controlled trial evaluating the efficacy and safety of DBS of the mammillary bodies and mammillotha-
lamic tracts was announced but results have not been published yet; authors were contacted but results could not be
provided yet. Further efforts will be made
AED: antiepileptic drug
DBS: deep brain stimulation
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Characteristics of ongoing studies [ordered by study ID]
Boon 2007b
Trial name or title Prospective randomized controlled study of neurostimulation in the medial temporal lobe for patients with
medically refractory medial temporal lobe epilepsy;: Controlled Randomized Stimulation Versus Resection
(CoRaStiR)
Methods Prospective, multicentre, parallel-group, single-blind (participant) randomized controlled trial
Participants Presurgical candidates with pharmacoresistant partial seizures despite optimal medical treatment and history
of temporal lobe epilepsy
Video-EEG characteristics showing temporal lobe seizure onset (left-sided or right-sided seizure onset) in at
least one recorded habitual seizure
Presence of a structural abnormality in the medial temporal lobe, suggestive of hippocampal sclerosis as
evidenced by optimum MRI
Age ≥ 18 years
Total IQ > 80
Interventions Group 1: electrode implantation in the medial temporal lobe and immediate unilateral hippocampal neu-
rostimulation (12 months)
Group 2: electrode implantation in the medial temporal lobe but unilateral hippocampal neurostimulation
(6 months) is delayed for 6 months
Group 3: amygdalohippocampectomy
Outcomes (1) Proportion of participants with a ≥ 50% seizure frequency reduction (responder rate)
(2) Seizure frequency reduction
(3) Adverse events
(4) Neuropsychological outcome
(5) Quality of life (QOLIE 89)
Starting date June 2007
Contact information Kristl Vonck, MD, PhD - Ghent University, Belgium - kristl.vonck@UGent.be
Notes Currently still recruiting participants (December 2014)
Sponsored by Medtronics
Chabardes 2014
Trial name or title Clinical and medico-economical assessment of deep brain stimulation of the anterior nucleus of the thalamus
for the treatment of pharmacoresistant partial epilepsy
Methods Open-label parallel-group randomized controlled trial
Participants Pharmacoresistant (≥ 2 AEDS) focal or multifocal epilepsy patients
Epilepsy inoperable at the time of inclusion
Failure of vagus nerve stimulation
Age 16-60 years
IQ > 55
98Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chabardes 2014 (Continued)
Interventions Group 1: anterior thalamic nucleus deep brain stimulation
Group 2: maintaining ’usual’ treatment, including vagus nerve stimulation
Outcomes (1) Seizure severity
(2) Adverse events (special focus on depression)
(3) Neuropyschological outcome
(4) Quality of life
Starting date March 2014
Contact information Sandra David-Tchouda, MD - University Hospital of Grenoble Michallon, France - SDavidTchouda@chu-
grenoble.fr
Sandrine Massicot, CRA - University Hospital of Grenoble Michallon, France - SMassicot@chu.grenoble.fr
Notes Currently still recruiting patients (December 2015)
Sponsored by Grenoble University Hospital
Koubeissi 2015
Trial name or title Low frequency electrical stimulation of the fornix in intractable Mesial Temporal Lobe Epilepsy (MTLE)
Methods Parallel-group single-blind (participant) randomized controlled trial
Participants Patients with intractable (failure of≥ 2 AEDs) uni- or bilateral medial temporal lobe epilepsy (based on non-
invasive video-EEG monitoring; lesional or non-lesional hippocampus)
Demonstration that the hippocampus ipsilateral to seizure onset is contributing to memory function
Not candidates for resective surgery for reasons that include an increased risk of memory decline
Age 18-65 years
IQ ≥ 70
Interventions Group 1: 1 Hz low-frequency electrical stimulation of the fornix using a Medtronic deep brain stimulation
device
Group 2: 5 Hz low-frequency electrical stimulation of the fornix using a Medtronic deep brain stimulation
device
Outcomes (1) Seizure frequency
(2) Adverse events, especially safety and tolerability with regards to memory function - Psychiatriac Health
(3) Quality of life (QOLIE-31 and SF-36)
Starting date December 2013
Contact information Mohamad Z Koubeissi, MD - George Washington University, Washington DC, USA - mkoubeissi@mfa.
gwu.edu
Notes Currently still recruiting participants (March 2015)
Sponsored by George Washington University
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Zhang 2015
Trial name or title Prospective randomized trial comparing vagus nerve stimulation and deep brain stimulation of the anterior
nucleus of the thalamus in patient with pharmacoresistant epilepsy
Methods Parallel-group randomized controlled clinical trial
Participants Patients with diagnosis of pharmacoresistant partial-onset seizures (persistent seizures despite at least 3 AEDs)
Prior electroencephalography and magnetic resonance imaging studies are consistent with the diagnosis
Age 12-60 years
Interventions Group 1: vagus nerve stimulation
Group 2: anterior thalamic nucleus deep brain stimulation
Outcomes (1) Seizure frequency reduction
(2) Adverse events including depression and anxiety
(3) Quality of life
Starting date January 2015
Contact information Zhang K - Beijing Neurosurgical Institute, China - zhangkai62035@sina.com
Notes Currently still recruiting participants (May 2015)
Sponsored by Beijing Tiantan Hospital, Capital Medical University
AED: antiepileptic drug
MRI: magnetic resonance imaging
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D A T A A N D A N A L Y S E S
Comparison 1. Stimulation versus sham stimulation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure freedom 11 Odds Ratio (Fixed, 95% CI) Subtotals only
1.1 Anterior thalamic nucleus 1 109 Odds Ratio (Fixed, 95% CI) 0.33 [0.01, 8.36]
1.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.11, 9.39]
1.3 Cerebellar stimulation 3 39 Odds Ratio (Fixed, 95% CI) 0.96 [0.22, 4.12]
1.4 Hippocampal stimulation
(1 to 3 months)
3 21 Odds Ratio (Fixed, 95% CI) 1.03 [0.21, 5.15]
1.5 Hippocampal stimulation
(4 to 6 months)
1 6 Odds Ratio (Fixed, 95% CI) 1.80 [0.03, 121.68]
1.6 Nucleus accumbens
stimulation
1 8 Odds Ratio (Fixed, 95% CI) 1.0 [0.07, 13.64]
1.7 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 4.95 [0.23, 104.44]
2 Responder rate 11 Odds Ratio (Fixed, 95% CI) Subtotals only
2.1 Anterior thalamic nucleus 1 108 Odds Ratio (Fixed, 95% CI) 1.20 [0.52, 2.80]
2.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.27, 3.69]
2.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 2.43 [0.46, 12.84]
2.4 Hippocampal stimulation
(1 to 3 months)
3 21 Odds Ratio (Fixed, 95% CI) 1.20 [0.36, 4.01]
2.5 Hippocampal stimulation
(4 to 6 months)
1 6 Odds Ratio (Fixed, 95% CI) 9.00 [0.22, 362.46]
2.6 Nucleus accumbens
stimulation
1 8 Odds Ratio (Fixed, 95% CI) 10.00 [0.53, 189.15]
2.7 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 1.12 [0.59, 2.11]
3 Seizure frequency reduction 10 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Anterior thalamic nucleus
stimulation
1 108 Mean Difference (Fixed, 95% CI) -17.44 [-32.53, -2.
35]
3.2 Centromedian thalamic
stimulation
1 12 Mean Difference (Fixed, 95% CI) 7.05 [-44.05, 58.15]
3.3 Cerebellar stimulation 3 33 Mean Difference (Fixed, 95% CI) -12.37 [-35.30, 10.
55]
3.4 Hippocampal stimulation
(1 to 3 months)
3 21 Mean Difference (Fixed, 95% CI) -28.14 [-34.09, -22.
19]
3.5 Nucleus accumbens
stimulation
1 8 Mean Difference (Fixed, 95% CI) -33.8 [-117.37, 49.
77]
3.6 Closed-loop ictal onset
zone stimulation
1 191 Mean Difference (Fixed, 95% CI) -24.95 [-42.00, -7.
90]
4 Quality of Life 4 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 Anterior thalamic nucleus
stimulation
1 105 Mean Difference (Fixed, 95% CI) -0.3 [-3.50, 2.90]
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4.2 Hippocampal stimulation
(1 to 3 months)
1 6 Mean Difference (Fixed, 95% CI) -5.0 [-53.25, 43.25]
4.3 Nucleus accumbens
stimulation
1 8 Mean Difference (Fixed, 95% CI) 2.78 [-7.41, 12.97]
4.4 Closed-loop ictal onset
zone stimulation
1 180 Mean Difference (Fixed, 95% CI) -0.14 [-2.88, 2.60]
Comparison 2. Stimulation versus sham stimulation - sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure freedom RR 11 Risk Ratio (Fixed, 95% CI) Subtotals only
1.1 Anterior thalamic nucleus 1 109 Risk Ratio (Fixed, 95% CI) 0.34 [0.01, 8.15]
1.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.14, 7.10]
1.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 0.96 [0.26, 3.52]
1.4 Hippocampal stimulation
(1 to 3 months)
3 21 Risk Ratio (Fixed, 95% CI) 1.03 [0.25, 4.19]
1.5 Hippocampal stimulation
(4 to 6 months)
1 6 Risk Ratio (Fixed, 95% CI) 1.67 [0.04, 64.08]
1.6 Nucleus accumbens
stimulation
1 8 Risk Ratio (Fixed, 95% CI) 1.0 [0.14, 7.10]
1.7 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 4.85 [0.24, 99.64]
2 Responder rate RR 11 Risk Ratio (Fixed, 95% CI) Subtotals only
2.1 Anterior thalamic nucleus 1 108 Risk Ratio (Fixed, 95% CI) 1.14 [0.62, 2.10]
2.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.38, 2.66]
2.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 2.00 [0.51, 7.86]
2.4 Hippocampal stimulation
(1 to 3 months)
3 21 Risk Ratio (Fixed, 95% CI) 1.12 [0.47, 2.66]
2.5 Hippocampal stimulation
(4 to 6 months)
1 6 Risk Ratio (Fixed, 95% CI) 5.00 [0.29, 87.54]
2.6 Nucleus accumbens
stimulation
1 8 Risk Ratio (Fixed, 95% CI) 4.00 [0.56, 28.40]
2.7 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 1.09 [0.69, 1.72]
3 Seizure freedom OR 0.25 11 Odds Ratio (Fixed, 95% CI) Subtotals only
3.1 Anterior thalamic nucleus 1 109 Odds Ratio (Fixed, 95% CI) 0.20 [0.00, 15.17]
3.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.05, 19.79]
3.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 0.96 [0.13, 6.83]
3.4 Hippocampal stimulation
(1 to 3 months)
3 21 Odds Ratio (Fixed, 95% CI) 1.03 [0.13, 8.41]
3.5 Hippocampal stimulation
(4 to 6 months)
1 6 Odds Ratio (Fixed, 95% CI) 1.89 [0.01, 608.05]
3.6 Nucleus accumbens
stimulation
1 8 Odds Ratio (Fixed, 95% CI) 1.0 [0.04, 27.83]
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3.7 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 8.91 [0.14, 560.31]
4 Responder rate OR 0.25 11 Odds Ratio (Fixed, 95% CI) Subtotals only
4.1 Anterior thalamic nucleus 1 108 Odds Ratio (Fixed, 95% CI) 1.20 [0.52, 2.80]
4.2 Centromedian thalamic
stimulation
1 12 Odds Ratio (Fixed, 95% CI) 1.0 [0.31, 3.24]
4.3 Cerebellar stimulation 3 33 Odds Ratio (Fixed, 95% CI) 2.98 [0.39, 22.77]
4.4 Hippocampal stimulation
(1 to 3 months)
3 21 Odds Ratio (Fixed, 95% CI) 1.15 [0.35, 3.77]
4.5 Hippocampal stimulation
(4 to 6 months)
1 6 Odds Ratio (Fixed, 95% CI) 17.00 [0.15, 1934.
66]
4.6 Nucleus accumbens
stimulation
1 8 Odds Ratio (Fixed, 95% CI) 21.00 [0.51, 864.51]
4.7 Closed-loop ictal onset
zone stimulation
1 191 Odds Ratio (Fixed, 95% CI) 1.12 [0.59, 2.11]
5 Seizure freedom RR 0.25 11 Risk Ratio (Fixed, 95% CI) Subtotals only
5.1 Anterior thalamic nucleus 1 109 Risk Ratio (Fixed, 95% CI) 0.21 [0.00, 14.95]
5.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.06, 15.99]
5.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 0.96 [0.15, 6.04]
5.4 Hippocampal stimulation
(1 to 3 months)
3 21 Risk Ratio (Fixed, 95% CI) 1.02 [0.16, 6.46]
5.5 Hippocampal stimulation
(4 to 6 months)
1 6 Risk Ratio (Fixed, 95% CI) 1.80 [0.01, 369.24]
5.6 Nucleus accumbens
stimulation
1 8 Risk Ratio (Fixed, 95% CI) 1.0 [0.06, 15.99]
5.7 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 8.72 [0.14, 538.18]
6 Responder rate RR 0.25 11 Risk Ratio (Fixed, 95% CI) Subtotals only
6.1 Anterior thalamic nucleus 1 108 Risk Ratio (Fixed, 95% CI) 1.14 [0.62, 2.10]
6.2 Centromedian thalamic
stimulation
1 12 Risk Ratio (Fixed, 95% CI) 1.0 [0.40, 2.52]
6.3 Cerebellar stimulation 3 33 Risk Ratio (Fixed, 95% CI) 2.28 [0.40, 13.02]
6.4 Hippocampal stimulation
(1 to 3 months)
3 21 Risk Ratio (Fixed, 95% CI) 1.08 [0.46, 2.55]
6.5 Hippocampal stimulation
(4 to 6 months)
1 6 Risk Ratio (Fixed, 95% CI) 9.00 [0.16, 494.41]
6.6 Nucleus accumbens
stimulation
1 8 Risk Ratio (Fixed, 95% CI) 7.00 [0.44, 111.91]
6.7 Closed-loop ictal onset
zone stimulation
1 191 Risk Ratio (Fixed, 95% CI) 1.09 [0.69, 1.72]
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Analysis 1.1. Comparison 1 Stimulation versus sham stimulation, Outcome 1 Seizure freedom.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 1 Seizure freedom
Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.0986 (1.6442) 100.0 % 0.33 [ 0.01, 8.36 ]
Subtotal (95% CI) 54 55 100.0 % 0.33 [ 0.01, 8.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.1429) 100.0 % 1.00 [ 0.11, 9.39 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.11, 9.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.1667) 40.6 % 1.00 [ 0.10, 9.84 ]
Velasco 2005 3 2 -0.3365 (2.1647) 11.8 % 0.71 [ 0.01, 49.71 ]
Wright 1984 12 12 0 (1.0769) 47.6 % 1.00 [ 0.12, 8.25 ]
Subtotal (95% CI) 20 19 100.0 % 0.96 [ 0.22, 4.12 ]
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.3333) 37.9 % 1.00 [ 0.07, 13.64 ]
Tellez-Zenteno 2006 4 4 0 (1.2) 46.8 % 1.00 [ 0.10, 10.51 ]
Velasco 2007 4 5 0.2007 (2.0986) 15.3 % 1.22 [ 0.02, 74.73 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.21, 5.15 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 0.5877 (2.1499) 100.0 % 1.80 [ 0.03, 121.68 ]
Subtotal (95% CI) 2 4 100.0 % 1.80 [ 0.03, 121.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 0 (1.3333) 100.0 % 1.00 [ 0.07, 13.64 ]
Subtotal (95% CI) 4 4 100.0 % 1.00 [ 0.07, 13.64 ]
0.002 0.1 1 10 500
Favours control Favours stimulation
(Continued . . . )
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Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 1.5989 (1.556) 100.0 % 4.95 [ 0.23, 104.44 ]
Subtotal (95% CI) 97 94 100.0 % 4.95 [ 0.23, 104.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.56, df = 6 (P = 0.96), I2 =0.0%
0.002 0.1 1 10 500
Favours control Favours stimulation
Analysis 1.2. Comparison 1 Stimulation versus sham stimulation, Outcome 2 Responder rate.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 2 Responder rate
Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1848 (0.4304) 100.0 % 1.20 [ 0.52, 2.80 ]
Subtotal (95% CI) 54 54 100.0 % 1.20 [ 0.52, 2.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.6667) 100.0 % 1.00 [ 0.27, 3.69 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.27, 3.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.7678) 23.1 % 1.00 [ 0.03, 31.97 ]
Velasco 2005 3 2 2.1203 (1.8619) 20.8 % 8.33 [ 0.22, 320.40 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Stimulation Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Wright 1984 9 9 0.7985 (1.1328) 56.2 % 2.22 [ 0.24, 20.47 ]
Subtotal (95% CI) 17 16 100.0 % 2.43 [ 0.46, 12.84 ]
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.3333) 21.2 % 1.00 [ 0.07, 13.64 ]
Tellez-Zenteno 2006 4 4 0 (0.75) 66.8 % 1.00 [ 0.23, 4.35 ]
Velasco 2007 4 5 1.5506 (1.7704) 12.0 % 4.71 [ 0.15, 151.49 ]
Subtotal (95% CI) 10 11 100.0 % 1.20 [ 0.36, 4.01 ]
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 2.1972 (1.8856) 100.0 % 9.00 [ 0.22, 362.46 ]
Subtotal (95% CI) 2 4 100.0 % 9.00 [ 0.22, 362.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 2.3026 (1.5) 100.0 % 10.00 [ 0.53, 189.15 ]
Subtotal (95% CI) 4 4 100.0 % 10.00 [ 0.53, 189.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.1133 (0.3236) 100.0 % 1.12 [ 0.59, 2.11 ]
Subtotal (95% CI) 97 94 100.0 % 1.12 [ 0.59, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 3.86, df = 6 (P = 0.70), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.3. Comparison 1 Stimulation versus sham stimulation, Outcome 3 Seizure frequency reduction.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 3 Seizure frequency reduction
Study or subgroup Stimulation Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus stimulation
Fisher 2010 54 54 -17.44 (7.7) 100.0 % -17.44 [ -32.53, -2.35 ]
Subtotal (95% CI) 54 54 100.0 % -17.44 [ -32.53, -2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 7.05 (26.07) 100.0 % 7.05 [ -44.05, 58.15 ]
Subtotal (95% CI) 6 6 100.0 % 7.05 [ -44.05, 58.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Cerebellar stimulation
Van Buren 1978 5 5 -7.12 (31.3) 14.0 % -7.12 [ -68.47, 54.23 ]
Velasco 2005 3 2 -36.7 (29.51) 15.7 % -36.70 [ -94.54, 21.14 ]
Wright 1984 9 9 -7.98 (13.95) 70.3 % -7.98 [ -35.32, 19.36 ]
Subtotal (95% CI) 17 16 100.0 % -12.37 [ -35.30, 10.55 ]
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 -28.13 (3.13) 94.1 % -28.13 [ -34.26, -22.00 ]
Tellez-Zenteno 2006 4 4 -20.32 (13.84) 4.8 % -20.32 [ -47.45, 6.81 ]
Velasco 2007 4 5 -63.2 (29.01) 1.1 % -63.20 [ -120.06, -6.34 ]
Subtotal (95% CI) 10 11 100.0 % -28.14 [ -34.09, -22.19 ]
Heterogeneity: Chi2 = 1.78, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 9.27 (P < 0.00001)
5 Nucleus accumbens stimulation
Kowski 2015 4 4 -33.8 (42.64) 100.0 % -33.80 [ -117.37, 49.77 ]
Subtotal (95% CI) 4 4 100.0 % -33.80 [ -117.37, 49.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
6 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 -24.95 (8.7) 100.0 % -24.95 [ -42.00, -7.90 ]
-200 -100 0 100 200
Favours stimulation Favours control
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Study or subgroup Stimulation Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 97 94 100.0 % -24.95 [ -42.00, -7.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Chi2 = 4.71, df = 5 (P = 0.45), I2 =0.0%
-200 -100 0 100 200
Favours stimulation Favours control
Analysis 1.4. Comparison 1 Stimulation versus sham stimulation, Outcome 4 Quality of Life.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 1 Stimulation versus sham stimulation
Outcome: 4 Quality of Life
Study or subgroup Favours control Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus stimulation
Fisher 2010 52 53 -0.3 (1.6319) 100.0 % -0.30 [ -3.50, 2.90 ]
Subtotal (95% CI) 52 53 100.0 % -0.30 [ -3.50, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
2 Hippocampal stimulation (1 to 3 months)
Tellez-Zenteno 2006 3 3 -5 (24.617) 100.0 % -5.00 [ -53.25, 43.25 ]
Subtotal (95% CI) 3 3 100.0 % -5.00 [ -53.25, 43.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 Nucleus accumbens stimulation
Kowski 2015 4 4 2.78 (5.2) 100.0 % 2.78 [ -7.41, 12.97 ]
Subtotal (95% CI) 4 4 100.0 % 2.78 [ -7.41, 12.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
4 Closed-loop ictal onset zone stimulation
-100 -50 0 50 100
Favours control Favours stimulation
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Study or subgroup Favours control Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Morrell 2011 93 87 -0.14 (1.4003) 100.0 % -0.14 [ -2.88, 2.60 ]
Subtotal (95% CI) 93 87 100.0 % -0.14 [ -2.88, 2.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.36, df = 3 (P = 0.95), I2 =0.0%
-100 -50 0 50 100
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Analysis 2.1. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 1 Seizure
freedom RR.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 1 Seizure freedom RR
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.0806 (1.6219) 100.0 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 54 55 100.0 % 0.34 [ 0.01, 8.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1) 100.0 % 1.00 [ 0.14, 7.10 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.14, 7.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1) 43.6 % 1.00 [ 0.14, 7.10 ]
Velasco 2005 3 2 -0.288 (1.8484) 12.8 % 0.75 [ 0.02, 28.07 ]
Wright 1984 9 9 0 (1) 43.6 % 1.00 [ 0.14, 7.10 ]
0.005 0.1 1 10 200
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Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.26, 3.52 ]
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.96)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.2247) 34.3 % 1.00 [ 0.09, 11.03 ]
Tellez-Zenteno 2006 4 4 0 (1) 51.5 % 1.00 [ 0.14, 7.10 ]
Velasco 2007 4 5 0.1823 (1.9061) 14.2 % 1.20 [ 0.03, 50.31 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.25, 4.19 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 0.5108 (1.8619) 100.0 % 1.67 [ 0.04, 64.08 ]
Subtotal (95% CI) 2 4 100.0 % 1.67 [ 0.04, 64.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 0 (1) 100.0 % 1.00 [ 0.14, 7.10 ]
Subtotal (95% CI) 4 4 100.0 % 1.00 [ 0.14, 7.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 1.5783 (1.5425) 100.0 % 4.85 [ 0.24, 99.64 ]
Subtotal (95% CI) 97 94 100.0 % 4.85 [ 0.24, 99.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 1.55, df = 6 (P = 0.96), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 2.2. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 2
Responder rate RR.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 2 Responder rate RR
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1335 (0.3113) 100.0 % 1.14 [ 0.62, 2.10 ]
Subtotal (95% CI) 54 54 100.0 % 1.14 [ 0.62, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.5) 100.0 % 1.00 [ 0.38, 2.66 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.38, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 24.4 % 1.00 [ 0.06, 15.99 ]
Velasco 2005 3 2 1.3218 (1.3478) 26.8 % 3.75 [ 0.27, 52.64 ]
Wright 1984 9 9 0.6931 (1) 48.8 % 2.00 [ 0.28, 14.20 ]
Subtotal (95% CI) 17 16 100.0 % 2.00 [ 0.51, 7.86 ]
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.2247) 13.1 % 1.00 [ 0.09, 11.03 ]
Tellez-Zenteno 2006 4 4 0 (0.5) 78.4 % 1.00 [ 0.38, 2.66 ]
Velasco 2007 4 5 1.2809 (1.5166) 8.5 % 3.60 [ 0.18, 70.34 ]
Subtotal (95% CI) 10 11 100.0 % 1.12 [ 0.47, 2.66 ]
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 1.6094 (1.4606) 100.0 % 5.00 [ 0.29, 87.54 ]
Subtotal (95% CI) 2 4 100.0 % 5.00 [ 0.29, 87.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 1.3863 (1) 100.0 % 4.00 [ 0.56, 28.40 ]
0.005 0.1 1 10 200
Favours control Favours stimulation
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Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 4 4 100.0 % 4.00 [ 0.56, 28.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.0819 (0.234) 100.0 % 1.09 [ 0.69, 1.72 ]
Subtotal (95% CI) 97 94 100.0 % 1.09 [ 0.69, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 3.30, df = 6 (P = 0.77), I2 =0.0%
0.005 0.1 1 10 200
Favours control Favours stimulation
Analysis 2.3. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 3 Seizure
freedom OR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 3 Seizure freedom OR 0.25
Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.5912 (2.1992) 100.0 % 0.20 [ 0.00, 15.17 ]
Subtotal (95% CI) 54 55 100.0 % 0.20 [ 0.00, 15.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.523) 100.0 % 1.00 [ 0.05, 19.79 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.05, 19.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.5428) 42.2 % 1.00 [ 0.05, 20.57 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Velasco 2005 3 2 -0.3677 (2.9584) 11.5 % 0.69 [ 0.00, 228.30 ]
Wright 1984 9 9 0 (1.4708) 46.4 % 1.00 [ 0.06, 17.86 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.13, 6.83 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.6971) 39.9 % 1.00 [ 0.04, 27.83 ]
Tellez-Zenteno 2006 4 4 0 (1.5713) 46.5 % 1.00 [ 0.05, 21.75 ]
Velasco 2007 4 5 0.2113 (2.9027) 13.6 % 1.24 [ 0.00, 365.22 ]
Subtotal (95% CI) 10 11 100.0 % 1.03 [ 0.13, 8.41 ]
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 0.636 (2.9461) 100.0 % 1.89 [ 0.01, 608.05 ]
Subtotal (95% CI) 2 4 100.0 % 1.89 [ 0.01, 608.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 0 (1.6971) 100.0 % 1.00 [ 0.04, 27.83 ]
Subtotal (95% CI) 4 4 100.0 % 1.00 [ 0.04, 27.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 2.1867 (2.1132) 100.0 % 8.91 [ 0.14, 560.31 ]
Subtotal (95% CI) 97 94 100.0 % 8.91 [ 0.14, 560.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.63, df = 6 (P = 0.95), I2 =0.0%
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Analysis 2.4. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 4
Responder rate OR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 4 Responder rate OR 0.25
Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1848 (0.4304) 100.0 % 1.20 [ 0.52, 2.80 ]
Subtotal (95% CI) 54 54 100.0 % 1.20 [ 0.52, 2.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.6) 100.0 % 1.00 [ 0.31, 3.24 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.31, 3.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.7678) 34.5 % 1.00 [ 0.03, 31.97 ]
Velasco 2005 3 2 2.785 (2.3851) 18.9 % 16.20 [ 0.15, 1736.64 ]
Wright 1984 9 9 1.2098 (1.5204) 46.6 % 3.35 [ 0.17, 66.00 ]
Subtotal (95% CI) 17 16 100.0 % 2.98 [ 0.39, 22.77 ]
Heterogeneity: Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.6971) 12.7 % 1.00 [ 0.04, 27.83 ]
Tellez-Zenteno 2006 4 4 0 (0.6734) 80.4 % 1.00 [ 0.27, 3.74 ]
Velasco 2007 4 5 2.089 (2.3018) 6.9 % 8.08 [ 0.09, 735.42 ]
Subtotal (95% CI) 10 11 100.0 % 1.15 [ 0.35, 3.77 ]
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 2.8332 (2.4156) 100.0 % 17.00 [ 0.15, 1934.66 ]
Subtotal (95% CI) 2 4 100.0 % 17.00 [ 0.15, 1934.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 3.0445 (1.8968) 100.0 % 21.00 [ 0.51, 864.51 ]
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Study or subgroup Experimental Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 4 4 100.0 % 21.00 [ 0.51, 864.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.1133 (0.3236) 100.0 % 1.12 [ 0.59, 2.11 ]
Subtotal (95% CI) 97 94 100.0 % 1.12 [ 0.59, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 4.36, df = 6 (P = 0.63), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 2.5. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 5 Seizure
freedom RR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 5 Seizure freedom RR 0.25
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 55 -1.5734 (2.1826) 100.0 % 0.21 [ 0.00, 14.95 ]
Subtotal (95% CI) 54 55 100.0 % 0.21 [ 0.00, 14.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (1.4142) 100.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.06, 15.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 44.0 % 1.00 [ 0.06, 15.99 ]
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Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Velasco 2005 3 2 -0.3365 (2.7045) 12.0 % 0.71 [ 0.00, 143.20 ]
Wright 1984 9 9 0 (1.4142) 44.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 17 16 100.0 % 0.96 [ 0.15, 6.04 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.4142) 44.2 % 1.00 [ 0.06, 15.99 ]
Tellez-Zenteno 2006 4 4 0 (1.4142) 44.2 % 1.00 [ 0.06, 15.99 ]
Velasco 2007 4 5 0.2007 (2.7561) 11.6 % 1.22 [ 0.01, 271.12 ]
Subtotal (95% CI) 10 11 100.0 % 1.02 [ 0.16, 6.46 ]
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 0.5878 (2.7162) 100.0 % 1.80 [ 0.01, 369.24 ]
Subtotal (95% CI) 2 4 100.0 % 1.80 [ 0.01, 369.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 0 (1.4142) 100.0 % 1.00 [ 0.06, 15.99 ]
Subtotal (95% CI) 4 4 100.0 % 1.00 [ 0.06, 15.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 2.166 (2.1032) 100.0 % 8.72 [ 0.14, 538.18 ]
Subtotal (95% CI) 97 94 100.0 % 8.72 [ 0.14, 538.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.62, df = 6 (P = 0.95), I2 =0.0%
0.002 0.1 1 10 500
Favours control Favours stimulation
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Analysis 2.6. Comparison 2 Stimulation versus sham stimulation - sensitivity analyses, Outcome 6
Responder rate RR 0.25.
Review: Deep brain and cortical stimulation for epilepsy
Comparison: 2 Stimulation versus sham stimulation - sensitivity analyses
Outcome: 6 Responder rate RR 0.25
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Anterior thalamic nucleus
Fisher 2010 54 54 0.1335 (0.3113) 100.0 % 1.14 [ 0.62, 2.10 ]
Subtotal (95% CI) 54 54 100.0 % 1.14 [ 0.62, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Centromedian thalamic stimulation
Fisher 1992 6 6 0 (0.4714) 100.0 % 1.00 [ 0.40, 2.52 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.40, 2.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Cerebellar stimulation
Van Buren 1978 5 5 0 (1.4142) 39.5 % 1.00 [ 0.06, 15.99 ]
Velasco 2005 3 2 1.8608 (1.9387) 21.0 % 6.43 [ 0.14, 287.32 ]
Wright 1984 9 9 1.0986 (1.4142) 39.5 % 3.00 [ 0.19, 47.96 ]
Subtotal (95% CI) 17 16 100.0 % 2.28 [ 0.40, 13.02 ]
Heterogeneity: Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
4 Hippocampal stimulation (1 to 3 months)
McLachlan 2010 2 2 0 (1.4142) 9.6 % 1.00 [ 0.06, 15.99 ]
Tellez-Zenteno 2006 4 4 0 (0.4714) 86.1 % 1.00 [ 0.40, 2.52 ]
Velasco 2007 4 5 1.8101 (2.0967) 4.4 % 6.11 [ 0.10, 372.25 ]
Subtotal (95% CI) 10 11 100.0 % 1.08 [ 0.46, 2.55 ]
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
5 Hippocampal stimulation (4 to 6 months)
Wiebe 2013 2 4 2.1972 (2.044) 100.0 % 9.00 [ 0.16, 494.41 ]
Subtotal (95% CI) 2 4 100.0 % 9.00 [ 0.16, 494.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
6 Nucleus accumbens stimulation
Kowski 2015 4 4 1.9459 (1.4142) 100.0 % 7.00 [ 0.44, 111.91 ]
0.001 0.01 0.1 1 10 100 1000
Favours control Favours stimulation
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 4 4 100.0 % 7.00 [ 0.44, 111.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
7 Closed-loop ictal onset zone stimulation
Morrell 2011 97 94 0.0819 (0.234) 100.0 % 1.09 [ 0.69, 1.72 ]
Subtotal (95% CI) 97 94 100.0 % 1.09 [ 0.69, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 3.41, df = 6 (P = 0.76), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours control Favours stimulation
A P P E N D I C E S
Appendix 1. Calculation of treatment effects in Van Buren 1978
We illustrate the way we calculated treatment effects for Van Buren 1978 taking patient two of their trial as an example. Van Buren
1978 reported 183% seizure frequency increase during the early double-blind stimulation ON period, a 125% increase during the
late double-blind stimulation ON period, a 812% increase during the early double-blind stimulation OFF period and finally a 156%
increase during the late double-blind stimulation OFF period. This can be formulated as 283%, 225%, 912% and 256% of baseline
seizure frequency, respectively. Comparing stimulation ON to stimulation OFF periods with regard to baseline seizure frequency would
result in a 330% seizure reduction with stimulation ON [(283-912+225-256)% x ½]. As four out of five patients’ seizure frequency
increased during the trial (more accurate seizure detection? spontaneous evolution of their disease?), we decided to directly compare
stimulation ON to stimulation OFF periods to avoid treatment effects > 100%. For patient two, this results into 69% (1-[283/912]) and
12% (1-[225/256]) seizure frequency reductions during early and late double-blind evaluations respectively, or a mean 41% ([69+12)%
x ½) reduction in seizure frequency across both periods. Responders during stimulation ON periods were defined as participants
experiencing a ≥ 50% seizure frequency reduction with regard to stimulation OFF periods (direct comparison), whereas the inverse
definition was used to define responders during stimulation OFF periods.
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Appendix 2. Search strategies
1. Cochrane Epilepsy Group Specialized Register search strategy
#1 MeSH DESCRIPTOR Deep Brain Stimulation Explode All
#2 (cort* OR brain OR thalam* OR hippocamp* OR cerebel* OR cerebr*) NEAR4 stimul*
#3 MeSH DESCRIPTOR Vagus Nerve Stimulation Explode All
#4 MeSH DESCRIPTOR Transcranial Magnetic Stimulation Explode All
#5 (“transcranial magnetic stimulation” OR rTMS OR “vagus nerve stimulation” OR “vagal nerve stimulation”):TI
#6 #3 OR #4 OR #5
#7 #2 NOT #6
#8 #1 OR #7
2. CENTRAL search strategy
#1 MeSH descriptor Epilepsy explode all trees
#2 MeSH descriptor Seizures explode all trees
#3 epilep* OR seizure* OR convulsion*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Deep Brain Stimulation explode all trees
#6 stimul*
#7 (#5 OR #6)
#8 (#4 AND #7)
3. PubMed search strategy
Our search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE
(sensitivity-maximizing version, 2008 revision; Pubmed format) (Lefebvre 2011).
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 random* [tiab]
#4 placebo [tiab]
#5 sham [tiab]
#6 trial [tiab]
#7 groups [tiab]
#8 blind* [tiab]
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 animals [mh] NOT humans [mh]
#11 (#9 NOT #10)
#12 epilepsy [MeSH]
#13 seizures [MeSH]
#14 epileps* OR epilept*
#15 seizure*
#16 convulsion*
#17 (#12 OR #13 OR #14 OR #15 OR #16)
#18 deep brain stimulation [MeSH]
#19 stimulat* OR stimuli* OR stimulu*
#20 (#18 OR #19)
#21 (#11 AND #17 AND #20)
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4. ClinicalTrials.gov
Epilepsy in the Condition
AND Stimulation in the Intervention
5. WHO International Clinical Trials Registry Platform ICTRP
Epilepsy in the Condition
AND Stimulation in the Intervention
Recruitment status is ALL
Appendix 3. Quality of life in Tellez-Zenteno 2006
Tellez-Zenteno 2006 reported mean QOLIE-89 scores of 57 (standard deviation (SD) 47), 55 (SD 33) and 27 (SD 60) during baseline,
stimulation ON and stimulated OFF periods. These scores are based on repeated testing (once per month) in three patients, resulting
in 9 QOLIE-89 scores in total. Tellez-Zenteno 2006 also reported median QOLIE-89 scores (with corresponding interquartile ranges),
being 57 (24 to 90), 64 (30 to 78) and 61 (39 to 80) respectively. Taking into account the total number of QOLIE-89 scores (only
nine), the different effect estimators and their corresponding measures of variability, we assume that the authors switched figures for
the QOLIE-89 score during the stimulation OFF period, the mean being 60 and 27 representing the standard deviation. Indeed, it is
impossible to calculate a mean score of 27 when the median is 61 and the interquartile range (39 to 80), with only nine measurements
in total.
WH A T ’ S N E W
Date Event Description
16 November 2016 New citation required but conclusions have not
changed
Conclusions are unchanged.
5 November 2016 New search has been performed Searched updated 5 November 2016; two new studies
have been included and three studies have been added
as ongoing studies
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of the review was changed from ’Deep brain and cerebellar stimulation for epilepsy’ to ’Deep brain and cortical stimulation for
epilepsy’ as we thought neocortical stimulation also fits the scope of this review (which may be particularly relevant for future updates
of the review).
The percentage seizure frequency reduction was added as an additional outcome measure. This was done in a prespecified way after
one author involved in the writing of the protocol (Annelies Van Dycke) was replaced by another author (MS). The reason to do so
was to allow a more precise estimation of the efficacy of the different invasive intracranial neurostimulation treatments.
We planned to express the treatment effect for dichotomous outcome measures by risk ratio (RR). However, for reasons outlined in
the Methods section, we used odds ratios (OR) and performed a sensitivity analysis with RRs to evaluate any possible influence of this
change.
As we judged that (future) trials comparing deep brain or cortical stimulation versus other neurostimulation treatments (e.g. vagus
nerve stimulation, other intracranial target,...) might also be relevant to the reader and fit the scope of this review, this type of control
group was added to the selection criteria.
We performed various sensitivity analyses and not all of these were mentioned in the initial protocol, including several post-hoc
sensitivity analyses. See Methods section on Sensitivity analysis for more details.
121Deep brain and cortical stimulation for epilepsy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anterior Thalamic Nuclei; Cerebral Cortex; Deep Brain Stimulation [instrumentation; ∗methods]; Electrodes, Implanted [adverse
effects]; Epilepsy [∗therapy];Hippocampus; Mediodorsal ThalamicNucleus; Nucleus Accumbens; OutcomeAssessment (HealthCare);
Randomized Controlled Trials as Topic
MeSH check words
Humans
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